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Enterovirus (EV71) is the agent of Hand, foot and mouth disease (HFMD), a 
common and mild illness amongst infants and young children. However, in recent 
years, this pathogen has posed a serious threat; large scale outbreaks of HFMD have 
been reported in the Asia-Pacific region with an increasing number of cases of 
neurological complications which resulted in high fatality rates. 
 
In this study, characterization of the linear neutralizing epitopes on the VP1 
capsid protein of the Enterovirus 71 strain 41 (5865/SIN/00009) (belonging to 
subgenogroup B4 and isolated from a fatal case in Singapore) was undertaken. 
Antisera were raised in adult Balb/c mice against 95 overlapping diphtheria toxoid-
conjugated synthetic peptides of 15 amino acids in length spanning the entire VP1 
capsid protein. Two synthetic peptides, designated SP55 (VP1 amino acid residues 
162 to 177) and SP70 (VP1 amino acid residues 208 to 222) were capable of eliciting 
neutralizing antibodies against EV71. 
 
Based on in vitro microneutralization assay, the synthetic peptide SP70 was 
able to elicit a higher EV71-neutralizing response with a neutralizing antibody titer of 
1:32 in mice when compared to the synthetic peptide SP55, eliciting an EV71-
neutralizing antibody titer of 1:8. The anti-SP70 antiserum was found to be almost as 
efficient as the immune serum raised against the heat-inactivated homologous EV71 
whole virion with a neutralizing antibody titer of 1:64. In addition, the total IgG 
response specific to EV71 whole virion measured in the anti-SP55 or anti-SP70 
antiserum was found to be as high as that measured in the immune serum raised 
 xxi
against the heat-inactivated homologous EV71 strain 41. Immunization of mice with 
either synthetic peptide predominantly enhanced IgG1 production, suggesting that the 
neutralizing antibodies elicited are likely belonging to the IgG1 subtype. 
 
The amino acid sequences represented by SP55 and SP70 lie towards the C-
terminal part of the VP1 capsid protein of EV71 strain 41. The hydrophobicity 
profiles showed that these regions are located within the major hydrophilic regions of 
VP1 and hence they are expected to be exposed at the surface of the protein. 
Alignment with databases showed that the amino acid residues represented by SP70 
are highly conserved amongst the VP1 sequences of 25 representative EV71 strains 
from different subgenogroups. In vitro microneutralization assay has shown that the 
immune serum raised against SP70 was able to neutralize heterologous EV71 strains 
with similar efficiencies to that obtained with the homologous EV71 strain 41, 
thereby suggesting that SP70 might represent an interesting and promising peptide-
based vaccine candidate for EV71. 
 
In addition, when passively administered to one-day-old suckling Balb/c mice 
challenged with a lethal dose of 103 TCID50 virus/mouse, the anti-SP70 antibodies 
were able to confer 80% in vivo protection comparable to antiserum raised against the 
homologous heat-inactivated EV71 whole virion. The level of protection conferred by 
the anti-SP70 antiserum against heterologous EV71 strains was almost similar to that 
obtained against the homologous strain, supporting that the VP1 amino acid 
sequences represented by SP70 contain a highly conserved neutralizing linear epitope. 
 
 xxii
Histological examination and real-time RT-PCR hybridization probe-based 
assay revealed viral infiltration in the small intestines of EV71-infected mice and the 
neutralizing anti-SP70 antibodies plays a major role in the inhibition of EV71 
replication in vivo which significantly reduced the viral titer. The cytokine profiles for 
EV71-challenged mice showed elevated IL-6 and IFN-γ levels in unprotected mice 
whereas significant lower levels were observed for mice which were protected by 
passively-transferred immune sera. This observation suggests a correlation between 
pro-inflammatory cytokines and the severity of EV71 infection. 
 
The use of synthetic peptide(s) as capture antigen(s) in immunoassays 
represents an interesting approach for the serodiagnostic of EV71 infection as it 
would avoid the need for propagating infectious viruses. Antigenic sites on VP1 
protein of EV71 strain 41 (5865/SIN/00009) were mapped by Pepscan analysis using 
the 95 overlapping synthetic peptides spanning the entire VP1 amino acid sequence 
against EV71-neutralizing sera from pediatric patients. A major IgG-specific 
immunodominant linear epitope (VP1 amino acid residues 91 to 111), defined by the 
core amino acid sequence ‘LEGTTNPNG’, was identified. 
 
Therefore, a 15 amino acid-based synthetic peptide SP32 
(DLPLEGTTNPNGYAN) which contains the core sequence of the immunodominant 
VP1 linear epitope was over-expressed in Escherichia coli as a soluble recombinant 
GST-SP32 fusion protein. When used as a capture antigen in Western blot, the 
recombinant GST-SP32 fusion protein significantly reacted with human anti-EV71 
IgG antibodies with high specificity when compared to both the recombinant GST-
VP1 fusion protein and EV71 whole virion as capture antigen. In addition, 
 xxiii
computational analysis also showed that the amino acid sequence represented by 
SP32 was highly specific for EV71 strains with no significant homology with other 
enteroviruses. Altogether, these data indicate that recombinant GST-SP32 fusion 
protein which harbored the immunodominant VP1 linear epitope of EV71 could be 
potentially used as a capture antigen in Western blot for detecting human anti-EV71 
IgG antibodies. 
 
The identification of human CD4+ T-cell epitopes within a protein vaccine 
candidate is of great interest as it provides a better understanding of the mechanisms 
involved in protective immunity and may therefore help in the design of effective 
vaccines and diagnostic tools. The entire amino acid sequence representing the VP1 
capsid protein of EV71 strain 41 was submitted to analysis using a virtual matrix-
based prediction program (ProPred) for the identification of promiscuous HLA-DR 
ligands. Three regions spanning amino acids 66 to 77, 145 to 159 and 247 to 261 of 
VP1 were predicted to bind more than 25 different HLA-DR alleles. 
 
The corresponding peptides (SP1 to SP3) were then tested for their abilities to 
induce proliferation of CD4+ T cells isolated from peripheral blood mononuclear cells 
of five human volunteers screened positive for previous EV71 exposure and one 
EV71-negative volunteer. Upon stimulation with either peptide, CD4+ T cell 
proliferative responses were observed for all EV71-positive volunteers, indicating the 
presence of EV71-specific memory CD4+ T cells. The amplitude of the proliferative 
responses was peptide- and HLA-DR-dependent, and correlated well with the ProPred 
predicted binding efficiencies. 
 
 xxiv
This study also showed that CD4+ T cells from EV71-positive volunteers 
produced significant levels of IL-2 and IFN-γ upon stimulation, indicative of a T cell 
differentiation into Th1-type subset. Among the three peptides, SP2 induced the 
highest proliferative response and cytokine production. In addition, the SP2-induced 
proliferative response could be inhibited with anti-major histocompatibility complex 
(MHC) class II antibody, indicating that SP2 may represent a MHC class II-restricted 
CD4+ T-cell epitope. Hence, this study demonstrates that the ProPred algorithm can 
accurately predict the presence of human CD4+ T-cell epitopes within the VP1 capsid 
protein of EV71, and therefore represents a useful tool for the design of subunit 
vaccines against EV71. The identification of CD4+ T-cell epitopes also provides a 
better understanding in protective immunity and may help in diagnostic tools against 
EV71. 
CHAPTER 1 LITERATURE REVIEW 
_____________________________________________________________________ 
__________________________________________________________________ 1
CHAPTER 1 LITERATURE REVIEW 
1.1 Picornaviruses 
Picornaviruses are one of the oldest known viruses. At present, the 
Picornaviridae family is divided into five main genera which consist of rhinoviruses, 
enteroviruses, aphthoviruses, cardioviruses and heptaviruses (REACH). The 
enteroviruses mostly inhabit the alimentary tract and include polioviruses, 
coxsackieviruses, echoviruses, human enteroviruses 68 to 71 and human hepatitis A 
virus (Melnick, 1996).  
 
Not until 1908 was poliovirus identified by two Austrian physicians, Karl 
Landsteiner and E. Popper.  Following their discovery, polio became a reportable 
disease entity, and the state of Massachusetts began counting polio cases in 1909 
(Bradshaw, 1989). The acid-sensitive rhinoviruses and aphthoviruses are known to 
cause common cold and the foot-and-mouth disease in cattle, respectively. The acid 
stability of enteroviruses enabled them to be well-ingested and reach the intestinal 
tracts of both animals and humans (Levy et al., 1994). The human enteroviruses were 
originally classified on the basis of human disease manifestations, replication and 
pathogenesis in newborn mice, and propagation using in vitro cell culture method. 
However, based mostly on molecular properties, they have recently been re-classified 
into five different species which includes human enteroviruses A through D and 
polioviruses (King et al., 2000).  
 
Most enterovirus infections are either mild or asymptomatic. However, 
infections in neonates are frequently life-threatening. Study has shown that 
enteroviruses can also cause common chronic diseases such as dilated 
CHAPTER 1 LITERATURE REVIEW 
_____________________________________________________________________ 
__________________________________________________________________ 2
cardiomyopathies, insulin dependent diabetes mellitus and chronic fatigue syndrome 
(Muir et al., 1998). Several enteroviruses have been shown to be associated with 
gastrointestinal disorders, meningitis/encephalitis and respiratory illness (Levy et al., 
1994). Table 1.1 summarizes the various clinical symptoms associated with 
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Table 1.1 Clinical manifestations of enteroviruses. Each symptom may 
potentially be caused by more than one enterovirus (Melnick, 1996). 
 
 
Clinical Manifestations  
 
 




Poliovirus 1 to 3; Coxsackievirus A7, A9,  
B2 to B5; Echovirus 4, 6, 9, 11, 30; 
Enterovirus 70, 71 
 
Aseptic Meningitis Poliovirus 1 to 3; Coxsackievirus A2, A4, 
A7, A9, A10, B1 to B6; Echovirus 1 to 11, 
13 to 23, 25, 27, 28, 30, 31; Enterovirus 70, 
71 
 
Hand, foot and mouth disease 
(HFMD) 
Coxsackievirus A5, A10, A16,  
Enterovirus 71 
 
Herpangina Coxsackievirus A2 to A6, A8, A10 
 
Acute hemorrhagic conjunctivitis Coxsackievirus A24, Enterovirus 70 
 
Encephalitis Echovirus 2, 6, 9, 19 
 
Meningoencephalitis Coxsackievirus B1 to B5, Enterovirus 70, 
71 
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1.2 Genomic and organization of enteroviruses 
 Enteroviruses possess a single positive-stranded RNA genome of 
approximately 7,500 nucleotides. The complete genomic sequences of several 
Enterovirus 71 (EV71) strains have been determined, including the prototype BrCr 
strain (Accession no. U22521), the neurovirulent MS/7423/87 strain (Accession no. 
U22522) (Brown and Pallansch, 1995), the fatal 5865/sin/000009 strain (Accession 
no. 316321) and the non-fatal 5666/sin/002209 strain (Accession no. 352027) isolated 
from two patients during the Hand, foot and mouth disease (HFMD) outbreak in 
Singapore in the year 2000. (Singh et al., 2002). 
 
The enteroviral genome comprises a 5’ untranslated region (5’UTR), a long 
open reading frame (ORF) encoding a polyprotein of 2,194 amino acids, a short 3’ 
untranslated region (UTR) and a poly-adenylated tail. The 5’UTR contains 
determinants for translation of the viral RNA by internal ribosome entry site (IRES) 
mechanism for the amplification of viral RNA and for its neurovirulence (Evans et 
al., 1985), and its end is modified by the presence of a covalently bound protein VPg. 
The polyprotein is sub-divided into three regions, namely P1, P2 and P3. The P1 
region encodes four structural proteins (VP1 to VP4), the P2 and P3 regions encode 
seven non-structural proteins (2A to 2C and 3A to 3D, respectively) (Figure 1.1). The 
polyprotein is co- and post-translationally cleaved to give rise to four structural 
proteins, namely VP1, VP2, VP3 and VP4. The 3’UTR region contains a pseudo-knot 





















Figure 1.1 Genome structure of EV71. The single open reading frame (ORF) is 
flanked by UTRs at the 5' and 3' ends. A variable length poly-A tail is found at the 3' 
UTR. The ORF is divided into three regions: the P1 region encodes four structural 
proteins VP1 to VP4, the P2 and P3 regions encode seven non-structural proteins 2A 
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1.2.1 The enteroviral capsid proteins 
The single large open reading frame (ORF) encodes a polyprotein of 
approximately 250 kDa in size which is proteolytically processed by virus-encoded 
proteinases to yield structural and non-structural proteins. This is a full-length 
molecule on which RNAs are translated, while others are packaged as viral genomes 
by the newly synthesized coat proteins (Harper, 1998; Johnson and Sarnow, 1995). 
The viral capsid is icosahedra (T=1) in symmetry and is composed of sixty identical 
units (protomers). Each promoter is comprised of four structural proteins: VP1 to 
VP4. Among them, VP1, VP2 and VP3 are the main structural components of the 
viron, whereas VP4 is relatively unstructured and wholly internal (Hogle et al., 1985). 
The VP1 capsid protein contains all three major neutralization sites that have been 
identified on the surface of poliovirus. However, VP2 and VP3 capsid proteins 
contain two and one neutralization site, respectively (Van der Marel et al., 1983; Van 
Wezel et al., 1983). Since X-ray crystallographic structures have been obtained for 
several picornaviruses, a consensus structural model for the EV71 coat protein was 
also developed to facilitate diagnostic immunoassays and vaccine development 
(Ranganathan et al., 2002). The unique surface features of EV71 were characterized 
by homology modeling and comparing its structural model with experimental 
structures of other enteroviruses such as bovine enterovirus, rhinovirus and poliovirus. 
Although the antigenic determinants for EV71 have not been fully characterized but 
surface topography analysis and protein structure modeling have shown that the 3D 
structure of VP1 protein forms peaks separated by canyons and the immunogenic sites 
were surface-exposed and thus constituted a large immunogenic site for EV71 (Figure 
1.2). Among all enteroviruses, a study has indicated that the VP1 region appears to be 
the most immunodominant amongst the other capsid proteins (Oberste et al., 1999). 



















Figure 1.2 Diagrammatic representation of the EV71 icosahedra virus capsid. 
The capsid protein surface is assigned colors by depth, the deepest being dark grey 
and the outermost being white. The antigenic regions of VP1 are denoted by light 
green, red, green, yellow and salmon (Ranganathan et al., 2002). (Permission granted 
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1.2.2 Infection cycle 
Typically, in an early event of any infection by enteroviruses, the initial 
uncoating of viral genome is the primary objective to gain entry into the host cell. To 
begin, endocytosis of viruses generally involves receptors, which is mediated by 
clathrin-coated pits and vesicles (Racaniello, 1995). Upon entry into the host cell, the 
virus genome is translated to produce the RNA polymerase and other enzymes. As 
shown in Figure 1.3, the entire replicative cycle of enteroviruses occur in the 
cytoplasm of infected cells. During viral replication, one of the products made is the 
viral RNA-dependent RNA polymerase which copies the genomic RNA to produce a 
negative-sense strand. This forms the template for positive-stranded genomic RNA 
synthesis which occurs via a multi-stranded replicative intermediate complex, some of 
which are translated whereas others are believed to be packaged as viral RNA into 
preformed capsids (Ansardi et al., 1996; Whitton et al., 2005). Once infected, cells 
typically displayed cytopathic effects (CPE) that comprise a series of cellular changes 
(Schlegel and Kirkegaard, 1995). The cell nucleus gradually alters in morphology 
until it acquires a characteristic crescent shape late in infection. This is followed by 
migration of the chromatin, in which chromosomal DNA is found in increasingly 
smaller regions of the nucleus that are often associated with the nuclear membrane 
(pkynosis). Ribosomes are aggregated in the cytoplasm and clusters of membranous 

















Figure 1.3 Life cycle of Picornaviruses (Whitton et al., 2005). (Permission granted 
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1.3 Enterovirus 71 (EV71) infection 
1.3.1 Epidemiological studies 
EV71 was first identified in the United States from the stool of an infected 
infant in the year 1969 (Schmidt et al., 1974). Australia was the first country in which 
EV71 was isolated outside of the United States during an epidemic of aseptic 
meningitis between 1972 and 1973 (Kennett et al., 1974). In the year 1975, the 
neurovirulence of EV71 was manifested during a large EV71 outbreak in Bulgaria 
which resulted in 44 fatalities (Chumakov et al., 1979). However, an association of 
EV71 with the Hand, foot and mouth disease (HFMD) was not made until the year 
1973, during the small epidemics in both Sweden and Japan (Blomberg et al., 1974; 
Hagiwara et al., 1978). 
 
In the last 10 years, there was an increase of epidemics and 
neuropathogenicity of HFMD caused by EV71, particularly in the Asia-Pacific region. 
Before 1997, outbreaks caused by EV71 were of smaller scale and most were not 
associated with acute neurological disease. Since 1997, several large epidemics and 
high-level endemic circulations of EV71 strains have been reported. A summary of 
the main outbreaks from 1997 to present is presented in Table 1.2. Ever since the 
major HFMD outbreaks within the Asia-Pacific region in 2000, small scale outbreaks 
were also reported in countries such as Malaysia, Taiwan, China, Hong Kong, Brunei, 
India, Singapore, USA and Germany from year 2000 to 2006 
(http://www.promedmail.org). Recently, in 2006, a large scale of HFMD outbreak 
occurred in Sarawak, Malaysia and 13 fatalities were reported. At the same time, 
approximately 3,000 of non-fatal HFMD cases were recorded in Singapore and 75% 
of the cases were caused by EV71 (Ministry of Health, Singapore). 
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1.3.2 Phylogenetic studies 
The comparison of nucleotide and deduced amino acid sequences have 
identified four major phylogenetic groups within the enterovirus genus: 
coxsackievirus A16 (CA16)-like viruses (cluster A), a coxsackievirus B (CB)-like 
group containing all CB and echoviruses, as well as CA9 and enterovirus 69 (EV69) 
(cluster B), poliovirus-like viruses (cluster C), and EV68 and EV70 (cluster D) (Pöyry 
et al., 1996; Pringle, 1999). EV71 was also found to be very closely linked to CA16 
where they share a nucleotide sequence homology of approximately 77% and 89% 
homology based on deduced amino acid sequences and hence falls within cluster A.  
 
1.3.2.1 VP1-based classification 
The understanding of the molecular epidemiology and evolution of EV71 took 
a major step forward when Brown et al. (1999) reported the phylogenetic analysis of 
EV71. To investigate the genetic variability of various EV71 strains and their 
associations with outbreaks, the complete cDNA sequence (891bp) encoding the VP1 
capsid protein of EV71 strains isolated from various countries over a 30-year period 
was analyzed and the monophylogenetic serotype was further divided into three 
distinct genogroups A, B and C (Brown et al., 1999). Genogroup A contains a single 
member, the prototype EV71 strain BrCr-CA-70 whereas genogroup B consists of 65 
strains isolated from 1972 to 1997 in the United States, Australia, Columbia and East 
Malaysia (Sarawak). Genogroup C is made up of 47 strains isolated from 1986 to 
1988 from the United States, Australia, the Republic of China, Canada and mainland 
Malaysia (Brown et al., 1999) (Figure 1.4). Within each genogroup, EV71 strains 
were classified into subgenogroups (B1 to B5 and C1 to C4) mostly based on their 
VP1 or VP4 gene sequences. Within similar subgenogroup, EV71 strains share more 
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than 92% nucleotide sequence identity whereas the nucleotide sequence identity 
between the three genogroups ranges from 78% to 83%.  
 
1.3.2.2 VP1- and VP4-based classification 
Phylogenetic relationships of EV71 strains isolated from major outbreaks in 
the Asia-Pacific region were also established based on other parts of the EV71 
genome such as the 5’UTR (Abubakar et al., 1999; Wang et al., 2000) and the VP4 
(Shimizu et al., 1999; Chu et al., 2001; Cardosa et al., 2003; Lin et al., 2006). Chu et 
al. (2001) examined a partial VP4 region (207 bp) of 23 EV71 Taiwanese strains from 
the 1998 epidemic and 21 other strains deposited in the GenBank, (the prototype BrCr 
strain, the neurovirulent 7423/MS/87 strain, three strains isolated during the 1986 
outbreak in Taiwan, and 16 strains isolated from Japan). Cardosa et al. (2003) 
analyzed the partial VP1 and VP4 regions of 128 EV71 strains isolated from the year 
1970 to 2002 from the United States, Japan, Taiwan, Malaysia, Singapore, China, 
Bulgaria, Hungary and the United Kingdom. Analysis of either the VP1 or VP4 gene 
sequences provided similar phylogenetic classification of the EV71 strains. However, 
higher bootstrap values were observed in the VP1 dendrograms, hence providing 
greater confidence when elucidating new genogroups (Cardosa et al., 2003). Similar 
phylogenetic classification between the VP1 and VP4 regions was further shown in 
two recent separate studies which carried out genetic analysis of a 414 bp region 
within the VP1 sequence and a 207 bp region within the VP4 sequence on the EV71 
strains isolated in Taiwan from the year 1988 to 2005 (Lin et al., 2006; Kung et al., 
2007). Both studies demonstrated the predominance of the subgenogroup B1 before 
the year 1998 whilst the subgenogroup C2 was the major etiologic group in the 1998 
outbreak. The subgenogroup B4, which was a minor etiologic group during the 1998 
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outbreak, became the major sub-genogroup isolated from 1999 to 2003. During the 
year 2004, the subgenogroup C4 emerged to be the predominant sub-genogroup in 
Taiwan.  
 
1.3.2.3 Relationship between subgenogroups and outbreak occurrence 
There seems to be no correlation between the severity of disease and the 
genetic lineage of the EV71 strains since viruses from all three genogroups are 
capable of causing disease (Brown et al., 1999). McMinn et al. (2001a) compared the 
complete VP1 gene sequence of 66 EV71 strains isolated from Malaysia, Singapore, 
Taiwan and Western Australia between 1997 and 2001 and established two sub-
lineages within the genogroup B which circulated in Southeast Asia between 1997 
and 2001. EV71 strains in the subgenogroup B3 were the predominant strains isolated 
from the epidemics in Sarawak and peninsular Malaysia in 1997 and in Western 
Australia in 1999 (Figure 1.5). Partial genetic analysis (500 bp) of the VP1 capsid 
protein from 18 EV71 strains involved in the 1998 outbreak in Taiwan has shown that 
majority of the viruses belonged to subgenogroup C2 (Shih et al., 2000b). Based on 
the phylogenetic analysis of the VP1 region of 45 EV71 strains which were isolated 
over a 6-years period in Yamagata, Mizuta et al. (2005) found that outbreaks in 
Yamagata were mainly caused by EV71 strains belonging to the subgenogroups B4, 
C2 and C4. However, there were a few isolated EV71 strains that could not be 
classified into any of the three subgenogroups and they were classified under a new 
subgenogroup known as B5 (Figure 1.6). More EV71 strains were classified into the 
subgenogroup B5 when Ooi et al. (2007) analyzed the VP1 regions of EV71 isolated 
from 277 patients in Malaysia from 2000 to 2004. It was shown that 168 patients were 
infected with EV71 strains from the subgenogroup B4 whereas 68 patients were 
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infected with strains from the subgenogroup C1 and 41 patients were infected with the 
newly emerged EV71 strain belonging to the subgenogroup B5. 
 
At present, a total of 10 subgenogroups have been identified. It was 
established that there is a great diversity of EV71 strains circulating in the Asia-
Pacific region and other parts of the world. However, no significant differences in 
genome sequence were found between EV71 strains isolated from fatal and non-fatal 
cases. In the year 2000, EV71 strains belonging to the subgenogroup B4 were 
responsible for the HFMD outbreak in Singapore. Using a comparative sequence 
analysis, Singh et al. (2002) showed that the fatal Singapore strain 5865/sin/000009 
which belongs to the subgenogroup B4 had 99% nucleotide and 100% amino acid 
homology with the non-fatal Singapore strain 5666/sin/002209 from similar 
subgenogroup. However, both strains displayed significant differences when 
compared to other EV71 strains including the prototype BrCr strain (genogroup A) 
and the neurovirulent strain MS/7423/87 (subgenogroup B2). Therefore, there is no 
particular subgenogroup that is associated with severe neurological complications 
(Singh et al., 2002; Cardosa et al., 2003). Due to its potential in causing severe 
neurological diseases, further studies on EV71 are necessary to understand the factors 




















Figure 1.4 Classification of 113 EV71 strains into genogroups based on the VP1 
gene (nucleotide position 2442 to 3332). The dendrogram was generated by the 
neighbor-joining method with the DNADIST distance measure program (PHYLIP, 








Figure 1.5 Phylogenetic tree showing classification of 25 EV71 field isolates into 
subgenogroups based on alignment of the complete VP1 sequence (nucleotide 
position 2442 to 3332). Branch lengths are proportional to the number of nucleotide 
differences. Strain names indicate a unique number/country or US state of 
isolation/year of isolation: AUS – Australia; CA – California, USA; CT – 
Connecticut, USA; IA – Indiana, USA; MAA – peninsular Malaysia; OR – Oregon, 
USA; SAR – Sarawak, Malaysia; SIN – Singapore; TW – Taiwan; TX – Texas, USA. 
The VP1 nucleotide sequence of CA16 was used as an out-group in the analysis 
(McMinn et al., 2001a). (Permission granted by publisher, ASM Journals). 
 
 









Figure 1.6 Phylogenetic classification based on the complete VP1 region (891 
nucleotides). Representative EV71 strains were isolated in Yamagata, Japan, between 
1998 and 2003, and reference strains (Mizuta et al., 2005). (Permission granted by 




CHAPTER 1 LITERATURE REVIEW 
_____________________________________________________________________ 
__________________________________________________________________ 19
1.3.3 Clinical features of diseases caused by enterovirus 71 (EV71) 
A typical clinical course for all fatal EV71-associated cases has been 
observed: the symptoms are displayed for less than a week before hospitalization and 
subsequently the conditions of the patients rapidly deteriorates with a fatal outcome 
within hours to a few days of hospitalization (Liu et al., 2000; Chan et al., 2000). 
However, EV71 infections cause very diverse symptoms, ranging from none to 
fatality and it remains unknown why different hosts have such a range of clinical 
outcomes. 
 
1.3.3.1 Hand, foot and mouth disease (HFMD) 
EV71 has been increasingly recognized as the main etiological agent of 
HFMD which is described as a mild childhood disease usually characterized by three 
to four days of fever. This disease is commonly associated with the development of 
vesicular exanthem on the buccal mucosa, tongue, gums and palate, as well as 
papulovesicular exanthem on the hands, feet and buttocks (Figure 1.7). Other 
frequently encountered symptoms include poor appetite, vomiting as well as lethargy 
(Liu et al., 2000). Other enterovirus serotypes that are commonly known to cause 
HFMD include CA16, CA5, CA9 and Echo 7 (Melnick, 1996). EV71 has been 
identified as the main causative agent of large scale HFMD outbreaks over the last 
few years in the Asia-Pacific region. 
 
The HFMD clinical symptoms caused by EV71 are generally indistinguishable 
from those caused by CA16. Based on clinical features observed in patients suffering 
from HFMD in Japan (Komatsu et al, 1999), Malaysia (Chan et al., 2000) and 
Western Australia (McMinn et al., 2001b), larger vesicles were observed in children 
CHAPTER 1 LITERATURE REVIEW 
_____________________________________________________________________ 
__________________________________________________________________ 20
suffering from CA16 infection as compared to those with EV71 infection. The rashes 
were more frequently papular and/or petechial with areas of diffuse erythema on the 

































Figure 1.7 Vesicles on the palm of a child infected with hand, foot and mouth 
disease (HFMD). Adapted from the Dermatologic Image Database, Department of 
Dermatology, University of Iowa College of Medicine, USA, 1996 
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1.3.3.2 Other EV71-associated diseases 
Apart from HFMD, EV71 also causes a variety of neurological diseases 
including aseptic meningitis, acute flaccid paralysis (AFP), encephalitis and 
poliomyelitis-like paralysis (Melnick, 1984; Lum et al., 1998a; Liu et al., 2000), 
which are frequently accompanied by complications such as herpangina, pulmonary 
edema and myocarditis (Chang et al., 1999; Chan et al., 2000). Children under five 
years of age were found to be highly susceptible to EV71-associated neurological 
diseases (Liu et al., 2000; Chan et al., 2000). These observations were recorded for 
children with acute EV71 infection during the large scale HFMD outbreaks in the 
Asia-Pacific region. However, these were not presented in children suffering from 
CA16 infection (Alexander et al., 1994; Lum et al., 1998a). In the 1999 Perth 
epidemic, only one of the five cases of acute flaccid paralysis had poliomyelitis-like 
disease, with two cases identified as transverse myelitis and two others as Guillain-
Barré Syndrome (GBS) (McMinn et al., 2001a). Acute cerebella ataxia has been 
linked to EV71 infection in many previous epidemics (Ishimaru et al., 1980; 
Takimoto et al., 1998; Komatsu et al., 1999). Studies of neurogenic pulmonary edema 
due to EV71 infections were carried out (Lum et al., 1998b; Cardosa et al., 1999).  In 
each case, the infections appeared to be confined to the brainstem, with histological 
evidence of acute inflammatory encephalitis, isolation of EV71 or identification of the 
EV71 antigen within the neurons (Lum et al., 1998b; Wang et al., 1999). These 
studies supported the hypothesis that pulmonary edema was of neurogenic origin and 
was secondary to autonomic dysfunction, resulting from infection of specific 
regulatory structures within the brainstem. Non-specific febrile illnesses are common 
clinical manifestations of enterovirus infections in young children and have been 
described in association with EV71 (Ho et al., 1999; Merovitz et al., 2000). 
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Respiratory diseases associated with EV71 infection include pharyngitis, croup, 
bronchiolitis and pneumonia (Gilbert et al., 1988; Merovitz et al., 2000). A single 
case of intrauterine infection with EV71 was reported by Chow et al (2000).  
 
1.3.4 Immunopathogenesis of EV71 infection 
A recent study has shown that EV71 patients suffering from brainstem 
encephalitis and pulmonary edema had a significantly lower phytohemagglutinin 
stimulation index, suggesting that lower EV71-specific cellular response may be 
associated with the immunopathogenesis of EV71-related pulmonary edema (Chang 
et al., 2006). A previous study suggested that EV71 enters the host through the 
alimentary tract and uses the lymphatic circulatory system to reach target organs 
(Melnick, 1996). Pro-inflammatory cytokine profiles in association with EV71-
associated pulmonary edema and brainstem encephalitis were studied and the levels 
of IL-6 and IFN-γ were found to be significantly higher in patients with severe EV71 
infections (Lin et al., 2003; Wang et al., 2007). These findings suggest that both IL-6 
and IFN-γ seems to play prominent roles in the overwhelming disease process caused 
by EV71. 
 
1.4 Diagnosis of enterovirus 71 (EV71) 
1.4.1 Tissue culture isolation and serotyping 
 EV71 infections are conventionally diagnosed on the basis of viral isolation 
and in vitro microneutralization tests. The standard procedure of enterovirus detection 
and isolation involves inoculation of cell line in cultures with patient throat swabs, 
vesicular fluid, cerebrospinal fluid or stool samples. The cell lines used are Vero 
(African green monkey kidney) cells, human Rhabdomyosarcoma (RD) cells, MRC-5 
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(human lung fibroblast) cells and MDCK (monkey kidney) cells (Ho et al., 1999; 
Wang et al., 2000). For some enteroviruses such as EV71, cytopathic effects (CPE) 
are often difficult to discern as it does not involve the entire cell monolayer on initial 
isolation and may be mistaken for a non-specific degeneration or toxic effect of the 
sample (Landry et al., 1995). Therefore, several blind passages of the virus are 
required in certain cases before CPE becomes apparent and the presence of virus 
ascertained. 
 
Although virus isolation has been regarded as the ‘gold standard’ for 
enterovirus identification, the procedures are poorly standardized and virus isolation 
data may vary considerably between laboratories. However, there are a number of 
problems associated with conventional diagnosis of EV71. This approach is very 
time-consuming (requiring at least three to four weeks for an accurate diagnosis) and 
it also faces issues regarding sensitivity and specificity of the test method. Sensitivity 
is largely dependent on the type and quality of the specimen, the timing of the 
specimen collection, and specimen storage before arriving in the laboratory (Morens 
et al., 1991; Grandien et al., 1995; Landry et al., 1995). Upon isolation, enterovirus 
identification is determined using in vitro microneutralization assay with serotype-
specific sera. However, typing by such approach using reference sera for all serotypes 
individually is clearly impractical. To overcome this problem, type-specific 
hyperimmune sera have been mixed to give intersecting pools containing different 
combinations of individual antisera (Schmidt et al., 1961; Grandien et al., 1995; 
Melnick, 1996). The Lim Benyesh-Melnick (LBM) pool scheme consists of eight 
pools (designated A to H) containing antisera raised against forty-two different 
enterovirus types (Lim & Benyesh-Melnick, 1960; Melnick, 1973). Alternative 
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intersecting pools of antisera developed by the National Institute of Public Health and 
Environment in the Netherlands allowed identification of enteroviruses 68 to 71 
(Kapsenberg, 1998). Enterovirus isolates are incubated with each antiserum pool 
before re-inoculated onto susceptible cells. After several days of incubation, the 
neutralizing pattern is recorded and the serotype of the viral isolate can be inferred. 
Finally, serotypic identification of enteroviruses could be determined using serotype-
specific antisera. 
 
The use of intersecting pools for typing enterovirus isolates is time-
consuming, labor-intensive and costly. Moreover, the supply of antisera is limited, 
which poses a significant problem in virus serotyping during a HFMD epidemic 
(Melnick & Wimberly, 1985). Finally, this approach does not permit classification of 
identified enterovirus into respective genogroup or subgenogroup and a large number 
of enterovirus isolates are frequently classified as ‘untypeable’ by in vitro 
microneutralization assay (Morens et al., 1991). There may be several reasons: (i) 
‘untypeable’ isolates may contain mixtures of enterovirus (especially in an outbreak 
situation) (Blomberg et al., 1974; Schmidt et al., 1974; Nagy et al., 1982; Kok et al., 
1992); (ii) not all enterovirus serotypes can be identified with intersecting pools. For 
examples, EV71 along with CA3, CA11, CA15, CA17 and CA24 cannot be typed 
using LBM pools; (iii) enteroviruses may form aggregates which can be neutralized 
only after treatment with sodium deoxycholate or chloroform, or by ultrafiltration to 
dissociate the aggregates (Wallis & Melnick, 1967; Kapsenberg et al., 1980); (iv) 
isolates may be antigenic variants of recognized serotypes which are neutralized 
poorly or may not be neutralized at all by antiserum to the homologous prototype 
strain; (v) and finally, isolates that are genuinely ‘untypeable’ after excluding the 
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above possible reasons may truly represent a new or previously unrecognized 
enterovirus type (Caro et al., 2001; Palacios et al., 2002). 
 
When initial attempts to serotype viral isolates using intersecting sera pools 
are unsuccessful, the additional labor and expenses required to achieve proper 
identification deters further investigations and such isolates may be left untyped. A 
small-scale quality control scheme on enterovirus identification involving eleven 
laboratories and ten samples was carried out in 1999 but none of the participating 
laboratories managed to report the standardized results for enterovirus serotyping (van 
Loon et al., 1999). 
 
1.4.2 Immunofluorescence assay 
Another approach for EV71 detection is the indirect immunofluorescence 
assay (IFA) which involves the use of serotype-specific monoclonal antibodies for 
virus identification (Manzara et al., 2002). This method allows serotype-specific 
identification of EV71 grown in cell culture without using antisera pools. Vero 
(African green monkey kidney) cells, human Rhabdomyosarcoma (RD) cells and 
MRC-5 (human lung fibroblast) cells are commonly used for inoculations of clinical 
specimens (Ho et al., 1999). 
 
To identify the presence of EV71, immunohistological staining with a Pan-
Enterovirus Blend of monoclonal anti-EV71 antibodies (Chemicon International, 
USA) can be performed. The serotype-specific monoclonal antibody will bind to 
EV71 isolated from the cell culture and the antigen-antibody complex can be detected 
with a capture FITC-labeled (fluorescent isothiocyanate) antibody. Such approach is 
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an alternative to the in vitro microneutralization test for the serotype-specific 
identification of EV71. However, this method still involves the isolation and 
propagation of EV71 in cell cultures which generally require one to two weeks of 
labor-intensive work. In addition, the Pan-Enterovirus Blend of monoclonal anti-
EV71 antibodies (Chemicon International, USA) was also reported to cross-react with 
CA16 (Yan et al., 2001) and the monoclonal antibodies were raised against the 
prototype BrCr strain. Therefore, it might not be able to detect newly evolved EV71 
strains. 
 
1.4.3 Enzyme-Linked Immunosorbent Assay (ELISA) 
Diagnosis of EV71 infection by ELISA can generally be carried out efficiently 
with up to ninety-six clinical samples at a time. It is low in cost and has reduced the 
need for experienced personnel and dedicated laboratories. A recombinant protein-
based ELISA has been developed as a commercially available diagnostic kit for EV71 
infection. The concept involves interactions between specific anti-EV71 antibodies in 
patient sera with the polyhistidine-VP1 fusion protein (Shih et al., 2000a). However, 
studies on antibody cross-reactivity between enteroviruses showed that antisera 
targeted to the VP1 capsid protein cross-reacted widely with other enteroviruses 
(Hovi and Roivainen, 1993). Further analysis uncovered a region within VP1 (amino 
acids 42 to 58 of VP1) that is highly conserved throughout the enteroviruses. Based 
on these findings, it follows that the use of the entire VP1 capsid protein as a capture 
antigen for human anti-EV71 antibody detection may not be appropriate as the assay 
would lead to false positive results in cases where the infection is caused by 
enteroviruses other than EV71. In addition, a previous study has also shown that the 
VP1 protein of EV71 when produced as a recombinant His-VP1 fusion protein was 
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highly insoluble and hence required tedious denaturation and renaturation steps before 
it could be used as capture antigens in immunoassay (Shih et al., 2000a). 
 
The detection of IgM in sera from EV71-infected patients by ELISA was 
shown to be effective in diagnosing acute EV71 infection (Tano et al. 2002; Shih et 
al., 2000a) with a high sensitivity and specificity of 97.7% and 93.3%, respectively 
(Wang et al., 2004). However, in the IgM-capture ELISA, the whole EV71 viral 
particle was used as the capture antigen and the need to prepare large quantities of 
purified virion for interactions with anti-human IgM antibodies in the assay is an 
expensive, laborious and lengthy process. Moreover, cross-reactions with antibodies 
against other enteroviruses could result in false positives. Therefore, the specificity of 
the IgM-based ELISA could be compromised by the presence of common epitopes 
within enteroviruses. 
 
The use of synthetic peptide as capture antigen in immunoassay has been 
explored as well. Using broad-reactive peptides from the VP1 capsid protein of 
enteroviruses as capture antigens in IgG-based ELISA, it was shown to be useful for 
serodiagnosis of enteroviral infections (Samuelson et al., 1993). Although this may be 
useful for identifying enterovirus, it is not specific for the detection of EV71 
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1.4.4 Molecular detection methods 
1.4.4.1 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
More recently, several research groups have attempted to develop assays for 
the identification of EV71 based on conventional reverse transcription polymerase 
chain reaction (RT-PCR) followed by nucleic acid hybridization or sequencing. PCR 
has been accepted as the “new” standard for the detection of viruses in diagnostic 
microbiology laboratories bypassing the need for the tedious and lengthy process of 
isolating the virus from clinical specimens. Most PCR primers designed for the 
detection of enteroviruses were targeted at the highly conserved 5′UTR region 
(Rotbart, 1990; Zoll et al., 1992) as well as the VP2 capsid protein-coding region. The 
advantage of a detection strategy for enteroviruses based on the 5′UTR is that a single 
pair of primers could be used for identifying enteroviruses in general. However, no 
information could be obtained with regard to the identity of specific enterovirus 
without proceeding to sequence the amplicons. Due to a lack of correlation between 
the nucleotide sequence of these genomic regions and enterovirus serotypes, neither 
the 5′UTR (Rueckert, 1996), the VP2-coding region (Oberste et al., 1998) nor the 
RNA polymerase-coding region (Casas et al., 2001) can be used for enterovirus 
typing. Although there were phylogenetic studies targeting the VP4-VP2 junction 
which suggested that this region might be more suitable for developing serotype 
specific diagnostics, it appeared to correlate partially with serotypes (Arola et al., 
1998; Oberste et al., 1998).  
 
Since genomic analysis of the VP1 capsid protein was shown to correlate more 
closely with serotypes, conventional PCR was developed to target at the VP1-
encoding DNA region (Brown et al., 2000; Singh et al., 2000, 2002; Yan et al., 2001). 
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Brown et al. (2000) designed two pairs of primers that targeted at regions within and 
around the VP1 ORF and were successfully able to amplify EV71 genome 
specifically from 125 different EV71 tissue culture isolates. This was followed by 
Singh et al. (2000) who designed another pair of primers which could detect EV71 
specifically from tissue cultures which were inoculated with clinical specimens. In a 
separate study, Yan et al. (2001) developed two sets of primers for the specific 
detection of EV71 and CA16, respectively. Both primer pairs were designed based on 
the VP1 regions of respective viruses and were evaluated against 57 isolates of EV71, 
16 isolates of CA16 and several other enteroviruses. Although the EV71-specific 
primers were shown to be highly specific for the amplification of EV71 genome, the 
primers designed for CA16 detection were found to be non-specific as they were able 
to amplify EV71 genome as well (Yan et al., 2001).  
 
The study by Singh et al. (2002) was the first group to detect EV71 directly 
from clinical specimens using specific primers targeted at the VP1 region. In this 
study, it was demonstrated that the three pairs of primers which were designed 
previously by Brown et al. (2000) and Singh et al., (2000) had low sensitivities (only 
5%) in the detection of EV71 directly from clinical specimens. Therefore, a semi-
nested RT-PCR strategy was used and this method achieved a higher sensitivity 
(53%) in detecting EV71 directly from clinical specimens in contrast to only 20% 
detection rate for the cell culture method. An improvement of the conventional RT-
PCR, known as the miniature RT-PCR system was developed by Liao et al. (2005) for 
rapid diagnosis of RNA viruses, such as Dengue virus and EV71. The principle was 
based on conventional RT-PCR carried out in a miniature volume of 12cm by 21cm 
by 8.5cm and was operated by 9V batteries. Serum collected from a patient was 
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loaded into a valve and the one-step RT-PCR process was carried out in the 
automated system which reduced cross-contamination. Since a microchip was used to 
control the temperature, high efficiencies of PCR with detection limits as low as 
6pg/µl can be achieved. 
 
1.4.4.2 Combination of RT-PCR and microarray 
In a recent study, a combination of both multiplex RT-PCR and microarray 
method was developed to specifically differentiate EV71 from CA16 (Chen et al., 
2006). Using specific primers, RT-PCR was first carried out to amplify both EV71 
and CA16 viral RNAs. The amplicons are then labeled with fluorescent dyes and 
added to array slides which are spotted with 60-mers degenerate oligonucleotide 
probes specific for the detection of either EV71 or CA16. A diagnostic accuracy of 
92% and 95.8% was achieved for specific detection of EV71 and CA16, respectively. 
In another study, a microchip method involving conventional RT-PCR, followed by 
hybridizing the biotinylated PCR products to specific probes of EV71 with 82% 
sensitivity was developed (Tsao et al., 2006). However, the detection of EV71 from 
clinical specimens by this approach is laborious and the time for a diagnosis requires a 
minimum of ten hours which is too long in any outbreak situations. 
 
1.4.4.3 PCR-ELISA 
The detection of enteroviruses by PCR-ELISA approach was developed by 
Rotbart et al. (1994, 1997) based on their earlier work on the identification of 
enteroviruses using conventional RT-PCR involving the principle of amplification by 
RT-PCR and detection of amplified DNA products by ELISA. Sets of primers which 
are specific for highly conserved sequences within the 5′UTR as well as the VP2 
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capsid protein-coding regions have been successfully used to develop efficient 
methods for the rapid and sensitive detection of enteroviruses (Romero, 1999). Such 
approach is currently available commercially as a Chemicon Pan-Enterovirus 
OligoDetectTM kit (Chemicon International, USA). This detection kit is based on the 
amplification and detection of nucleic acid products produced by RT-PCR. 
Theoretically, this detection method can be used to detect enteroviruses in different 
sample types which may escape detection by traditional cell culture approach due to 
small quantities of virus. As the primers were designed to target at the 5′UTR region 
of the viral genome, the PCR-ELISA method was applicable for the detection of 
enteroviruses in general, but not the specific serotype.  
 
1.4.4.4 Real-time PCR 
Real-time PCR is an improvement of the classical PCR amplification process 
in which monitoring of the accumulating amplicons during the course of the PCR can 
be carried out in real time. It was first described by Higuchi et al. (1993), who 
proposed a kinetic model that the process of denaturation, primer annealing and 
template extension did not just occur at discrete temperatures as in the case of 
conventional PCR, but may be occurring simultaneously during temperature 
transitions. In real-time PCR, monitoring of the DNA amplification process in real-
time was made possible by labeling of probes and amplicons with fluorogenic 
molecules (Mackay et al., 2002; Espy et al., 2006). Due to the relatively small sample 
volume and high sensitivity of the real-time PCR system, small changes in 
fluorescence emission can be monitored readily, thereby enable small initial amount 
of templates to be detected (Wittwer et al., 2001). Quantitation of the amount of 
templates in any specimen can also be achieved based on standard curves generated 
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from real-time PCR (Rasmussen, 2000). There are three major chemistries available 
for amplicon detection based on real-time PCR. They can be generally classified into 
amplicon sequence specific methods or non-specific methods. 
 
The sequence non-specific detection method is based on DNA-binding 
fluorogenic molecules. A dye known as SYBR Green I is widely used in real-time 
PCR these days. Upon exposure to a suitable wavelength of light, it will fluoresce 
when associated with dsDNA which will be detected by sensitive fluorimeters in the 
real-time PCR instrument. For the SYBR Green I approach, fluorescent melting curve 
analysis can be applied for detection of different amplification products based on 
differences in melting temperature (Tm) which depends on the total GC content and 
length of the amplified product (Wittwer et al., 2001). However, formation of primer-
dimers can confuse interpretation of results, as the fluorogenic dye can bind to any 
dsDNA product. Therefore, the melting curve analysis is useful here where the shorter 
primer-dimer can be discriminated by its reduced Tm compared to the actual DNA 
amplicon (Wittwer et al., 2001). As SYBR Green I-based assays are not specific, they 
are often used for screening assays where further analysis of specimen is usually 
required for confirmation (Espy et al., 2006). 
 
For amplicon sequence specific method, real-time PCR uses a Taq polymerase 
that has a 5′exonuclease activity. The principle of this process was first described by 
Holland et al. (1991) and it was later utilized with fluorescent and quencher dye by 
Livak et al. (1995). In the TaqMan probe-based approach, the probe contains one 
fluorophore (6-carboxy-fluoroscein) at its 5’ terminus and a quencher (6-
carboxytetramethyl-rhodamine; TAMRA) at its 3’ terminus. In close proximity, both 
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dyes form a quenched system and no fluorescence is observed. However, when the 
probe hybridizes to the template, the 5′exonuclease activity of the Taq polymerase 
will hydrolyze the probe during PCR amplification. Once the fluorophore is separated 
from the quencher, the emission of the fluorophore is no longer being quenched and 
hence fluorescence will be detected. TaqMan probe-based real-time PCR assay has 
been used in diagnosis of viruses such as Epstein-Barr virus and Cytomegalovirus 
(Jebbink et al., 2003). However, since the 5′exonuclease activity is irreversible, 
analysis of the results is finalized once the PCR amplification is completed. 
Therefore, unlike SYBR Green I assay, no secondary confirmation like the melting 
curve analysis is available for TaqMan probe-based assays. 
 
Another approach involves the use of a pair of adjacent, fluorogenic 
hybridization oligoprobes. The upstream oligoprobe is labeled with a 3′ donor 
fluorophore (Fluorescein) and the downstream probe is labeled with either 
LightCycler Red 640 or Red 705 acceptor fluorophore at the 5′ terminus. When both 
oligoprobes are hybridized to the target template, they are located within 10 bp of 
each other. This approach involves the principle of fluorescence resonance energy 
transfer (FRET), a method in which the donor dye transfers a quantum of energy to 
the acceptor dye upon excitation by ultraviolet, and the acceptor dye releases a photon 
of different wavelength upon return to rest. Since more fluorescence is emitted with 
increased number of amplicons, quantification can be performed (Bernard et al., 
2001). In addition, since the probes are not significantly hydrolyzed, the LightCycler 
is able to monitor changes in fluorescence emission when the oligoprobes are 
denatured from their amplicons (Mackay et al., 2003; Espy et al., 2006). When the 
temperature is slowly raised, the probes will not be able to anneal to the target PCR 
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product and the FRET signal will be lost. The temperature where half the FRET signal 
is lost is usually referred to as the Tm of the Hybridization probe system which 
depends on the GC content and length of the hybridization probes. This strategy has 
been successfully used for differentiating Varicella-Zoster virus (Espy et al., 2000a) 
from herpes simplex virus (Espy et al., 2000b) and Hepatitis C virus (Ratge et al., 
2000).  
 
Several studies have been carried out to detect enteroviruses based on the real-
time PCR approach. Read et al. (2001) developed a real-time SYBR Green I assay to 
detect enteroviruses, differentiating them from other viruses such as HSV-1, HSV-2 
and Varicella-Zoster virus that are able to cause central nervous system (CNS) 
infections. Using the ABI Prism 7700 PCR instrument (USA), Verstrepen et al. 
(2001) and Nijhuis et al. (2002) developed TaqMan probe-based assays for specific 
detection of enteroviruses. In the study published by Verstrepen et al. (2001), a 95% 
detection rate of enterovirus was achieved and the assay was successfully able to 
detect up to 11.8 genome equivalents of enterovirus per ml of cerebrospinal fluid 
(CSF). Similarly, in the study reported by Nijhuis et al. (2002), the TaqMan probe-
based assay developed was able to detect 60 different enteroviruses and no cross-
reactivity with other viruses was observed. Direct detection of enteroviruses from the 
clinical specimens by real-time TaqMan RT-PCR was developed by Watkins-Riedel 
et al. (2002) and Petitjean et al. (2006) using the LightCycler real-time detection 
system (Roche Molecular Biochemicals, Germany) and the ABI Prism 7700 PCR 
instrument (USA). In another study, Kares et al. (2004) developed a Hybridization 
probe-based assay which not only could simultaneously detect enteroviruses and 
rhinovirus but it was able to differentiate them. 
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1.5 Treatment of enterovirus 71 (EV71) infection 
A number of therapeutic agents with significant anti-viral activities against 
enteroviruses have been developed but none has come close to commercialization. 
Several stages in enterovirus replication such as cell susceptibility, attachment to host 
cell, uncoating, synthesis of viral mRNA and maturation of new virus proteins could 
serve as potential targets for therapeutic intervention. 
 
1.5.1 Antiviral drugs 
The “WIN” group of compounds is the most promising drugs to date. The 
antiviral activities of such compounds were thought to be mediated by stabilizing the 
viral capsid and preventing virus uncoating upon binding to host cell (Rotbart et al., 
1998). One of the “WIN” compounds – pleconaril was found to have significant 
therapeutic effects in aseptic meningitis, acute flaccid paralysis and encephalitis as a 
result of enteroviral infections (Rotbart et al., 1998; Pevear et al., 1999). Pleconaril 
(VP-63843) is a novel, broad-spectrum anti-picornaviral agent. This characteristic is 
highly desirable for any antiviral agent which targets a virus causing CNS and 
respiratory tract infections. Currently, pleconaril is undergoing Phase III clinical trials 
in the US. Clinical studies have shown that there was a reduction in the duration and 
the intensity of symptoms in children and adults with enteroviral meningitis (Romero, 
2001). However, despite having a very good side effect profile which was attributed 
to its metabolic stability, pleconaril was found to show limited effectiveness against 
EV71 (Pevear et al., 1999), especially against EV71-associated neurological 
complications. Other drugs that showed therapeutic potentials include enviroxime 
which inhibited RNA replication by targeting at the 3A region of the viruses (Heinz 
and Vance, 1995). The 3C protease inhibitors were developed by the Agouron 
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Pharmaceuticals which resulted in inhibition of specific viral protein processing 
(Patick et al., 1997). However, studies of these antiviral agents were mainly based on 
polioviruses and rhinoviruses which are the two most important members of the 
Piconarviridae family and their effects on EV71 are still unknown. 
 
1.5.2 Other therapeutic approaches 
1.5.2.1 Intravenous immunoglobulin (IVIG) 
IVIG is a blood product which contains pooled IgG antibodies extracted from 
the plasma of over a thousand blood donors. IVIG was used extensively in the 
management of neurological cases during HFMD outbreaks in Taiwan (Huang, 2001) 
and Western Australia (McMinn et al., 2001a). Recently, a study has shown that the 
administration of IVIG could effectively reduce the level of pro-inflammatory 
cytokines such as interleukin-6 (IL-6) and interleukin-8 (IL-8) in patients suffering 
from autonomic nervous system (ANS) dysfunction and pulmonary edema, which 
arise from EV71-associated brainstem encephalitis (Wang et al., 2006). Moreover, 
milrinone was shown to display therapeutic effects in EV71-induced pulmonary 
edema and/or pulmonary hemorrhage (Wang et al., 2005; Wang et al., 2006), 
suggesting that both milrinone and IVIG when used together, might be good 
therapeutic agents for EV71 infections. The antiviral activities of Salvia miltiorrhiza 
(Danshen) were also tested against EV71 in an in vitro system and were able to 
neutralize EV71 and hence preventing cytopathic effects (CPE) in Vero cells, RD 
cells or MRC-5 cells, suggesting that the chinese herb might have a potential to be 
used as an therapeutic agent against EV71 (Wu et al., 2007). 
 
 




Interferons have also been shown to be a potent inhibitor of most enteroviral 
infections and synergistic protection was observed when used in conjunction with 
capsid-binding compounds (Kandolf et al., 1985; Langford et al., 1985). Interferon-γ 
(IFN-γ) is a cytokine secreted mainly by Th1 T-cells and it enhances specific T-cell 
mediated immune responses. Direct antiviral effects of interferons include 
degradation of the viral mRNA and inhibition of protein synthesis. A recent study 
indicated that type I IFNs may play an important role in the host defense of EV71 and 
that an earlier detection of viral involvement of the central nervous system followed 
by immediate type I IFN therapy should be considered an appropriate treatment 
regimen for EV71 (Liu et al., 2005). However, another study has shown that this 




Jenner’s cowpox vaccine represented the first use of a live-attenuated 
organism which became the first generation of vaccines introduced in science. In the 
years following 1770, EEnglish physician Edward Jenner (1749-1823) observed that 
milkmaids infected with a viral disease called cowpox rarely developed a similar 
disease, smallpox, which was prevalent during that period. On May 1796, Jenner 
tested his theory by inoculating James Phipps, a healthy young boy who had never 
had cowpox or smallpox, with material from the cowpox blisters of the hand of Sarah 
Nelmes, a milkmaid who had caught cowpox. Six weeks later, Jenner injected the boy 
with fluid from a smallpox pustule, which would have been the routine attempt to 
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produce immunity at that time. However, the boy remained free of the dreaded 
smallpox. 
 
The development of novel antiviral agents and vaccines that are effective 
against microorganisms resistant to current therapies is of paramount importance in 
the global fight against infectious diseases. Efforts have been substantially facilitated 
by the progress in the fields of molecular biology, which have enabled the production 
of new generation vaccines. Vaccines have been an effective device for mankind to 
control and even eradicate human diseases. In spite of the undeniable success of using 
vaccines against a large number of infectious diseases, the resourceful strategies of 
virus to escape their host’s immune defense still pose a tough challenge to scientists 
for the development of effective vaccines. The increasing knowledge of the molecular 
basis of interactions between the pathogen and its host enables better and smarter 
approaches to design effective vaccines. 
 
The host’s immune defense mechanisms against infectious agents can be 
divided into two main components which include innate (native) and adaptive 
(acquired) immunity. The adaptive immunity can be further divided into two general 
types, namely, humoral immunity and cell-mediated immunity. Humoral immunity 
involves B-cells, which recognize and bind circulating soluble antigen via surface 
antibody receptors and respond by secreting antigen-specific antibodies. These 
activated B-cells will subsequently become plasma cells that provide long-term 
memory (Davis and McCluskie, 1999). For cell-mediated immunity, T-cells are the 
effector cells which will recognize antigen(s) presented on cell surfaces in the context 
of the major histocompatibility complex (MHC) genes. The CD8+ T-cells are usually 
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activated and differentiated into cytotoxic T-cells which can destroy the infected host 
cells, induce apoptosis, or reduce the ability of the pathogen to replicate inside cells. 
The CD4+ T-cells are activated to become T-helper cells which will secrete 
lymphokines that stimulate the activation and function of both B- and T-cells. 
Therefore, an ideal vaccine candidate should be able to trigger both humoral and cell-
mediated immune responses in the host. In addition, the delivery system of a vaccine 
may contribute to the orientation of the immune response elicited and hence this must 
be taken into consideration when assessing the immunogenicity and protective 
efficacy of the vaccine candidate. 
 
1.6.1 Live-attenuated vaccines 
Live-attenuated vaccines are live micro-organisms that have been cultivated 
under conditions which disable their virulent properties. They are highly effective in 
evoking a full range of immune responses. The advantage of live attenuated vaccines 
is that one or two doses are able to provide immunity that can last for a long period of 
time. The use of live-attenuated organisms has since proven effective for rabies, 
yellow fever, poliomyelitis, measles, mumps, rubella and chicken pox (Gordon, 
1997). A good example is the polio vaccine where two approaches are currently used. 
The first (Salk vaccine) was developed by Jonas Salk in 1955 which consists of an 
injected dose of inactivated poliovirus. Thereafter, Albert Sabin produced an oral 
polio vaccine (OPV) using live-attenuated poliovirus and human trials of Sabin's 
vaccine started in 1957 and it was finally licensed in 1962. The live-attenuated 
poliovirus replicates very efficiently in the gut which is the primary site of viral 
infection and replication. However it is unable to replicate efficiently within nervous 
system tissue. The OPV also proved to be superior in administration and is able to 
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provide longer and lasting immunity as compared to the Salk vaccine (Sabin et al., 
1960). 
 
A recent study has shown that active immunization of 1-day-old mice with 
avirulent EV71 strain or CA16 virus via the oral route developed anti-EV71 
antibodies with neutralizing activities and passive immunization with the CA16-
immune serum prolonged the survival rate of mice upon lethal EV71 challenge (Wu 
et al., 2007). However, live vaccine carries the risk of contamination with potentially 
dangerous viruses and has been reported to cause complications and an example of 
such occurrence is the smallpox vaccine. Because this vaccine comprises of live virus, 
even though it is a weakened virus, occasionally it can cause infections in susceptible 
vaccinated people or those in close contact with them. People with weakened immune 
systems or certain skin conditions are also susceptible to complications from such 
vaccine (Gordon, 1997). In addition, reversion to the original pathogenic form is also 
possible. Interference from circulating antibody of any source like immunoglobulins 
or blood products can also result in vaccine failure. In addition, numerous studies 
have shown that frequent mutations of the viral genome might give rise to evolving 
strains within the community (Brown et al., 1999; Mizuta et al., 2005; Wang et al., 
2002) and these mutated strains may not be neutralized by antisera raised against the 
selected vaccine strain. 
 
1.6.2 Killed whole vaccines 
Killed vaccines are known to be stable, safe and can be given as polyvalent 
vaccines. However, multiple injections are required and cell-mediated immunity may 
not be induced (Nathanson and Langmuir, 1995). A previous study has used 0.1% 
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(v/v) formaldehyde as a chemical formulation to kill live virus prior to immunization 
and has shown a significant level of immunogenicity elicited in ICR mice by such 
approach (Yu et al., 2000). Another study by Wu et al. (2002) showed that heat-
inactivation at 56oC for 30 min was also able to kill and inactivate EV71 as well as to 
elicit a significant immune response in immunized mice. Hence, the immunogenicity 
of the heat-inactivated EV71 is comparable to that of the formaldehyde-inactivated 
virus. Jonas Salk developed formaldehyde-inactivation process to inactivate 
poliovirus (Nathanson and Langmuir, 1995; Minor, 1997). Being the first successful 
vaccine for enteroviruses, it was also known as the inactivated polio vaccine (IPV), 
which was first licensed for human use in the year 1955 (Plotkin and Mortimer, 
c1994). However, the most dramatic effects on the incidence of poliomyelitis 
worldwide are due to the use of Sabin polio vaccine which was first licensed for 
human use in the year 1962 (Plotkin and Mortimer, c1994). Inactivation can also be 
carried out by β-propionolactone treatment and γ-irradiation. Although inactivated 
viruses may not be potent inducers of CTL response (Gordon, 1997) but the laborious 
and costly procedures involved in virus cultivation and purification as well as safety 
issues are the major concerns.  
 
1.6.3 DNA vaccines 
An alternative approach for vaccination is through direct inoculation of the 
host with DNA encoding a protein vaccine candidate. The use of DNA or mRNA for 
immunization is a recent development in the vaccine field. The DNA vaccine consist 
of a plasmid bearing the ORF of interest as well as control elements such as 
terminators, promoters and polyadenylators that allow expression of the target gene in 
eukaryotic cells. DNA vaccines against foot and mouth disease virus (FMDV) have 
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been developed based on virus genome (Beard et al., 1999) and DNA encoding viral 
capsid protein (Chinsangaram et al., 1998). Unfortunately, the DNA-vaccinated 
animals were either partially protected or unprotected from viral challenge, suggesting 
the need for further improvements (Chinsangaram et al., 1998; Beard et al., 1999). 
However, in a recent study, the VP1 gene of EV71 was cloned and expressed in a 
cell-free in vitro expression system using a eukaryotic expression vector, pVAX1 
(Tung et al., 2007). Female Balb/c mice were immunized with the DNA vaccine 
constructs and the anti-VP1 IgG antibody exhibited neutralizing activity against 
EV71. 
 
1.6.4 Subunit or purified component vaccines 
These third generation vaccines comprise purified components from 
pathogenic organisms which sometimes mimic a small region of microbial protein; 
hence they are considerably stable and safe for usage. A recent study conducted by 
Wu et al. (2002) compared the potency of a heat-inactivated EV71 vaccine with two 
subunits vaccines (DNA-based vaccine and recombinant VP1 protein-based vaccine) 
to elicit immunity and provide protection against lethal EV71 challenge in susceptible 
newborn Institute of Cancer Research (ICR) mice. All vaccine candidates were 
observed to elicit high titers of anti-EV71 neutralizing antibody in the mice model. 
With a challenge dose of 2,300 LD50 virus/mouse, suckling mice born to dams 
immunized with the inactivated virus showed 80% survival. However, the subunit 
viral vaccine provided protection only at a lower challenge dose of 230 LD50 
virus/mouse with 40% survival for DNA vaccine and 80% survival for recombinant 
protein vaccine (Wu et al., 2002). This suggests that the VP1 capsid protein contains 
neutralizing epitopes independent of other proteins of EV71.  
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In another recent study, a vaccine strategy using attenuated Salmonella 
enterica serovar Typhimurium strain to express and deliver the VP1 capsid protein of 
EV71 was shown to protect ICR newborn mice against EV71 infection (Chiu et al., 
2006). Using transgenic tomatoes expressing VP1 capsid protein as an oral vaccine, 
Chen et al. (2006) showed that the antisera from immunized mice could neutralize 
EV71 infectivity and this further highlighted the potential use of VP1 as the antigen to 
develop vaccines against EV71.  
 
1.6.5 Synthetic peptide vaccines 
Synthetic peptide represents an interesting alternative candidate as subunit 
vaccine. Production of synthetic peptide is much easier and faster with lesser adverse 
effects when administered as a potential vaccine. However synthetic peptides are 
poorly immunogenic due to their small size. To increase the immunogenicity of a 
synthetic peptide, it can be linked to a larger carrier protein to enhance uptake and 
processing by antigen presenting cells (APCs) such as dendritic cells (DCs) and 
macrophages. The use of either natural or artificial adjuvants has been found to 
enhance the immunogenicity of synthetic peptide-based vaccines by promoting their 
uptake and activating DCs to initiate the immune response (Rosenthal and 
Zimmerman, 2006). The immunogenicity of synthetic peptides could also be 
enhanced by designing chimeric peptide constructs incorporating both B-cell 
epitope(s) and T-cell epitope(s), thereby activating B- and T-cell immune responses. 
This approach was used to develop a hepatitis C virus (HCV) vaccine where both B-
cell epitopes and T-helper epitopes when presented as a chimeric synthetic peptide 
elicited high titers of neutralizing antibody against the virus (Torresi et al., 2007). 
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1.7 Epitope mapping 
1.7.1 Approaches to epitope mapping 
Several methods used for identifying protein epitopes have been described in 
several reviews (Berzofsky, 1985; Jemmerson & Paterson, 1986; van Regenmortel, 
1989). Among them, only X-ray crystallography is based on a structural analysis and 
can describe the spatial relationships found in an antigen-antibody complex. In 
contrast, the other methods rely on binding assays and are therefore based on 
functional analysis. 
 
1.7.2 X-ray crystallography 
 Crystallographic analysis of several protein-antibody complexes has permitted 
the direct visualization of interacting epitope and paratope residues (Padlan, 1992). In 
all cases, the epitope identified was found to be discontinuous and comprised between 
15 to 22 amino acid residues that were observed to be in contact with residues of the 
paratope. Using X-ray crystallography, a previous study has shown that the 
neuraminidase epitope of the influenza virus is characterized as a discontinuous 
epitope which is localized on four surface loops and made up about 15 residues that 
appeared to be in contact with the antibody (Colman et al., 1987). 
 
1.7.3 Viral mutants and monoclonal antibodies 
A most common method used in the mapping of viral epitopes involves the 
analysis of interactions between monoclonal antibodies and viral mutants. Viral 
variants with amino acid substitutions in their structural proteins are tested against a 
panel of neutralizing monoclonal antibodies which are raised against the whole virus. 
Amino acid substitutions of the monoclonal antibody-resistant (MAR) mutants are 
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analyzed and compiled to yield a list of residues thought to form a particular viral 
epitope. Among the picornaviruses, several escape mutant studies have been carried 
out with polio and rhinoviruses (Hogle and Filman, 1989; Mosser et al., 1989; Sherry 
et al., 1986). Stanway et al. (1983) has described that polioviruses can be divided into 
three serotypes on the basis of their neutralization reactions with specific immune 
sera. The single, major antigenic site involved in the neutralization of poliovirus type 
3 was reported to be located at the N-terminal region of VP1 and this was based on 
the isolation of mutant polioviruses resistant to neutralization by monoclonal 
antibodies which had amino acid substitutions clustered in this region (Minor et al., 
1983; Minor et al., 1984; Minor et al., 1985). However, in contrast to this, the 
neutralization of poliovirus type 1 involves multiple epitopes, some of which 
appeared to be independent, and hence involve independent antigenic sites (Emini et 
al., 1982). However, the Sabin strain of poliovirus type 2 resembles poliovirus type 3 
in so far as most of the antibodies examined selected for mutations within the region 
homologous to the principal site of poliovirus type 3 and Minor et al., 1986 showed 
that poliovirus type 2 resembles poliovirus type 3 in having a major immunodominant  
locus in VP1. 
 
Picornaviral antigenic sites may appear to be mainly limited to the tips of 
some variable, solvent-exposed loops (Hogle et al., 1985; Lea et al., 1994; Page et al., 
1988; Rossmann et al., 1985). However, residues which are part of contact epitopes 
but not of the corresponding functional epitopes, and residues that are involved in 
functional epitopes but are not amenable to substitutions, will not be detected. 
Although amino acid substitutions which affect recognition of a protein by an 
antibody are generally limited to the antigen surface area in contact with the antibody 
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(Colman et al., 1987; Knossow et al., 1984), conformational differences in a surface 
loop may be induced by sequence and conformational changes in a neighboring loop 
as shown in studies on VP1 and VP3 by Filman et al. (1989). Similarly, studies on 
MAR mutants of Foot-and-mouth disease virus (FMDV) showed that substitutions at 
residues outside the antibody-binding site could also have an epitope-disrupting effect 
by forcing the immunodominant G-H loop to a different position, away from the C-
terminus of VP1 (Parry et al., 1990). In addition, Diamond et al. (1985) and Blondel 
et al. (1986) have raised the possibility that mutants located outside the binding site 
may escape viral neutralization by preventing some structural alterations. Therefore, 
the current view on the location and features of antigenic sites of epitopes mapped by 
MAR mutant analysis may be biased toward regions which do not compose the 
functional epitope itself but which, upon amino acid substitution, affect its structural 
conformation and hence its reactivity with the neutralizing monoclonal antibodies. 
 
1.7.4 Anti-peptide antibodies 
This approach consists of using peptide fragments for immunization, followed 
by testing to determine if the resulting anti-peptide antibodies react with the intact 
viral protein. A significant reactivity is usually considered as an indication that the 
respective peptide may be an epitope within the protein. It should be noted that 
epitope mapping studies undertaken with this approach are highly controversial due to 
‘order-disorder’ paradox (Dyson et al., 1988). Antibodies against a highly disordered 
state (the peptide) are able to recognize the highly ordered state (the folded protein in 
its native conformation), while the reverse may not necessarily be the case. Another 
common approach to epitope mapping involves measuring the ability of antibodies 
raised against the intact molecule to cross-react with recombinant or synthetic peptide 
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fragments. If a peptide is able to bind to the antibodies, it can be assumed that it 
contains a linear epitope of the protein. A more precise localization of the epitope is 
achieved by testing overlapping peptides of decreasing size and determining the 
smallest peptide that still possesses a significant level of antigenic activity (Benjamin, 
1977). 
 
1.7.5 Mapping using recombinant peptides 
Localization of epitopes can be carried out by expressing parts of the viral 
protein in a prokaryotic expression system and measuring the antigenic activity 
between the recombinant proteins and antibodies raised against the whole virus 
particle. A study has described that this approach is able to identify linear epitopes but 
may not be able to identify conformational epitopes because the conformation needed 
for antigenicity may not be retained in the fusion products (van Regenmortel, 1992). 
Using this method, Ketterlinus and Wiergers (1994) have managed to map antigenic 
domains within the VP1 capsid protein of poliovirus by introducing successive nested 
deletions into recombinant VP1 which are then subjected to immunoblotting with 
monoclonal antibodies raised against the entire VP1 protein. In studies carried out on 
the human T-cell lymphotropic virus (HTLV) by Hadlock et al. (1995), the 
immunodominant HTLV-specific epitope within the HTLV-1 transmembrane 
glycoprotein was delineated using neutralizing antibodies raised against the whole 
virus particles. 
 
1.7.6 Mapping using synthetic peptides 
Epitope mapping with synthetic peptides consists of synthesizing a large 
number of short peptides (usually via automated solid-phase synthesis on a polymeric 
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resin) and testing each of them for their capacity to be recognized by anti-protein 
antibodies. The pepscan method developed by Geysen et al. (1984, 1987) has been 
used extensively in the identification of viral epitopes. This method allows the 
concurrent synthesis of hundreds of peptides on polyethylene pins and hence suitable 
for systematic screening of all possible overlapping peptides of a protein. Antigenic 
sites on capsid proteins of poliovirus type 3 (Roivainen et al., 1991) and CA9 (Pulli et 
al., 1998) have been identified using the peptide-scanning technique. This approach 
has also enabled the identification of serotype-specific epitopes of coxsackievirus B3. 
By testing overlapping peptides spanning the entire VP1 capsid protein of CB3 with 
sera raised against the whole virus particle, several antigenic determinants were 
identified (Haarmann et al., 1994). Type-specificity of the peptides were further tested 
by using antisera raised against other coxsackieviruses (CB1 to CB6) to eliminate the 
possibility of cross-reactivities between serotypes. However, the nature of pepscan 
analysis restricts epitope detection to linear epitopes only. 
 
In addition, there is evidence that the antigenicity of peptides is highly 
dependent on the type of immunoassay used to determine their antigenic reactivity 
(van Regenmortel et al., 1988). Peptides adsorbed onto a solid phase tend to have a 
significant proportion of their surface not favourable for binding to antibody and 
hence often found to possess lower reactivity than free peptides in solution. 
Furthermore, the activity of certain peptides is found to increase when conjugated to a 
carrier, presumably because the lower steric hindrance at the surface of the carrier 
protein allows the peptide to adopt a more suitable conformation for antibody 
recognition. The choice of conjugation procedure as well as the use of different 
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coupling reagents have also been shown to greatly influence the antibody-binding 
properties of the peptide (van Regenmortel et al., 1988).  
 
1.8 Animal models for Enterovirus 71 (EV71) 
Although immune responses such as elevated antibody levels detected soon 
after vaccination may give some indication of the immunogenicity of a vaccine 
construct, they do not necessarily provide a reliable guide to the capability of the 
vaccine to prime an in vivo protective response. Successful protection against 
infection in an animal model remains the best mean to address the protective efficacy 
of a vaccine. Hoever, one of the major barriers to develop EV71 vaccine is the lack of 
a suitable universal animal model for the testing of vaccine immunogenicity and 
protective efficacy (McMinn et al., 2002). Mice are susceptible to EV71 infection in 
the first few days of life before they become completely resistant to the virus by 6 
days old (Roberts and Boyd, 1987; Yu et al., 2000). In addition, EV71 infection has 
been found asymptomatic in most strains of adult mice which include Balb/c, C3H, 
ICR, CD28 knock-out and TNF-α receptor knock-out mice (Wu et al., 2001). Hence, 
the efficacy of an EV71 vaccine candidate cannot be evaluated in actively immunized 
mice but can only be addressed via passive immunization whereby newborn mice are 
challenged with EV71 and subsequently injected with the immune serum from 
actively immunized adult mice (Foo et al., 2007b; Yu et al., 2000). Pathogenicity of 
enteroviruses had been studied in laboratory animals such as newborn mice (Koroleva 
and Gracheva, 1980) and cynomolgus monkeys (Hashimoto et al., 1982). Such 
experimental studies can yield various information regarding the pathogenicity of 
EV71 in different hosts. 
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In 1975, a widespread outbreak of a severe neuroparalytic disease occurred in 
Bulgaria. The disease was manifested as poliomyelitis, meningoencephalitis and acute 
flaccid paralysis, mostly ending lethally. Koroleva and Gracheva (1980) conducted 
animal model experiments for EV71 using the virus-specific materials as inoculants 
for subcutaneous injection into Newborn Cotton (NBC) rats and Newborn White 
(NBW) mice. In addition to newborn animals, three to four weeks old adult cotton rats 
and white mice were infected intracerebrally, intramuscularly or with a combination 
of both. EV71 strains isolated from material obtained during the outbreak of 
poliomyelitis-like disease in Bulgaria were found to be pathogenic for NBW mice and 
NBC rats. The disease symptoms were similar to those caused by coxsackie A 
viruses. In NBW mice, the infection manifested as paresis, paralysis and ended 
lethally and in NBC rats, the lethal outcome was preceded by a sharp deterioration of 
general condition and paresis. Myositis induced in the NBC rats and NBW mice was a 
characteristic of enterovirus A. In addition, diffuse inflammatory degenerative 
changes were noted in the central nervous system (CNS) of adult cotton rats and the 
infection was found to be asymptomatic in adult white mice. 
 
In contrast to the clinical lesions observed in various animals by the EV71 
strains isolated from the Bulgarian outbreak, the prototype EV71 BrCr strain did not 
induce a clinically manifested disease in both NBC rats or NBW mice as well as in 
the adults (Chumakov et al., 1979). Preliminary studies were also conducted on 
primates using rhesus monkeys and green marmosets as laboratory animals. Syrian 
hamsters were also used as an animal model for EV71 infection (Chumakov et al., 
1979). It is important to note that the EV71 strains isolated from Bulgarian outbreak 
possessed the ability to damage the CNS in monkeys and adult cotton rats. 
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Recently, experimental infections with EV71 were undertaken in Taiwan (Yu 
et al., 2000). EV71 was found to be able to induce death in neonatal mice in an age- 
and dosage-dependent manner. The mortality rate was 100% following intraperitoneal 
inoculation of one-day old ICR mice. Mortality gradually decreased as the age of 
mice increased at the time of inoculation and no deaths occurred for mice older than 
six days of age. Lethargy, failure to gain weight, rare limb tremors and paralysis were 
other symptoms observed in the EV71-infected mice prior death (Yu et al., 2000). 
 
Nagata et al. (2002) studied the neurovirulence of EV71 by neuropathological 
analysis of adult Cynomolgus monkeys after experimental infections with five EV71 
strains which were isolated from individual patients with fatal encephalitis, meningitis 
and HFMD. Upon intraspinal inoculation, the monkeys developed neurological 
manifestations within one to six days post inoculation, irrespective of the strains used. 
These manifestations included not only pyramidal tract signs such as flaccid paralysis 
but also signs such as tremors and ataxia. Histological and viral examinations 
confirmed virus replication in the spinal cord, brainstem, cerebella cortex and dentate 
nuclei and cerebrum. The EV71 strains isolated during the 1970s and 1990s showed 
no particular genetic differences with respect to neurotropism. Therefore, it is clear 
that EV71 has a wider neurotropism than polioviruses (Nagata et al., 2002). Although 
Cynomolgus monkeys were susceptible to infection with low passage clinical isolates 
of EV71 who eventually developed encephalomyelitis and poliomyelitis-like paralysis 
after subcutaneous (Hashimoto et al., 1978) or intraspinal inoculation (Hagiwara et 
al., 1984), the high cost of purchase and maintenance of these animals is a major 
barrier to their usage in large scale pathogenesis studies. A more promising approach 
to understand the pathogenesis of enterovirus encephalitis and for testing candidate 
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vaccine is through the development of transgenic mice that may express the 
appropriate human receptor molecule (McMinn et al., 2002). 
 
1.9 Specific aims 
 Enterovirus 71 has been regarded as the most important neurotropic 
enterovirus after the eradication of the poliovirus (McMinn, 2002). Currently, there 
are neither specific antiviral therapies nor effective vaccines available for EV71. 
Although inactivated whole virion has been suggested as potential vaccine candidate, 
studies have also shown that subunit vaccines expressing the full-length VP1 capsid 
protein were able to elicit neutralizing antibodies and conferred protection to newborn 
mice upon lethal viral challenge (Wu et al., 2002; Chiu et al., 2006). However, the 
exact location of these neutralizing epitopes along VP1 has not been identified.  
 
Therefore, this study aims to identify and characterize the linear neutralizing 
epitopes on the VP1 capsid protein of the Enterovirus 71 strain 41 (5865/SIN/00009) 
(belonging to subgenogroup B4). Immune sera raised against 95 diphtheria toxoid-
conjugated synthetic peptides spanning the entire VP1 region were raised in adult 
Balb/c mice to identify regions that are able to elicit neutralizing antibodies against 
EV71 and hence confer in vitro protection to Rhabdomyosacroma (RD) cells as host. 
The in vivo protective efficacy of these antibodies via maternally- and passively-
transferred routes was evaluated using suckling Balb/c mice challenged with a lethal 
viral dose.  
 
Previous studies have shown that the immunogenicity of a synthetic peptide 
could also be enhanced by designing a chimeric peptide construct incorporating both 
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B-cell and T-cell epitopes (Haro and Gomara, 2004; Torresi et al., 2007). Hence, this 
study also aims to identify human CD4+ T-cell epitopes on the VP1 capsid protein 
using the ProPred prediction software to predict promiscuous epitopes. The ability of 
the predicted epitopes to induce human EV71-specific CD4+ T-cell proliferation was 
tested experimentally. The identified CD4+ T-cell epitopes when linked to 
neutralizing linear VP1 epitopes as chimeric peptides can be further explored to elicit 
a higher titer of protective antibodies against EV71. 
 
Isolation of EV71 in cell cultures, followed by neutralization using serotype-
specific antisera such as the Lim Benyesh-Melnick (LBM) pool has been the practice 
in most diagnostic laboratories as the gold standard (Lim et al., 1960). ). However, the 
duration for the isolation and identification of EV71 may require approximately one 
to two weeks and require specialized personnel. As the viral titer present in clinical 
specimens may be low, there is a need to propagate the virus and this contributes to 
the lengthy period for virus isolation. Hence, to design a peptide-based diagnostic 
specifically for EV71, this study also aims to identify IgG-specific immunodominant 
linear epitope on the VP1 capsid protein based on Pepscan analysis by applying a 
series of overlapping synthetic peptides spanning the entire VP1 to screen against sera 
from pediatric patients containing specific anti-EV71 IgG antibodies. As an 
alternative to synthesize peptide, the identified epitope was over-expressed as a 
soluble recombinant GST-fusion protein and evaluated as a capture antigen in 
Western blot analysis for the specific detection of human anti-EV71 IgG antibodies. 
CHAPTER 2 MATERIALS AND METHODS 
___________________________________________________________________________________ 
_______________________________________________________________________________ 55
CHAPTER 2 MATERIALS AND METHODS 
2.1 Microbiology 
2.1.1 Bacterial work 
2.1.1.1 Bacterial strains and plasmids 
Bacterial strains and plasmids used for this study are listed in Table 2.1. The 
restriction map of pGEX-6p-1 vector (GE Healthcare Life sciences, UK) is shown in 
Figure 2.1. 
 
2.1.1.2 Culture and storage of bacterial cells 
LB medium was prepared according to Miller (1972) (Appendix I). LB agar 
was prepared by adding 1.5% (w/v) Oxoid Agar Technical No. 3 to liquid LB 
medium. All media with or without agar, were autoclaved for 20 min at 121ºC. 
Escherichia coli (E. coli) strains transformed with recombinant plasmids were 
maintained on LB agar plates supplemented with the appropriate antibiotics 
(ampicillin at 100μg/ml and/or chloramphenicol at 34µg/ml). Strains in current use 
were stored at 4°C on relevant plates for approximately 2 weeks. Long term storage 
was carried out by re-suspending exponential bacterial cultures in LB media 
supplemented with 20% glycerol (v/v) and stored at -80°C. 
 
2.1.1.3 Preparation of chemically competent E. coli cells 
E. coli strains were inoculated into 10 ml of LB media supplemented with the 
appropriate antibiotics and grown at 37ºC. An aliquot (1 ml) from the overnight 
culture was transferred into 50 ml of LB broth. The cells were grown to early 
exponential phase (OD600= 0.15 to 0.3) in an orbital shaker at 37ºC. Cells were 
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harvested via centrifugation at 8,000 x g for 20 min and washed with 10 ml of ice-
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Table 2.1 Bacterial strains and plasmids used in this study. 
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Figure 2.1 Vector map of the pGEX-6p-1 vector. The MCS is linked to the 3’ 
end of the gene encoding for glutathione S-transferase (GST) and the nucleotide 
sequence encoding the recognition sequence for PreScission™ Protease. The GST 
domain can thus be cleaved from the fusion protein. A beta-lactamase gene that 







CHAPTER 2 MATERIALS AND METHODS 
___________________________________________________________________________________ 
_______________________________________________________________________________ 59
The supernatant was discarded and the cell pellet was resuspended in 10 ml of 0.1M 
CaCl2 and incubated on ice for 30 min. The cells were subsequently centrifuged for 20 
min at 8,000 x g. The supernatant was discarded and the cell pellet was resuspended 
in 5 ml of ice-cold 75mM CaCl2 containing 15% (v/v) glycerol. The cell suspension 
was aliquoted into 200 µl aliquots and immediately stored at -80ºC immediately. 
Competent cells were capable of retaining their optimal competency if used within a 
month. 
 
2.1.1.4 Transformation of chemically competent E. coli cells 
The frozen chemically competent E. coli cells to be transformed were allowed 
to thaw on ice. Approximately 50 to 100 ng of plasmid DNA were added to 200 µl of 
thawed competent cells and incubated on ice for 30 min. The cells were subjected to 
heat shock for 1 min at 42ºC. LB broth (800 µl) was then added and incubated for 90 
min at 37ºC in an orbital shaker rotating at 250 rpm. Aliquots of 100 µl of the 
transformed cells were plated on LB agar supplemented with the appropriate 
antibiotics and incubated overnight at 37ºC. 
 
2.1.2 Virus work 
2.1.2.1 EV71 strains 
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Table 2.2 Virus strains used in this study. 
EV71 Strains Subgenogroups GenBank Accession no. 
 






5865/Sin/000009 (Strain 41) B4 AF316321 
 
2933-Yamagata-03 B5 AB213648 
 
1585-Yamagata-01 C2 AB177812 
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2.1.2.2 Virus propagation 
A 75cm2 tissue culture flask (Nunc, USA) containing a 2 to 3 days old 
confluent Rhabdomyosarcoma (RD) cell monolayer was rinsed once with sterile 
phosphate buffered saline (PBS) and replaced with fresh minimal essential medium 
(MEM) growth media (Appendix II). A volume of 100 µl of virus suspension was 
added onto the monolayer. The flask was incubated at 37oC and observed for 
cytopathic effect (CPE) as a result of viral infection. Infected cells were seen to round 
up, showed shrinkage and marked nuclear pyknosis, became refractile, eventually 
degenerated and fell off the surface (Lennette, 1969). The culture supernatants were 
harvested, transferred to a new vial and kept at -20oC for short term storage and -80oC 
for long term storage. 
 
2.1.2.3 Purification and concentration of virus 
Approximately 500 ml of culture supernatants containing viruses were 
obtained and clarified of the cell debris by centrifugation at 10,000 x g for 20 min at 
4oC. The virions were precipitated by adding 2.3% (w/v) sodium chloride (Sigma 
Aldrich, USA), followed by 7% (w/v) polyethylene glycol 8000 (PEG8000) (Sigma 
Aldrich, USA) with constant stirring for 1 h at 4oC and stored overnight. The mixture 
was then centrifuged at 10,000 x g for 20 min at 4oC to collect the PEG-virus pellet. 
The supernatant was gently discarded and the pellet was resuspended with 5 ml of TN 
buffer (Appendix II). The pellet was dislodged by gentle pipetting and the suspension 
was subjected to centrifugation at 3,000 x g for 30 min at 4oC. The supernatant was 
collected and the virus was purified by loading the supernatant over 1 ml of 30% 
sucrose gradient cushion (Appendix II). The mixture was centrifuged at 25,000 x g for 
4 h at 4oC. The supernatant was gently discarded and the pellet was resuspended in 
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500 µl of PBS. The purified virus stock was kept at -20oC for short term storage or -
80oC for long term storage. Before use as an immunogen, the virus was inactivated by 
heating at 56oC for 30 min. The amount of viral protein was quantified by the 
Bradford method using the commercially available Bradford assay kit (Bio-Rad 
Laboratories, USA) according to the manufacturer’s instructions. 
 
2.1.2.4 50% Tissue culture infective dose (TCID50) assay 
The assay was carried out in RD cells using the Reed and Muench formula 
(Reed and Muench, 1938) as outlined in Appendix III. To assay the number of 
infectious virion in a purified virus stock, serial 10-fold dilutions of the stock virus 
suspension were carried out in a 96-well microtiter plate using MEM growth media as 
diluent. A monolayer of RD cells from a 75cm2 tissue culture flask was harvested 
upon trypsinization with 3 ml of trypsin-EDTA (Gibco, USA) and the addition of 
MEM growth media to obtain a final concentration of 1 x 103cells/µl. A volume of 50 
µl cell suspension was seeded into each well of a 96-well microtiter plate and 25 µl of 
each viral dilution were inoculated into appropriate wells in quadruplicates. The 
control wells contained RD cells without any virus. The plate was incubated at 37oC 
and observed daily for CPE up to 48 h. 
 
2.1.2.5 In vitro microneutralization assay 
The presence of neutralizing antibodies in human or mouse antisera was 
assayed in an in vitro microneutralization assay. Human or mouse immune serum 
samples were incubated for 30 min at 56oC to inactivate the complement. Briefly, 25 
µl of two-fold serial serum dilutions were mixed with equal volumes of 103 TCID50 of 
virus per well in triplicates in a 96-well microtiter plate. The virus-serum mixture was 
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incubated at 37oC for 2 h and 5 x 104 RD cells were then seeded in all wells. The plate 
was then incubated in a 37oC incubator with 5% CO2 for 2 days. The control well 
contained virus and cell suspension with no mouse serum. The neutralizing antibody 
titer was read as the highest dilution of the mouse serum that inhibited virus growth. 
 
2.2 Cell biology 
2.2.1 Mammalian cell line 
2.2.1.1 Regeneration and culture of Rhabdomyosarcoma (RD) cells  
A vial of RD cells stored in liquid nitrogen was immediately transferred to a 
37oC water bath. Once thawed, the cell suspension was transferred to a sterile 75cm2 
tissue culture flask containing MEM reviving media (Appendix II) in order to dilute 
the toxic effect of dimethylsulphoxide (DMSO) which was present in the preserving 
media. The cells were allowed to grow for about 1 to 2 days. When the cells were 
confluent, the reviving media was discarded and the cell monolayer was rinsed once 
with 10 ml PBS. Trypsin-EDTA (3 ml) was then added and incubated for 1 to 2 min 
at 37oC. The flask was tapped gently to detach the cell monolayer and 7 ml of the 
MEM growth media were added to dilute the trypsinized cells. The suspension of RD 
cells was split with a ratio of 1:4 to 1:6 for seeding in a 75cm2 tissue culture flask 
followed by incubation in a 37oC incubator with 5% CO2. 
 
2.2.1.2 Storage of RD cells 
A confluent monolayer of RD cells in a 75cm2 tissue culture flask was washed 
with PBS. The cell monolayer was then treated with 3 ml of trypsin-EDTA to detach 
the RD cells from the flask, followed by the addition of 7 ml MEM growth media. 
After centrifugation for 10 min at 300 x g, the supernatant was gently discarded and 
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the cell pellet was resuspended in 2 ml of MEM freezing media (Appendix II). The 
cell suspension was transferred into a freezing vial and kept at -20oC for a day before 
transferring to a -80oC freezer to ensure gradual freezing. After 2 days, the vial was 
transferred to liquid nitrogen for long term storage.  
 
2.2.2 T cell proliferation assay 
2.2.2.1 Isolation of peripheral blood mononuclear cells (PBMCs) 
Blood cells were subjected to separation by Ficoll-Hypaque (GE Healthcare 
Life Sciences, UK) gradient centrifugation for 40 min at 400 x g. The buffy coats 
separated by Ficoll were carefully transferred into a falcon tube and diluted up to a 
volume of 50 ml with PBS supplemented with 2mM EDTA (PBS/EDTA). The 
mixtures were centrifuged for 10 min at 300 x g. The supernatants were gently 
discarded and the cell pellets were resuspended with 50 ml of PBS/EDTA. The 
washing step was repeated with centrifugation for 10 min at 300 x g. For removal of 
platelets, the cell pellets were resuspended with 50 ml of PBS/EDTA and were 
centrifuged for 15 min at 200 x g. The washing step was repeated once. After 
washing, PBMCs were then counted using a haemocytometer. 
 
2.2.2.2 In vitro culturing and activation of dendritic cells (DCs) 
PBMCs were resuspended in 80 µl of PBS/EDTA per 107 total cells followed 
by incubation with 20 µl CD14 MicroBeads (Miltenyi Biotec Inc., USA) for 15 min at 
4oC. The suspension was centrifuged for 10 min at 300 x g and the pellet was 
resuspended up to 108 cells in 500 µl of PBS/EDTA, followed by magnetic separation 
using LS columns (Miltenyi Biotec Inc. USA) according to the manufacturer’s 
instructions. Briefly, cell suspensions were applied on top of the column and the 
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unbound cells were washed three times with 3 x 3 ml of column buffer (PBS/EDTA 
supplemented with 0.5% BSA). CD14+ cells were eluted with 5 ml of column buffer 
by firmly flushing out the positive fraction using the plunger supplied with the 
column. After elution, the cells were centrifuged for 10 min at 300 x g. The 
supernatant was then gently discarded and the cell pellet was resuspended with RPMI 
1640 media (Invitrogen, USA) supplemented with human interleukin 4 (IL-4) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (each at 20ng/ml) to 
generate immature DCs (imDCs). The cells were counted using a haemocytometer, 
seeded in 6-well plates with 106 cells per well and cultured for 7 days in a 37oC 
incubator with 5% CO2. To activate imDCs, the cells were stimulated with the 
indicated peptide at 5mM concentration in the presence of LPS (0.5µg/ml) for 1 day 
and incubated at 37oC with 5% CO2 before being used as antigen-presenting cells 
(APCs) in proliferation assays. When indicated, monoclonal anti-human MHC class II 
(HLA-DP, DQ & DR) antibodies (Ancell Co. USA) were also added at a final 
concentration of 20µg/ml. 
 
2.2.2.3 CD4+ T cell selection and proliferation 
The isolation of CD4+ T cells using CD4 MicroBeads (Miltenyi Biotec Inc. 
USA) was carried out as described in section 2.2.2.2. CD4+ T cells were resuspended 
in AIM-V® media (Invitrogen, USA) supplemented with 10% autologous serum and 
seeded in flat-bottomed 96-well plates with 105 cells per well in the presence or 
absence of 104 activated DCs. The cells were cultured for 7 days in an incubator at 
37oC with 5% CO2. The stimulator (DCs) to responder cells (CD4+ T cells) ratio was 
1:10. At 24 h prior to the end of incubation for the proliferation assay, the cells were 
pulsed with 0.5µCi of [methyl-3H] thymidine per well and incubated for 24 h in an 
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incubator at 37oC with 5% CO2. The cells were then harvested and counted on a liquid 
scintillation counter. The radioactivities of the proliferated CD4+ T cells were 
expressed as the mean counts per min (cpm) from triplicate determinations. The 
stimulation index (SI) was calculated as the mean counts of cell-associated [3H] 
thymidine per min recovered from wells containing activated DCs divided by the 
mean counts of the cell-associated [3H] thymidine per min recovered from wells 
containing imDCs. 
 
2.3 Molecular biology 
2.3.1 Design and synthesis of EV71-specific primers and probes 
The VP1 nucleotide sequences of EV71 strain 41 were analyzed. Using the 
BLAST algorithm (http://www.ncbi.nlm.nih.gov/BLAST) together with the 
DNASTAR program, highly conserved nucleotide sequences of the VP1 capsid 
protein were defined. For the real-time hybridization probe-based RT-PCR, two 
primers (namely EvVP1F and EvVP1R) and two hybridization probes (namely 
EvVP1_FL and EvVP1_LC) were designed (Table 2.3). For cloning recombinant 
GST-VP1 fusion protein, two primers (namely GST-VP1F and GST-VP1R) were 
designed (Table 2.3). A pair of oligonucleotide encoding the synthetic peptide SP32 
(nt280 to nt324 of VP1 ORF) were synthesized and they contain a pair of start and 
stop codons (TAA) at the 5′ and 3′ ends, respectively. A BamHI and SalI restriction 
site were designed at the 5′ and 3′ ends, respectively. For annealing, both 
oligonucleotides were heated for 3 min at 90oC, followed by incubation for 15 min at 
37oC. The annealed product was stored at -80oC for long term storage.  
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Table 2.3 Nucleotide sequences of EV71-specific primers and hybridization 
probes. 
 




GAG AGT TCT ATA GGG GAC AGT 
 




AGC TGT GCT ATG TGA ATT AGG AA 
 




GAT GAC TGC TCA CCT GTG TGT TTT 
GAC C-FL 
 




LC640-GCT GGC AGG GCC TGG GTA AGT 
GCC-P 
 




TGG ATC CGG AGA TAG AGT GGC AG 
 




GCC GAA GTC GAC TCA AAG GGT AG 
 
 
3347 to 3325 
 
a EvVP1-FL was labeled with fluorescein at the 3' end. 
a EvVP1-LC was labeled with LC Red 640 at the 5' end and phosphorylated at the 3' 
end. 
bGST-VP1F was designed with the BamH1 restriction site (underlined). 
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2.3.2 Design and synthesis of conjugated and unconjugated synthetic peptides 
A set of 95 overlapping synthetic peptides spanning the entire sequence of the 
VP1 capsid protein of enterovirus 71 strain 41 (5865/Sin/000009) was synthesized at 
Mimotopes Pty Ltd (Clayton Victoria, Australia). Each peptide contains 15 amino 
acid residues with 12 residues overlapping with the adjacent peptides. For the 
conjugated synthetic peptide, a cysteine residue was added to the C-terminal end 
which was chemically linked to the carrier protein, Diphtheria toxoid (DKP), through 
a linker, Maleimidocaproyl-N-Hydroxysuccinimide. Unconjugated synthetic peptides 
do not contain the cysteine residue at the C-terminal end and are not linked to DKP. 
For the human CD4+ T-cell epitope study, four peptides (SP1, SP2, SP3 and SP4) 
within the VP1 capsid protein which consist of 15 amino acid residues each were 
synthesized by Mimotopes Pty Ltd (Clayton, Victoria, Australia). Peptides were 
>90% in purity as assessed by high-performance liquid chromatography (HPLC) and 
were used without further purification. Approximately 1.7 mg of peptide was 
dissolved in 340 µl DMSO (Sigma Aldrich, USA) to yield a 5mM working 
concentration. 
 
2.3.3 RNA work 
2.3.3.1 Total RNA extraction 
Small intestines from mice were harvested and homogenized for total RNA 
extraction using the RNeasy extraction kit (Qiagen, USA) according to the 
manufacturer’s instructions. The extracted RNA was then analyzed for the presence of 
EV71 using real-time hybridization probe Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR) for the detection of EV71 RNA (Tan et al., 2006). 
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2.3.3.2 Viral genomic RNA extraction 
Viral genomic RNA extraction was carried out using the QIAamp® Viral 
RNA Mini Kit (Qiagen, USA) according to the manufacturer’s instructions. Briefly, 
the extraction was based on the selective binding properties of a silica-gel based 
membrane together with microspin technology to extract RNA from the virus. The 
viral samples were first lysed with a lysis buffer which aids in denaturing RNases. 
The viral genomic RNA was then bound to the membrane in the presence of the 
carrier RNA and absolute ethanol, followed by two washes with wash buffer to 
remove any contaminating proteins and lipids. The RNA was then eluted in 80 µl of 
elution buffer (RNase-free water containing 0.04% sodium azide). 
 
2.3.3.3 Conventional RT-PCR amplification 
The EV71 genomic RNA was first denatured for 10 min at 70oC in the 




















Total reaction volume 12.0 µl 
 
To the reaction mix, 0.5mM dNTP mix, 0.01M dithiothreitol, 1x first strand 
buffer and 10 U of Superscript II™ RNase H-reverse transcriptase (Life 
Technologies, USA) was added and the total volume was adjusted to 20 µl with 
ddH2O. Reverse transcription was carried out for 1 h at 42oC following which the 
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enzyme was heat-inactivated for 15 min at 70oC. The VP1 cDNA was then amplified 
































Total reaction volume 50.0 µl 
 
The reaction was carried out in a thermal cycler (GeneAmp® PCR system 
2400PE, Applied Biosystems, USA) for 35 cycles with the following parameters: 
denaturation for 1 min at 95oC; annealing for 30 s at 55oC; extension for 90 s at 72oC; 
followed by a final extension step for 10 min at 72oC. The double-stranded VP1 
cDNA was stored at -80oC for long term storage.  
 
2.3.3.4 Hybridization probe-based real-time RT-PCR 
Real-time RT-PCR analysis was carried out in the LightCycler from Roche 
Molecular Biochemicals, Germany. The real-time RT-PCR assay for the specific 
detection of EV71 strain 41 was carried out using the LightCycler RNA Amplification 
Hybridization Probe kit according to manufacturer’s instructions (Roche Molecular 
Biochemicals, Germany). Briefly, the test kit allows a one-step RT-PCR to be 
performed in glass capillaries using the LightCycler instrument. The enzyme mix 
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contained a mixture of reverse transcriptase and “Faststart” Taq Polymerase that 
allowed reverse transcription of RNA template and subsequent cDNA amplification. 
The reaction mix also contained reaction buffer, dNTP mix (dUTP instead of dTTP) 
and 30mM MgCl2. Each reaction was performed in a reaction capillary by mixing the 
reagents, followed by spinning down the mixture briefly with the help of a special 
LightCycler Centrifuge Adapter. The assay was carried out in a final reaction volume 




























LightCycler RNA Amplification Enzyme Mix 0.2 µl 
 








Final reaction volume 10.0 µl 
 
cDNA was synthesized from the RNA for 10 min at 95oC and amplification 
was carried out for 40 cycles using the following parameters: denaturation for 30 s at 
95oC; annealing for 15 s at 55oC; and extension for 9 s at 72oC. The temperature 
transition rates for all preceding steps were set at 20oC/sec for rapid thermal ramping. 
Melting curve analysis was also carried out after the PCR reaction. A rapid thermal 
ramping to 95oC was achieved for the complete denaturation of the PCR amplicons 
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following hybridization for 10 s at 60oC. A slow steady transition from 60oC to 95oC 
was then performed. Subsequently, a graph was plotted using –dF/dT against 
temperature which would show a curve peak, corresponding to the melting 
temperature (Tm) of the PCR amplicons. 
 
2.3.4 DNA work 
2.3.4.1 Isolation of plasmid DNA 
The method employed for plasmid DNA isolation is governed by the nature of 
its subsequent manipulation. The modified alkaline lysis method of Birnbolm and 
Doly (1979) and the modified boiling method of Holmes and Quigley (1981) were 
routinely used for primary screening of recombinant clones. For DNA sequencing or 
molecular manipulations such as cloning, the plasmid DNA has to be of high purity as 
a template. Hence, a commercial plasmid mini-prep kit, Wizard™ SV Miniprep DNA 
purification Kit (Promega, USA) was used instead. 
 
2.3.4.1.1 Preparation of plasmids by the modified alkaline lysis method of 
Birnbolm and Doly (1979) 
A 1.5 ml overnight bacterial culture was harvested by centrifugation for 3 min 
at 8,000 x g and the cell pellet was resuspended in 200 µl of Solution I (50mM 
glucose, 50mM Tris-HCl and 10mM EDTA, pH 8.0 containing 5mg/ml lysozyme) in 
a clean eppendorf tube. For cell lysis, 400 µl of Solution II (0.2M NaOH containing 
1% SDS) were added and the contents were gently mixed by inversion until a clear 
solution was obtained.  The sample was then incubated for 10 min at room 
temperature before adding 300 µl of ice-cold 3M sodium acetate (pH 4.8). The sample 
was gently mixed by inversion, incubated for 10 min at 4oC and then subjected to 
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centrifugation for 10 min at 8,000 x g. The supernatant was transferred to a fresh 
eppendorf tube and one volume of phenol saturated with TE Buffer (10mM Tris-Cl 
and 1mM EDTA, pH 8.0) was added and mixed thoroughly. After centrifugation for 
10 min at 8,000 x g, the upper aqueous phase was collected. DNA precipitation was 
carried out by adding 2 volumes of ice-cold absolute ethanol and incubating the 
mixture for 2 h at -20°C. The DNA pellet was recovered by centrifugation for 15 min 
at 8,000 x g, washed once with ice-cold 75% ethanol, air-dried and then resuspended 
in 50 µl of DNase-free TE Buffer containing 10µg/ml RNase. 
 
2.3.4.1.2 Preparation of plasmids by the modified boiling method of Holmes 
and Quigley (1981) 
A 1.5 ml overnight bacterial culture was harvested by centrifugation for 3 min 
at 8,000 x g and the cell pellet was resuspended in 100 µl of STET buffer containing 
10 µl of a freshly-prepared lysozyme solution (10mM Tris-HCl containing 10mg/ml 
lysozyme, pH 8.0). The mixture was incubated for 5 min at room temperature and 
then boiled for 45 s. The cellular debris was removed by centrifugation for 15 min at 
8,000 x g. The plasmid DNA in the supernatant was precipitated with 10 µl of ice-
cold 3M sodium acetate and 200 µl of ice-cold absolute ethanol. The precipitated 
DNA was recovered by centrifugation for 15 min at 8,000 x g and the DNA pellet was 
washed once with ice-cold 70% ethanol and air-dried. The pellet was finally 
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2.3.4.1.3 Plasmid purification using the Wizard™ SV Miniprep DNA 
Purification Kit (Promega, USA) 
The Wizard ™ SV Miniprep DNA Purification Kit was routinely employed 
for small scale isolation of plasmid DNA. The method employed was essentially 
based on the alkaline lysis method with an additional column purification step. The 
column contains an anion exchange resin that allows the negatively-charged plasmid 
to bind to the resin whilst contaminating proteins are flushed away by the application 
of a wash buffer. The isolation of plasmid DNA was carried out according to the 
manufacturer’s instructions. Briefly, a 5 ml overnight bacterial culture was 
centrifuged for 5 min at 8,000 x g and the cell pellet was resuspended in Cell 
Resuspension Solution™. The suspension was subsequently clarified by the addition 
of 250 µl of Lysis Solution™ and incubated for 5 min with 10 µl of alkaline protease. 
The cleared lysate was then neutralized with 350 µl of Neutralization Solution™. The 
resulting precipitate containing proteins and cellular debris were removed by 
centrifugation for 10 min at 8,000 x g and the supernatant applied to the DNA binding 
column. The resin-bound plasmid DNA was washed twice with an ethanol-based 
wash solution (750 and 250 µl, respectively). The purified plasmid DNA was eluted 
from the column by the addition of 100 µl of pre-warmed TE buffer and 
centrifugation for 2 min at 8,000 x g. 
 
2.3.4.2 Restriction endonuclease digestion of DNA 
Digestion of DNA was carried out with restriction enzymes (New England 
Biolabs, USA) according to the manufacturer’s instructions. Briefly, the reaction was 
carried out in an eppendorf tube containing 1 to 2 µg of DNA, restriction enzyme(s) 
in the corresponding 1x digestion buffer. BSA was added according to the 
CHAPTER 2 MATERIALS AND METHODS 
___________________________________________________________________________________ 
_______________________________________________________________________________ 75
recommendations of the manufacturer. All reactions were incubated for at least 1 h at 
optimal temperatures specified by the manufacturer. 
 
2.3.4.3 Agarose gel electrophoresis of DNA 
DNA fragments were screened by horizontal gel electrophoresis using varying 
percentage of agarose (Sigma Aldrich, USA). For screening of recombinant clones 
and restriction mapping, the agarose gels were prepared in TBE buffer (45mM Tris, 
45mM Boric acid and 1.0mM EDTA, pH8.0). When the DNA restriction fragments or 
PCR products were needed for cloning, electrophoresis was performed in low melting 
point agarose (Sigma Aldrich, USA) prepared in TAE buffer (40mM Tris-acetate, 
1mM EDTA, pH 7.9). DNA products were mixed with a gel loading buffer (0.25% 
bromophenol blue and 40% w/v sucrose in water) and loaded into the wells. The size 
of each DNA fragment in the gel was estimated by comparison with standard DNA 
ladders (MBI Fermentas GeneRuler®, UK). Electrophoresis was carried out at 100 V 
and the gels were stained with a 0.5µg/ml ethidium bromide for 20 min before 
visualizing the DNA bands under UV illumination. 
 
2.3.4.4 Purification of DNA using the GFX™ Purification kit (GE Healthcare 
Life Sciences, UK) 
Digested DNA fragments were purified by the GFX™ Purifcation kit 
according to the manufacturer’s instructions. Briefly, the desired DNA fragments 
were carefully excised from the low melting point agarose gel. An aliquot (10 µl) of 
the Capture Buffer™ was added for every 10 mg of gel (up to a maximum 300 mg). 
The mixture was incubated for 15 min at 55ºC. For DNA purification from solution, a 
volume of approximately 50 to 100 µl PCR product was added to 500 µl of Capture 
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buffer™ instead. The mixture was passed through a column containing DNA-binding 
resin by centrifugation for 30 s at 8,000 x g. The column was then washed once with 
500 µl of Wash Buffer™. DNA was eluted from the column using 40 µl of TE buffer. 
 
2.3.4.5 DNA Ligation 
Reactions were carried out using T4 DNA ligase (New England Biolabs, 
USA) and the LigaFast™ Rapid DNA Ligation System (Promega, USA) according to 
the manufacturer’s instructions. Briefly, 1 µl of the digested plasmid vector and 3 µl 
of the digested insert DNA (in a molar ratio of 1:3) were added to 1 µl of T4 DNA 
ligase, 10 µl of 2x ligation buffer and 5 µl of ddH2O to a total reaction volume of 20 
µl. The ligation mixture was incubated for 5 min at room temperature before being 
used for transformation. 
 
2.3.4.6 DNA automated cycle sequencing 
Automated cycle sequencing was carried out using the Perkin Elmer Applied 
Biosystems BigDye Terminator Cycle Sequencing Ready Reaction kit (Perkin Elmer 
Applied Biosystems, USA). The kit contained the BigDye Terminator Ready Reaction 
Mix which was consisted of the A,C,G,T-dye terminators, dITP, dATP, dTTP, dCTP, 
Tris-HCl (pH 9.0), MgCl2 and AmpliTaq DNA polymerase FS. DNA Polymerase FS 
is a mutant form of Taq DNA polymerase which does not posses 5′→3′ nuclease 
activity and has a reduced discrimination for dideoxynucleotides, thereby permitting 
the use of lower level of dye-labeled terminators in the reaction. The dNTPs mix 
includes dITP in place of dGTP to minimize band compressions. Each sequencing 
reaction was carried out in a final reaction volume of 20 µl that comprised the 
following constituents: 

























Total reaction volume 20.0 µl 
 
The cycle sequencing reaction was carried out in the GeneAmp PCR system 
2400 Thermal Cycler (Perkin Elmer Applied Biosystems, USA). The sequencing 
reaction was carried out for 25 cycles using the following parameters: denaturation for 
30 s at 96ºC; annealing for 5 s at 50ºC; and extension for 4 min at 60ºC. 
Unincorporated dye terminators were removed by precipitating the DNA from the 
sequencing reaction with 2.5 volumes of ice-cold absolute ethanol and 0.1 volume of 
3M sodium acetate for 2 h at -20ºC. The DNA was recovered via centrifugation for 20 
min at 8,000 x g. The pellet was subsequently washed with 70% ice-cold ethanol and 
air dried. Automated sequencing of the DNA was carried out at the Clinical Research 
Centre Sequencing Laboratory, National University of Singapore. 
 
2.4 Biochemistry 
2.4.1 Denaturing PAGE 
2.4.1.1 Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was carried out using a vertical slab gel unit (Mini-Protean III 
Cell) (Bio-Rad Laboratories, USA) according to the manufacturer’s instructions. The 
slab gel (8.3cm X 7.3cm X 0.75mm) was made up of a 12% (w/v) polyacrylamide 
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separating gel (Appendix IV) and a 5% (w/v) polyacrylamide stacking gel (Appendix 
IV). Briefly, the separating gel was casted between two grease-free glass plates. The 
gel mixture was poured up to 1.5 cm below the bottom of the comb. Ethanol (70%) 
was then carefully layered over the gel mixture to ensure the formation of a straight 
meniscus and to prevent inhibition of gel polymerization by oxygen present in the air. 
The gel was allowed to polymerize for 45 min at room temperature. Thereafter, the 
ethanol was discarded and with the comb in position, the stacking gel mixture was 
layered over the separating gel. This was allowed to polymerize for 30 min at room 
temperature before the comb was removed and the wells were flushed with the SDS 
running buffer (Appendix IV). An aliquot of 20 μl of the protein sample (10 µg total 
protein) was prepared for electrophoresis by boiling for 5 min with 6 µl of the SDS 
gel loading dye (Appendix IV). The Precision Plus™ protein standards (Bio-Rad 
Laboratories, USA) with defined molecular weights were used as markers. 
Electrophoresis was carried out using a constant current of 80 to 120 V for 2 to 3 h at 
room temperature until the loading dye reached the bottom of the gel and the markers 
were well separated. 
 
2.4.1.2 Staining of polyacrylamide gels 
After the protein samples were separated by electrophoresis, the gels were 
soaked in a SDS staining solution (Appendix IV) for 1 h with constant shaking. 
Stained gels were soaked in a SDS destaining solution (Appendix IV) for 2 h with 
constant shaking or until protein bands could be visualized as sharp blue bands 
against a clear background. This was followed by a 1 h of final destaining step in 
distilled water. The protein gel was dried by placing it in between an appropriately 
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sized sheet of 3M Whatman™ filter paper in a Bio-Rad Gel Dryer (Bio-Rad 
Laboratories, USA) for 2 h at 80ºC. 
 
2.4.2 Western blot analysis 
2.4.2.1 Electrophoretic transfer of proteins 
The resolved protein bands in the SDS-PAGE gels were electro-blotted onto a 
pre-cut nitrocellulose membrane (Bio-Rad Laboratories, USA) using a Bio-Rad Mini 
Blot Cell (Bio-Rad Laboratories, USA). The polyacrylamide gel was equilibrated in 
the Western transfer buffer (Appendix V) for 30 min prior to the transfer. To facilitate 
the transfer, the nitrocellulose membrane was presoaked in the transfer buffer as well. 
After equilibration, the transblotting sandwich was assembled and the protein bands 
were transferred either overnight at a constant voltage of 30 V for 1 h at 4ºC or at a 
constant voltage of 100 V for 1 h at room temperature. 
 
2.4.2.2 Immunogenic development of Western blots 
The transferred nitrocellulose membrane was soaked in the Western blocking 
buffer (Appendix V) for 1 h at room temperature before incubation with the mouse or 
human immune sera at 1:50 dilution for 1 h at room temperature followed by three 
washes with the Western washing buffer (Appendix V). Detection was carried out 
using a alkaline phosphatase (AP)-conjugated goat anti-mouse IgG (H + L) secondary 
antibody from the WesternBreeze® chromogenic immunodetection system 
(Invitrogen, USA) or horseradish peroxidase (HRP)-conjugated goat anti-human IgG 
antibody (GE Healthcare Life Sciences, UK) according to the manufacturer’s 
instructions. Briefly, the membrane was incubated with the secondary antibody for 1 h 
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at room temperature, followed by three washes with the washing buffer. The reaction 
was visualized with the addition of the chromogenic substrate. 
 
2.4.3 Expression and analysis of recombinant GST-tagged fusion proteins 
2.4.3.1 Growth and induction of bacteria 
A freshly grown single colony of E. coli strain carrying the recombinant GST-
fusion protein was used to inoculate 10 ml of LB broth and grown overnight at 37ºC. 
An aliquot of 10 ml of this pre-culture was used to inoculate a 100 ml flask containing 
LB broth supplemented with the appropriate antibiotics. The culture was allowed to 
grow under the same conditions until it reached an OD600 of 0.5 to 0.6. The inducer, 
Isopropylthio-β-D-galactoside (IPTG) was added to the culture to a final 
concentration of 1mM for expression studies. The culture was allowed to grow for 
another 4 h. The bacterial cultures were harvested by centrifugation for 20 min at 
8,000 x g. The supernatants were gently discarded and the cell pellets resuspended in 
2 ml of PBS. The cell pellets were used immediately or stored at -80ºC until used. 
 
2.4.3.2 Preparation of cell extracts 
The bacterial cell suspensions were sonicated using a 1/8 inch probe in a 
MSE-Soniprep-150 Sanyo GallenKamp ultrasonic disintegrator (Leicester, UK). 
Sonication was performed for 10 cycles comprising pulses for 15 s interspersed with 
20 s of cooling intervals. Throughout the sonication process, cell suspensions were 
maintained at a low temperature by the use of ice-alcohol slurry. Bacterial cell wall 
debris as well as insoluble inclusion bodies were separated from the soluble fraction 
by centrifugation for 20 min at 8,000 x g. The supernatants which consisted of the 
soluble crude cell extracts were kept on ice until used. 
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2.4.3.3 Purification of recombinant GST-tagged fusion proteins 
2.4.3.3.1 MicroSpin™ GST Purification kit (GE Healthcare Life Sciences, UK) 
Fusion proteins are recovered from the matrix under mild elution conditions, 
incorporating 10mM glutathione in the elution buffer which preserves protein 
antigenicity and function according to the manufacturer’s instructions. Briefly, the 
resin in the Glutathione Sepharose™ 4B MicroSpin column was gently mixed by 
vortexing. The columns were spun down to discard the storage buffer before use. 
Approximately 600 µl of protein samples was added to the column and incubated for 
10 min at room temperature in order to ensure optimal binding of GST proteins to the 
Glutathione Sepharose matrix. The flow through was collected via centrifugation for 1 
min at 800 x g. The column was washed with 250 to 600 µl of PBS and the spin 
column was centrifuged for 1 min at 800 x g after each wash. Glutathione elution 
buffer (150 µl) was added to the column and incubated at room temperature for 10 
min. Eluents were collected by centrifugation for 1 min at 800 x g and stored at -80oC 
until used. 
 
2.4.3.3.2 GSTrap™ Fast Flow column kit (GE Healthcare Life Sciences, UK) 
The GSTrap™ Fast Flow column (1 ml) provides rapid and mild purification 
of GST-tagged fusion proteins to >90% purity in a single affinity purification step. 
Glutathione Sepharose™ Fast Flow column is designed for the purification of 
glutathione S-transferases and glutathione binding proteins. The fusion proteins were 
eluted under mild, non-denaturing conditions. The glutathione ligand was coupled via 
a 10-carbon linker to highly cross-linked 4% agarose. The coupling was optimized to 
give high binding capacity for GST-tagged fusion proteins and other glutathione 
binding proteins. Briefly, the column was equilibrated with 5 column volumes of 
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binding buffer (140mM NaCl, 2.7mM KCl, 10mM Na2HPO4, and 1.8mM KH2PO4, 
pH 7.3) Samples were applied using a syringe fitted to the luer adaptor with a flow 
rate of 0.2 to 1 ml/min during sample application. Approximately 5 column volumes 
of the binding buffer were loaded into the column for washing. The proteins were 
then eluted with 5 column volumes of elution buffer (50mM Tris-HCl, 10mM reduced 
glutathione, pH 8.0) and stored at -80oC until used. 
 
2.4.3.4 Bradford assay 
Protein concentrations were determined by the Bradford assay (Bio-Rad 
Laboratories, USA) according to the manufacturer’s instructions. The absorbance of 
the reaction mixture was measured at 595nm after 8 min of incubation at 23ºC. 
Bovine serum albumin (BSA) (Sigma Aldrich, USA) was used as the standard within 
the range from 1 to 10µg/µl. 
 
2.4.4 Enzyme-linked Immunosorbent Assay (ELISA) 
2.4.4.1 Detection of specific mouse or human IgG antibodies 
The 96-well microtiter plates were coated overnight at 4oC with 50 µl of 0.1M 
carbonate buffer (pH 9.6) containing 10µg/ml of synthetic peptide or purified whole 
EV71 strain 41. After blocking with 2% BSA, plates were incubated with 50 µl of 
mouse or human immune sera at 1:50 dilution for 1 h at 37oC and then washed three 
times with PBS containing 0.1% Tween 20 (PBS-T) (Sigma-Aldrich, USA). 
Detection was carried out using horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG (H+L) (Bio-Rad Laboratories, USA) or HRP goat anti-human IgG (H+L) 
secondary antibodies (GE Healthcare Life Sciences, UK) at 1:3000 and 1:6000 
dilutions, respectively. After 1 h incubation at 37oC and three washes with PBS-T. 
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The reaction was revealed by the addition of the o-Phenylenediamine dihydrochloride 
(OPD) substrate (Sigma Aldrich, USA) and the reaction was stopped after 30 min 
using 1M H2SO4. The absorbance at 490nm was measured by an ELISA plate reader 
(Tecan Sunrise, USA). 
 
2.4.4.2 IgG-subtying 
The profiles of specific IgG subtypes in the mice hyperimmune sera were 
determined by a commercially available mouse sub-type isotyping kit (Zymed 
Laboratories Inc., USA) according to the manufacturer’s instructions by using 
10µg/ml of the purified virion to coat the 96-well microtiter plates as described in 
section 2.4.4.1. In brief, this assay contains a complete set of ELISA reagents 
primarily designed for screening and determining the class and subclass of mouse 
antibodies. It is based on strepavidin-biotin amplification (LAB-SA) system and is 
coupled to horseradish peroxidase to serve as the signal generating reagent. 
 
2.4.5 Cytokine analysis 
Cytokines present in mouse serum samples or CD4+ T-cell culture 
supernatants were measured using the Bio-PlexTM suspension array system (Bio-Rad 
Laboratories, USA) according to the manufacturer’s instructions. Briefly, the 
multiplex suspension bead array immunoassay was performed using the mouse 4-Plex 
kit to specifically evaluate IL-6, IL-10, TNF-α and IFN-γ or the human 6-Plex kit to 
specifically evaluate cytokines of Th1- (IL-2, TNF-α, IFN-γ) and Th2- (IL-4, IL-6, 
IL-10) type subsets. Briefly, the Bio-PlexTM cytokine assays are designed in a capture 
sandwich immunoassay format. Antibody specifically directed against the cytokine of 
interest is covalently coupled to color-coded 5.6 μm polystyrene beads and the 
CHAPTER 2 MATERIALS AND METHODS 
___________________________________________________________________________________ 
_______________________________________________________________________________ 84
antibody-coupled beads are allowed to react with the sample. After performing a 
series of washes to remove unbound protein, a biotinylated detection antibody specific 
for a different epitope on the cytokine is added and the result is the formation of a 
sandwich of antibodies around the cytokine. The reaction mixture is then detected by 
the addition of streptavidin-phycoerythrin (streptavidin-PE), which binds to the 
biotinylated detection antibodies. 
 
2.4.6 Immunohistochemical analysis 
Cryosection of intestinal tissue with a thickness of 4 µm were made from the 
frozen tissue and fixed on Poly-L-lysine glass slide. Permeabilization of the fixed 
tissue section was carried out by incubation with 0.2% Triton (Sigma Aldrich, USA) 
for 10 min, followed by incubation with the mouse anti-EV71 monoclonal antibody 
(Chemicon International, USA) for 30 min at room temperature. The slide was 
washed three times with PBS, followed by incubation with biotinylated goat anti-
mouse IgG secondary antibodies (Zymed Laboratories, USA) for 30 min at room 
temperature. The reaction was visualized by the addition of aminoethyl carbazole 
substrate (Zymed Laboratories, USA) to give a red colored peroxidase stain and the 
slide was counterstained with haematoxylin (Zymed Laboratories, USA) to generate a 
blue background according to the manufacturer’s instructions. 
 
2.4.7 HLA-DR typing 
Blood samples from volunteers of both sexes, 25 to 31 years of age, were 
collected in tubes containing 4% sodium citrate as anti-coagulant. Genomic and 
serological typing was performed by WHO Immunology and Training Research 
Centre, Singapore as a kind gift from its director, Professor Chan SH. 
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2.5 In vivo work 
2.5.1 Immunization of mice 
Inbred Balb/c mice were purchased from the Centre for Animal Resources of 
the National University of Singapore. All institutional guidelines for animal care and 
use were strictly followed throughout this study. Groups of 5 adult (6 weeks old) 
female Balb/c mice were intraperitoneally immunized with either 50 µg of synthetic 
peptides conjugated to the Diphtheria toxoid or the heat-inactivated EV71 strain 41 
(10 µg total protein) in a 50% emulsion of Freund’s complete adjuvant (Sigma 
Aldrich, USA). Two booster doses in 50% emulsion with Freund’s incomplete 
adjuvant (Sigma Aldrich, USA) were given at 3 weeks intervals. The volume of each 
vaccine suspension administered was 400 µl. The immune sera were collected 7 days 
after the last immunization. Sera containing EV71-neutralizing antibodies were 
pooled and stored at -80oC until use. 
 
2.5.2 EV71 lethal challenges 
Groups of 6 mice at different age groups, ranging from one-day-old to two-
weeks-old were inoculated intraperitoneally with 100 µl of EV71 strain 41 (103 
TCID50). In another experiment, groups of 6 mice at day 1 after birth were given 
different doses of EV71 strain 41 (ranging from 1 TCID50 to 103 TCID50 per mouse) 
via the intraperitoneal route. Mice in the control group were given 100 µl of PBS. 
Mice were monitored daily for body weight gain/loss and the occurrence of mortality 
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2.5.3 Protection studies 
2.5.3.1 Protection afforded by maternal-transferred antibodies 
The immunized female adult mice as described in section 2.1.4 were allowed 
to breed at 2 weeks after the last immunization. One-day-old suckling mice born to 
immunized dams were inoculated with 100 µl of virus (103 TCID50) per mouse via the 
intraperitoneal route. Suckling mice in the control group were injected 
intraperitoneally with 100 µl of PBS. All suckling mice were monitored daily for 
body weight gain/loss and the occurrence of mortality up to day 21 post infection as 
the experimental endpoint. 
 
2.5.3.2 Passive protection afforded by mice immune sera 
Groups of 6 mice at day 1 after birth were injected intraperitoneally with a 
lethal dose of EV71 (103 TCID50 per mouse). One day after the viral challenge, 
suckling mice were injected intraperitoneally with mice immune sera containing 
different titers of EV71-neutralizing antibodies. Suckling mice in the control groups 
were either injected intraperitoneally with the naive sera containing no EV71-
neutralizing antibody or not injected with any antisera. All suckling mice were 
monitored daily for body weight gain/loss and the occurrence of mortality up to day 
21 post infection as the experimental endpoint. 
 
2.5.4 Harvesting of mouse organs 
The dead mice were cleaned with 70% ethanol, secured and bellied down onto 
a dissecting board. The abdomen was dissected open and the small intestine was 
aseptically harvested in MEM for total RNA extraction using the RNeasy extraction 
kit (section 2.3.3.1) or subjected to immunohistochemical analysis (section 2.4.6). 
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2.5.5 Human serum specimens 
Serum samples were collected from children attending a pediatric outpatient 
clinic at the National University Hospital of Singapore. All sera were screened for the 
presence of neutralizing antibodies against EV71 strain 41 using the in vitro 
microneutralization assay (section 2.1.2.6). A serum neutralizing antibody titer of 1:8 
and above was used as an indicator of previous EV71 exposure. 
 
2.6 Computational analysis 
2.6.1 Hydrophobic profile and BLAST search 
The protein sequence of VP1 was analyzed for hydrophobic and hydrophilic 
regions using the Kyte and Doolittle method. The amino acid sequences of the 
synthetic peptides were used as query sequences in a protein-protein BLAST (blastp 
2.2.17) search using the National Center for Biotechnology Information database 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi?CMD=Web&PAGE_TYPE=BlastHome
). Alignment of the amino acid sequences was also undertaken by using the Clustal 
method of DNASTAR MegAlign. 
 
2.6.2 T-cell epitope prediction 
The VP1 amino acid sequence of EV71 strain 41 was used as a protein 
candidate to identify promiscuous human CD4+ T-cell epitope(s) based on the 
ProPred prediction software (http://www.imtech.res.in/raghava/propred). This server 
is useful in identifying promiscuous binding regions which are able to bind to a total 
of 51 alleles belonging to 9 serologically defined HLA-DR molecules that are 
encoded by DRB1 and DRB5 genes. The quantitative matrices used in this prediction 
method include HLA-DR1 (2 alleles), HLA-DR3 (7 alleles), HLA-DR4 (9 alleles), 
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HLA-DR7 (2 alleles), HLA-DR8 (6 alleles), HLA-DR11 (9 alleles), HLA-DR13 (11 
alleles), HLA-DR15 (3 alleles) and HLA-DR51 (2 alleles). The server analyzed the 
VP1 sequence using each of the alleles independently and computed the binding 
strength of all the peptides. The prediction threshold was set at 3% and peptides 
predicted to bind at least 50% of the major histocompatibility complex (MHC) class II 
molecules were considered promiscuous for binding. 
 
2.7 Statistical analysis 
The results were analyzed using the unpaired Student t test. Differences were 
considered significant at a P value of <0.05. 
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CHAPTER 3 IDENTIFICATION OF NEUTRALIZING LINEAR 
EPITOPES FROM THE VP1 CAPSID PROTEIN OF 
ENTEROVIRUS 71 USING SYNTHETIC PEPTIDES 
 
3.1 Introduction 
EV71 is one of the main etiological agents of Hand, foot, and mouth disease 
(HFMD) and has been associated to neurological complications with various clinical 
severities (Hagiwara et al., 1978). Currently, the only means of preventing and 
controlling the spread of EV71 during outbreaks is by public health surveillance and 
quarantine. A number of promising antiviral agents with activity against enteroviruses 
are still undergoing clinical trials. However, one major obstacle to the successful use 
of any antiviral agents in EV71-associated encephalitis is that patients may have 
already suffered irreversible brain damage due to the high viral load at the time of 
treatment. Therefore, although the antiviral agent may have high level of activity 
against EV71, it is unlikely that much clinical improvement can be expected after 
treatment. Consequently, major research efforts are needed to emphasize on the 
prevention of EV71 infection instead of treatment and this can be carried out via the 
development of effective vaccines.  
 
Previous studies have focused and shown that VP1 to be highly immunogenic 
and contained neutralizing epitope(s) as compared to the other capsid proteins of 
EV71 (Chen et al., 2006; Chiu et al., 2006; Wu et al., 2001). Although there may also 
be regions along VP2, VP3 or VP4 that are able to elicit neutralizing antibodies 
against EV71 but these are yet to be identified. Hence, this study focused on the 
identification and characterization of linear neutralizing epitopes within VP1. 
Synthetic peptides are considered promising candidates for new-generation vaccines 
as large quantities of peptides can be chemically synthesized readily and safely. 
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Peptide vaccines containing neutralizing epitope(s) are capable of inducing specific 
antibodies that can inhibit the interaction between the viral capsid protein and its 
cellular receptor thereby preventing virus entry. In this study, characterization of the 
linear neutralizing epitopes on the VP1 capsid protein of the Enterovirus 71 strain 41 
(5865/SIN/00009) (belonging to subgenogroup B4 as the homologous EV71 strain 
and isolated from a fatal case) was undertaken. Balb/c mice antisera were raised 
against 95 diphtheria toxoid-conjugated synthetic peptides spanning the entire VP1 
region and their neutralizing abilities of the antisera were tested in in vitro 
microneutralization assay. Synthetic peptides, designated SP55 and SP70, were 
successfully reported to elicit high titers of neutralizing antibody against EV71. The 
in vivo protective potential of SP70 was compared to that of the heat-inactivated 
homologous EV71 whole virion and to synthetic peptide SP12 which represents an 
immunogenic but non-neutralizing VP1 linear epitope. Finally, the ability of anti-
SP70 antibodies to confer in vivo passive protection against heterologous EV71 















3.2.1 Identification of EV71-neutralizing antisera from mice immunized with 
synthetic peptides (preliminary study) 
A set of 95 overlapping diphtheria toxoid-conjugated synthetic peptides 
spanning the entire VP1 capsid protein of EV71 strain 41 were individually injected 
into groups of 2 female Balb/c mice via intraperitoneal route. Synthetic peptides were 
administered over 3 doses with Freund’s adjuvant at 3 weeks-interval between each 
dose. Each peptide consists of 15 amino acids in length with 12 residues overlapping 
with the adjacent peptides. The specific IgG antibody titers were determined by 
ELISA for all antisera raised against individual synthetic peptide. At the same time, 
the antisera were analyzed in in vitro microneutralization assay using 
Rhabdomyosarcoma (RD) cells infected with a viral dose of 103 TCID50 of EV71 
strain 41. Two distinct antisera, obtained from mice immunized with synthetic 
peptides SP55 (VP1 amino acid residues 162 to 177) and SP70 (VP1 amino acid 
residues 208 to 222), showed significant neutralizing activities against the 
homologous EV71 strain. 
 
3.2.2 EV71-neutralizing antisera from mice immunized with SP55, SP70 or 
heat-inactivated homologous EV71 whole virion  
To confirm the preliminary results obtained from the screening described in 
section 3.2.1, groups of 5 female Balb/c mice were immunized intraperitoneally with 
either the conjugated synthetic peptides SP55, SP70, SP12 or the heat-inactivated 
homologous EV71 strain 41, where SP12 (VP1 amino acid residues 34 to 48) and the 
EV71 whole virion represented negative and positive control groups, respectively. 
The neutralizing activities of individual antiserum obtained from the SP55-, SP70-, 
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SP12- or heat-inactivated EV71-immunized mice were determined by in vitro 
microneutralization assay. The infectivity of the homologous EV71 strain 41 was 
observed over a period of 48 hours (Figure 3.1). The anti-EV71 immune serum 
allowed a complete protection from cytopathic effect (CPE) at serum dilutions up to 
1:64 (Figure 3.2). As expected, antisera from the naive and SP12-immunized mice did 
not confer any protection to RD cells from CPE. Complete protection of RD cells 
from CPE was observed with dilutions ranging from neat to 1:32 of the antiserum 
from the SP70-immunized mice (Figure 3.3). The antiserum from the SP55-
immunized mice also showed a neutralizing activity with complete protection from 
CPE at serum dilutions from neat to 1:8 (Figure 3.4). These data demonstrate that the 
immune sera obtained from the SP70- and, to a lesser extent, the SP55-immunized 
mice contain neutralizing antibodies against the homologous EV71 strain 41 which 
suggests that neutralizing VP1 linear epitopes are present in both synthetic peptides 

































Figure 3.1 Infection of RD cells with a viral dose of 103 TCID50 EV71 strain 41. 
(A) Monolayer of RD cells at 4 h post infection. (B) RD cells showing signs of CPE 
at 16 h post infection. (C) 50% of RD cells rounded up, showed shrinkage and 
marked nuclear pyknosis at 28 h post infection. (D) RD cells became refractile and 
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Figure 3.2 In vitro microneutralization assay using a representative serum 
sample from mice (n=5) immunized with the heat-inactivated homologous EV71 
whole virion. RD cells were infected with 103 TCID50 EV71 pre-incubated with 
various dilutions of the anti-EV71 immune serum. Survival of cells was observed 
with neat serum (A); serum dilution of 1:8 (B); serum dilution of 1:16 (C); serum 
dilution of 1:32 (D); serum dilution of 1:64 (E). Moderate CPE of approximately 50% 






































Figure 3.3 In vitro microneutralization assay using a representative serum 
sample from mice (n=5) immunized with the synthetic peptide SP70. RD cells 
were infected with 103 TCID50 EV71 pre-incubated with various dilutions of the anti-
SP70 immune serum. Survival of cells was observed with neat serum (A); serum 
dilution of 1:8 (B); serum dilution of 1:16 (C); serum dilution of 1:32 (D). Moderate 
CPE of approximately 50% was observed with serum dilution of 1:64 (E) whereas 




































Figure 3.4 In vitro microneutralization assay using a representative serum 
sample from mice (n=5) immunized with the synthetic peptide SP55. RD cells 
were infected with 103 TCID50 EV71 pre-incubated with various dilutions of the anti-
SP55 immune serum. Survival of cells was observed with neat serum (A); serum 
dilution of 1:8 (B); serum dilution of 1:16 (C). CPE was observed with serum dilution 
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3.2.3 Immunoreactivity of antisera from mice immunized with SP12, SP55 or 
SP70 
Based on in vitro microneutralization assay, it was described in section 3.2.2 
that individual immune serum obtained from groups of SP55-, SP70- or SP12-
immunized mice had similar neutralizing antibody titer against the homologous EV71 
strain within respective groups and hence the immune serum samples from individual 
mouse within each group were pooled into anti-SP55 antisera, anti-SP70 antisera or 
anti-SP12 antisera, respectively. The immunoreactivity of the pooled antisera was 
assayed against EV71 total proteins by Western blot analysis. For each set of pooled 
antisera tested, a single band was revealed at an apparent molecular weight (MW) of 
32kDa (Figure 3.5). This band very likely corresponds to the VP1 monomer whose 
apparent MW is 32.7kDa, indicating that the mice antisera raised against synthetic 
peptides SP12, SP55 and SP70 contained specific anti-VP1 antibodies that do not 
cross-react with other viral proteins. The immuno-specificity of all three sets of 
pooled antisera towards the set of 95 synthetic peptides was also assayed by ELISA 
where the peptides were individually used as coating antigens. A strong positive 
signal was obtained when the pooled antisera were incubated with the corresponding 
peptide used for immunization (homologous peptide), demonstrating the effectiveness 
of intraperitoneal immunization with each synthetic peptide. Furthermore, a positive 
signal was also obtained when the pooled antisera were incubated with synthetic 
peptides whose amino acid sequences overlap the sequence of the homologous 
peptide (overlapping peptides). Interestingly, both the anti-SP12 and anti-SP55 
antisera showed reactivity against the synthetic peptides SP19, SP20, SP21 and SP40, 
suggesting that both SP12 and SP55 share common linear epitopes with SP19, SP20, 
SP21 and SP40 (Table 3.1). 
















Figure 3.5 Western blot analysis using the synthetic peptide-antisera as primary 
antibodies. The amount of EV71 total proteins loaded in each lane was 10 µg. The 
lanes are as follows: lane M, molecular weight marker, lane 1, pooled antisera raised 
against synthetic peptide SP12; lane 2, pooled antisera raised against synthetic peptide 
SP55; lane 3, pooled antisera raised against synthetic peptide SP70. Arrow indicates 
























Table 3.1 Immunospecificity of SP12-, SP55- and SP70-immune sera. 












SP12 34-48 AC - VSSHRLDTGEVPALQC - DKP +++ SP10, SP11, SP13, 
SP14, SP15 
SP19, SP20, SP21, 
SP40 
SP55 163-177 AC - PESRESLAWQTATNPC - DKP +++ SP54, SP56 SP19, SP20, SP21, 
SP40 




a AC denotes an acetyl group attached to the amino (N)-terminal end and DKP denotes the carrier protein (Diphtheria toxoid) conjugated 
at the carboxy (C)-terminal end. 
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3.2.4 Analysis of IgG responses elicited by SP55, SP70 and SP12 
To further characterize the antibody response raised upon immunization with 
the synthetic peptides SP12, SP55 or SP70, the total IgG response against EV71 
whole virion was measured by ELISA. The antibody level elicited by the individual 
respective synthetic peptide was found to be as high as those obtained upon 
immunization with the heat-inactivated EV71 whole virion (Table 3.2A). In addition, 
examination of the IgG subtypes revealed that IgG1 antibody was predominantly 
produced in pooled immune sera raised against the three respective synthetic peptides 
individually, and at levels comparable to that measured in the pooled immune sera 
obtained from mice immunized with the heat-inactivated homologous EV71 whole 
virion (Table 3.2B). In contrast, the levels of IgG2a, IgG2b and IgG3 measured in 
pooled immune sera from mice immunized with the respective synthetic peptide were 
not significantly different from the levels measured in naive mice whereas those 
measured in the pooled immune sera from mice immunized with the heat-inactivated 
homologous EV71 whole virion were significantly higher (Table 3.2B). Altogether, 
these data indicate that the intraperitoneal administration of conjugated synthetic 
peptides SP12, SP55 and SP70 elicited mainly a Th2 immune response whereas the 
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Table 3.2 Total and IgG sub-type responses in SP12-, SP55- and SP70-immune 
sera. 
 
(A) Total IgG response 
 
Immunogen  OD450nm 
SP55 0.87 (0.02) 
SP70 0.88 (0.04) 
SP12 0.87 (0.03) 
Heat-inactivated virus 0.98 (0.01) 
Naive 0.17 (0.02) 
 
 
(B) IgG sub-type response 
 
OD450nm  
Immunogen IgG1 IgG2a IgG2b IgG3 
SP55 0.47 (0.04) 0.10 (0.02) 0.09 (0.02) 0.11 (0.04) 
SP70 0.80 (0.02) 0.18 (0.01) 0.14 (0.03) 0.12 (0.01) 
SP12     0.72(0.02) 0.11 (0.01) 0.10 (0.01) 0.17 (0.03) 
Heat-inactivated virus 0.83 (0.03) 0.73 (0.01) 0.78 (0.01) 0.80 (0.02) 
Naive 0.08 (0.02) 0.09 (0.02) 0.08 (0.01) 0.07 (0.01) 
 
(A) IgG-based ELISA was carried out using individual sera at a dilution of 1:50. The 
96-well microtiter plates were coated with purified virions (10µg/ml). OD450nm 
readings are expressed as the average of 5 antisera per group. Standard deviation of 
OD readings is in parenthesis. 
 
(B) IgG-based ELISA was carried out using pooled sera (n=5) at a dilution of 1:50. 
Wells of the 96-well microtiter plates were coated with the corresponding 
unconjugated synthetic peptide (10µg/ml). The data represents the average of three 
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3.2.5 In silico analysis of VP1 amino acid sequences represented by SP55 and 
SP70 
The Kyte and Doolittle hydrophobicity profile of the VP1 capsid protein of 
EV71 strain 41 indicated that both synthetic peptides SP55 and SP70 contained amino 
acid sequences which are located within the major hydrophilic regions of the VP1 
protein (Figure 3.6), therefore in regions likely to be exposed on the surface of the 
capsid protein. A protein-protein BLAST (blastp 2.2.17) search demonstrated that the 
VP1 amino acid sequences represented by SP55 and SP70 were highly specific for 
EV71 strains and no significant homology with other enteroviruses such as 
coxsackieviruses and echoviruses was found. Alignment using the Clustal method of 
MegAlign (DNASTAR program) also indicated that the amino acid sequence 
represented by SP70 was found to be totally conserved amongst 25 other EV71 strains 
from subgenogroups A to C4 whereas the amino acid sequence represented by SP55 
showed 80% identity with the genogroup A, BrCr-CA-70 strain, from US and 85 to 














Figure 3.6 Kyte and Doolittle hydrophobicity profiles of the VP1 capsid protein of EV71 strain 41. The horizontal axis represents the 
amino acid position in VP1 and the vertical axis represents the hydropathy scores. Positive scores indicate hydrophobicity while negative scores 





 Figure 3.7 Alignment of amino acid sequences represented by the synthetic peptides SP55 and SP70 against heterologous EV71 strains 
from different subgenogroups based on the VP1 amino acid sequences. 
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3.2.6 In vitro protection afforded by antisera from mice immunized with SP55, 
SP70 or heat-inactivated homologous EV71 strain 41 against heterologous 
EV71 strains 
The neutralizing potential of the immune sera raised against the synthetic 
peptides SP55 or SP70, against heterologous strains of EV71 was addressed. 
Representative EV71 strains from subgenogroups B2, B5, C2 or C4 were incubated 
individually with each set of pooled antisera and in vitro microneutralization assay 
was carried out as described in section 3.2.2. The pooled antisera from mice 
immunized with the heat-inactivated homologous EV71 strain 41 was also assayed 
and it was observed that this pooled antisera was able to protect RD cells from CPE 
against heterologous EV71 strains from subgenogroups B5, C2 and C4 as efficiently 
as against the homologous EV71 strain 41 (subgenogroup B4) (Table 3.3). However, 
it was found slightly less efficient to protect against heterologous EV71 strains from 
the subgenogroup B2 (Table 3.3). 
 
The pooled antisera from mice immunized with SP70 showed neutralizing 
activities against heterologous EV71 strains from subgenogroups C2 and C4 as high 
as the one obtained against the homologous EV71 strain 41 with significant 
neutralizing antibody titer of 1:32. However, neutralizing activities against 
heterologous EV71 strains from subgenogroups B2 and B5 were slightly lower with 
neutralizing antibody titer of 1:16 (Table 3.3). In contrast, the pooled antiserum from 
mice immunized with SP55 displayed the same neutralizing activity against all EV71 
strains tested, with a neutralizing antibody titer of 1:8 (Table 3.3). Therefore, the data 
demonstrated the protective potential of SP70 and, to a lesser extent, SP55 against 
heterologous EV71 strains. In addition, this further supports the in silico analysis 
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(section 3.2.5) which indicated that the neutralizing VP1 linear epitopes present in 
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Table 3.3 Neutralizing antibody titers elicited by SP55, SP70 and heat-
inactivated homologous EV71 whole virion in mice against heterologous EV71 
strains. 
 
 Subgenogroups of EV71 
Immunogen B2c B4b B5c C2c C4c 
Whole viriona 1:32 1:64 1:64 1:64 1:64 
SP55 1:8 1:8 1:8 1:8 1:8 
SP70 1:16 1:32 1:16 1:32 1:32 
 
a  Heat-inactivated EV71 strain 41 (5865/SIN/00009). 
b  Homologous EV71 strain. 
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3.2.7 EV71 infection in suckling mice 
Using suckling Balb/c mice as an infection model for EV71, the infection was 
characterized by hairless skin lesions and paralysis of limbs, and both clinical 
manifestations persisted throughout the observation period (Figure 3.8). Suckling 
Balb/c mice from different age groups were infected intraperitoneally with the 
homologous EV71 strain 41 at a lethal dose of 103 TCID50 per mouse. Mice which 
were infected at day 1 after birth died by day 11 post infection. With mice infected at 
day 4 after birth, death was delayed but all mice died by day 16 post infection. Mice 
which were infected at day 7 or day 10 after birth had higher survival rates of 60% 
and 90%, respectively by day 21 post infection. All mice which were infected at day 
14 after birth survived throughout the experimental period. 
 
To determine the lethal viral dosage, groups of mice at day 1 after birth were 
infected intraperitoneally with different doses of the homologous EV71 strain 41, 
ranging from 1 TCID50 to 103 TCID50 per mouse. A dose-dependent mortality was 
observed with a high viral dose resulting in mice death at an earlier time point. With 
an infective dose of 103 TCID50 virus, all mice died by day 11 post infection whereas 
a 30% survival rate was observed for those which were infected with a lower viral 
dose at 1 TCID50 per mouse (Figure 3.9). When the viral dose was reduced to 102 
TCID50 or 10 TCID50 per mouse, the mice survival was delayed to day 14 or day 17 
post infection, respectively (Figure 3.9). With a viral dose of 1 TCID50, an overall 
20% survival rate was observed up to day 21 post infection as the experiment 
endpoint and mice which were not infected did not show any sign of distress and all 
of them survived (Figure 3.9). 
 



























Figure 3.8 Viral infection of suckling Balb/c mice with the homologous EV71 
strain 41 at a lethal dose (103 TCID50 per mouse). (A) Mice at day 3 post infection 
are shown. The mouse on the right side is a non-infected age-matched control. (B) 
Mice at day 9 post infection are shown. The mouse on the left side is a non-infected 
age-matched control.  Limb paralysis is represented by * and skin lesion is 
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Figure 3.9 Dose dependency of EV71-induced death. Groups of Balb/c mice (n=6) 
at day 1 after birth were intraperitoneally infected with increasing doses of the 
homologous EV71 strain 41 (ranging from 1 TCID50 to 103 TCID50 per mouse). Mice 
in the control group were given 100 µl of PBS. Death was monitored daily until day 









CHAPTER 3 IDENTIFICATION OF NEUTRALIZING LINEAR EPITOPES 
___________________________________________________________________________________ 
_______________________________________________________________________________ 111
3.2.8 In vivo protection against the lethal homologous EV71 strain 41 challenge 
in suckling Balb/c mice born to immunized dams 
To evaluate the protective efficacy of maternal-transferred antibodies, 
suckling Balb/c mice born to immunized dams were challenged with the homologous 
EV71 strain 41 and their mortality rates were observed. As described in section 3.2.2, 
the synthetic peptide SP70 was able to elicit a higher anti-EV71 neutralizing antibody 
titer of 1:32 as compared to SP55 which elicited a lower titer of 1:16. Hence, SP70 
was selected as a representative vaccine candidate for immunization. At a lethal virus 
challenge dose of 103 TCID50 per mouse, the group of suckling mice born to dams 
which received the heat-inactivated homologous EV71 whole virion showed a 
protective efficacy of 80% whereas only 1 mouse among 6 suckling mice born to 
dams which received the synthetic peptide SP70 survived (Figure 3.10A). The control 
mice born to non-immunized dams including those born to dams immunized with the 
synthetic peptide SP12 did not survive by day 11 post infection (Figure 3.10A). To 
evaluate the severity of EV71 infection, body weights for all suckling mice were 
recorded every 3 days until day 21 post infection. The EV71-infected suckling mice 
did not gain much weight as compared to those who were protected against the viral 
infection. The protected mice had an average of approximately 7g in body weight as 
compared to those who were unprotected with a significant reduction in average body 
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Figure 3.10 In vivo protection of suckling Balb/c mice with maternal-transferred 
antibodies upon challenged with the homologous EV71 strain 41. (A) One-day-old 
mice (n=6) born to dams immunized with heat-inactivated homologous EV71 whole 
virion, SP70 or SP12 were infected with 100 µl of virus (103 TCID50 per mouse) via 
intraperitoneal route. Control mice born to non-immunized dams were infected with 
similar viral dose. Death was monitored until day 21 post infection. (B) Monitoring of 
body weight gain/loss in suckling mice upon EV71 challenge. On day 11 after 
infection, control mice were dead. Body weights were recorded for all surviving mice 
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3.2.9 In vivo passive protection against lethal EV71 challenge in suckling Balb/c 
mice 
3.2.9.1 Homologous EV71 strain 41 challenge 
To assess the efficacy of in vivo passive protection by immune sera raised 
against the heat-inactivated homologous EV71 whole virion (anti-EV71) or synthetic 
peptide SP70 (anti-SP70), suckling Balb/c mice born to naive dams were administered 
with the respective antisera one day after challenge with the homologous EV71 strain 
41 at a lethal dose of 103 TCID50 per mouse. Groups of mice that received the pooled 
anti-EV71 antisera with neutralizing antibody titers of 1:64 or 1:32 survived 
throughout the experimental period (Figure 3.11A). The pooled anti-SP70 antisera 
with a neutralizing antibody titer of 1:32 provided 80% protection whereas EV71-
infected suckling mice which did not receive any antisera and those which received 
either pooled naive sera or pooled immune sera from mice immunized with the 
synthetic peptide SP12 (anti-SP12) did not survive by day 12 post infection (Figure 
3.11A). The body weight of mice that were protected against EV71 infectivity rose 
steadily up to an average of approximately 12g at day 21 post infection (Figure 
3.11B). At day 9 post infection, they weighed approximately 8g on average when 
compared to unprotected mice that had significant reduction in body weight to 
approximately 3g in average before they died from EV71 infection (Figure 3.11B). 
When the neutralizing antibody titer of anti-EV71 antisera was reduced to 1:16, the 
survival rate of EV71-infected suckling mice dropped to 70% and subsequently to 
50% when the neutralizing antibody titer was further reduced to 1:8 (Figure 3.12A). A 
50% and 20% survival rate were observed with the anti-SP70 antisera at reduced 
neutralizing titer of 1:16 and 1:8, respectively (Figure 3.12B). 
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3.2.9.2 Heterologous EV71 strains challenge 
Groups of suckling Balb/c mice born to naive dams were challenged with 
heterologous EV71 strains at a lethal dose of 103 TCID50 per mouse and immune sera 
raised against the heat-inactivated homologous EV71 whole virion (anti-EV71) or 
synthetic peptide SP70 (anti-SP70) were administered one day after challenge. When 
suckling mice were infected with any of the heterologous EV71 strains followed by 
administering with the pooled anti-EV71 antisera at a neutralizing antibody titer of 
1:32, all of them survived up to day 21 post infection (Table 3.4). Mice infected with 
heterologous EV71 strains from the subgenogroup B2 or B5 had 80% survival rates 
when they were administered with the pooled anti-SP70 antisera with a neutralizing 
antibody titer of 1:32 (Table 3.4). Upon lethal challenge with heterologous EV71 
strains from the subgenogroup C2 or C4, the pooled anti-SP70 antisera protected 70% 
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Figure 3.11 In vivo passive protection of suckling Balb/c mice upon challenged 
with the homologous EV71 strain 41. (A) Groups of one-day-old mice (n=6) were 
intraperitoneally infected with a lethal viral dose of 103 TCID50 per mouse. One day 
post infection, suckling mice were administered with pooled immune sera from 
EV71-, SP70- or SP12-immunized mice. Mice in control groups were given naive 
sera or not administered with any sera. Death was monitored daily until day 21 post 
infection. (B) Monitoring of body weight gain/loss in suckling mice upon EV71 
challenge. Body weights were recorded for all surviving mice every 3 days until day 
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Figure 3.12 In vivo passive protection study conferred by different anti-EV71 
neutralizing antibody titers. Groups of one-day-old Balb/c mice (n=6) were infected 
with the homologous EV71 strain 41 at a lethal dose of 103 TCID50 per mouse. One 
day after infection, suckling mice were administered with serially diluted pooled 
immune sera from (A) EV71-immunized mice or (B) SP70-immunized mice. Mice in 
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Table 3.4 Survival rates of suckling Balb/c mice upon challenged with the 
homologous or heterologous EV71 strains. 
 






































a One day upon EV71 challenge at a lethal dose of 103 TCID50 per mouse, 
suckling mice were administered with a 1:32 dilution of immune sera from mice 
immunized with the homologous heat-inactivated EV71 strain 41 (anti-EV71) or 
synthetic peptide SP70 (anti-SP70) and monitored until day 21 post infection. Each 
group contained 6 mice. 
b Homologous EV71 strain. 
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3.2.10 Histological examination in EV71-infected suckling Balb/c mice 
To evaluate the severity of virus infection and its route of infectivity, 
histological examinations revealed EV71 infiltration in small intestines of suckling 
Balb/c mice infected with the homologous EV71 strain 41 at a lethal dose of 103 
TCID50 per mouse. The presence of EV71 was detected with the commercially 
available mouse anti-EV71 monoclonal antibody. From micrographs of representative 
cryosections, infected mice displayed damaged intestinal structures indicating 
extensive viral replications within the gut. Mice which received either pooled anti-
EV71 or anti-SP70 antisera upon lethal EV71 challenge were protected against virus 
infection and they presented intact intestinal structures (Figure 3.13C & D). However, 
non-protected mice which either received pooled anti-SP12 antisera or did not receive 
any sera upon lethal EV71 challenge showed signs of tissue damage in their small 
intestines (Figure 3.13B & E). The red colored peroxidase stain indicated EV71 
infiltration of intestinal tissues (Figure 3.13). 
 
3.2.11 Detection of EV71 by real-time RT-PCR hybridization probe-based assay 
In order to quantify the viral load in infected animals, intestinal tissues were 
harvested from suckling Balb/c mice upon challenge with the homologous EV71 
strain 41 at a lethal dose of 103 TCID50 per mouse and viral RNA was extracted from 
homogenized tissues for the detection of EV71. Upon real-time RT-PCR assay, a 204-
base pairs PCR product mapping within the VP1 region was obtained. Quantification 
analysis showed that the EV71 complete RNA transcript as the positive control for the 
real-time RT-PCR assay has a Ct value of 13 which represents 5 x 108 EV71 copies 
and every 3.3 Ct value difference represents a ten-fold difference in viral copies (Tan 
et al., 2006). Viral RNA sample from a representative mouse belonging to the group 
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which did not receive any sera indicated a Ct value of 33. In addition, viral RNA 
samples from representative mice belonging to groups which received either pooled 
anti-SP12 antisera or naive sera also indicated a Ct value of 33 (Figure 3.14B). This 
represents the presence of 50 EV71 copies in the three respective samples. However, 
representative mice belonging to groups which received either pooled anti-EV71 or 
anti-SP70 antisera had EV71 RNA transcripts with a higher Ct value of 37, 

















































































Figure 3.13 Detection of EV71 infection in small intestines of suckling Balb/c 
mice upon challenged with the homologous EV71 strain 41 at a lethal dose of 103 
TCID50 per mouse. Representative intestinal structures from: (A) Non-infected 
mouse as the negative control. (B) EV71-infected mouse as the positive control. (C) 
Mouse receiving the pooled anti-EV71 antisera. (D) Mouse receiving the pooled anti-
SP70 antisera. (E) Mouse receiving the pooled anti-SP12 antisera. Cryosections of 
intestinal tissues were prepared and EV71 was detected with mouse anti-EV71 
monoclonal antibody and biotinylated anti-mouse IgG before visualizing with 
aminoethyl carbazole substrate to give a red colored peroxidase stain as positive 



































Figure 3.14 Detection of EV71 by real-time RT-PCR hybridization probe-based 
assay in suckling Balb/c mice upon challenge studies. (A) EV71 complete RNA 
transcript as the positive control with a Ct value of 13 representing 5 x 108 viral 
copies (Tan et al., 2006). (B) RNA transcripts from representative mice belonging to 
groups that received pooled immune sera from SP12-immunized mice (n=5), pooled 
sera from non-immunized mice (n=5) or no sera with a Ct value of 33 representing 50 
viral copies. (C) RNA transcripts from representative mice belonging to groups that 
received pooled immune sera from the homologous EV71 whole virion- or SP70-
immunized mice (n=5) with a higher Ct value of 37 representing 5 viral copies. (D) 
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3.2.12 Cytokine profiles in suckling Balb/c mice protected against lethal 
homologous EV71 strain 41 challenge 
To assess the role of pro-inflammatory and anti-inflammatory cytokines 
during EV71 infection, one-day-old suckling Balb/c mice were infected with the 
homologous EV71 strain 41 at a lethal dose of 103 TCID50 per mouse followed by 
administering pooled naive sera or immune sera from mice immunized with the heat-
inactivated homologous EV71 whole virion (anti-EV71) or synthetic peptide SP70 
(anti-SP70) at day 1 post infection. With a lethal viral dose, the levels of IL-6, IL-10, 
IFN-γ and TNF-α in mice were measured at different time points. However, at day 12 
post infection, the unprotected mice from groups which received either pooled naive 
sera or no sera died from EV71 infection and hence it was not possible to obtain any 
data beyond this time point for these groups of mice. For IL-6, the unprotected mice 
displayed significant level throughout the viral infection and peaked at day 10 post 
infection with a concentration of approximately 260pg/ml (Figure 3.15A). However, 
the mice died at day 12 post infection whereas the protected mice survived up to day 
22 post infection as the experimental endpoint. For the protected mice who received 
either pooled anti-SP70 or anti-EV71 antisera, the IL-6 level at day 10 post infection 
was significantly lower than that observed for the unprotected mice (Figure 3.15A). 
Similar pattern was observed for the IFN-γ production with a peak concentration of 
approximately 400pg/ml at day 10 post infection in the unprotected mice whereas the 
protected mice produced IFN-γ at a peak concentration of approximately 100pg/ml 
(Figure 3.15B). For IL-10, the level in protected mice increased up to day 10 post 
infection and remained high up to day 22 post infection as compared to the early onset 
of the viral infection (Figure 3.15C). The levels of TNF-α in unprotected and 
protected mice were elevated throughout the viral infection (Figure 3.15D). 







(B)     
 
Figure 3.15 Cytokine profile in suckling Balb/c mice upon EV71 challenge. 
Groups of one-day-old suckling mice were challenged with the homologous EV71 
strain 41 at a lethal dose of 103 TCID50 per mouse followed by the administration of 
pooled naive sera or immune sera from mice immunized with the heat-inactivated 
homologous EV71 whole virion (anti-EV71) or synthetic peptide SP70 (anti-SP70) at 
day 1 post infection. At day 2, 3, 4, 10, 16 and 22 post infection, one mouse per group 
was sacrificed and serum samples were collected for cytokine analysis. (A) IL-6 
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Figure 3.15 Cytokine profile in suckling Balb/c mice upon EV71 challenge. 
Groups of one-day-old suckling mice were challenged with the homologous EV71 
strain 41 at a lethal dose of 103 TCID50 per mouse followed by the administration of 
pooled naive sera or immune sera from mice immunized with the heat-inactivated 
homologous EV71 whole virion (anti-EV71) or synthetic peptide SP70 (anti-SP70) at 
day 1 post infection. At day 2, 3, 4, 10, 16 and 22 post infection, one mouse per group 
was sacrificed and serum samples were collected for cytokine analysis. (C) IL-10 
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3.2.13 Immunogenicity of SP55 and SP70 
To address whether VP1 regions represented by synthetic peptides SP55 or 
SP70 are potential peptide vaccine candidates for human, serum samples were 
collected from children attending a pediatric outpatient clinic at the National 
University Hospital (NUH) of Singapore and screened for the presence of anti-EV71 
neutralizing antibodies by in vitro microneutralization assay. A serum neutralizing 
antibody titer of 1:8 and above was considered positive for EV71 exposure. In total, 
40 individuals were found to be positive and their sera were designated as EV71-
positive sera. The 95 overlapping unconjugated synthetic peptides spanning the entire 
VP1 sequence of EV71 strain 41 were used individually as coating antigens in an 
IgG-based ELISA. In this study, the cut-off absorbance for identifying reactive 
peptides is set as the mean optical density obtained from EV71-negative sera plus two 
standard deviation of the respective mean. With the EV71-positive or EV71-negative 
human sera as primary antibodies, no significant IgG-specific immunoreactivity was 
observed with SP55 or SP70 as coating antigens (Figure 3.16). Instead, two regions 
designated I and II, represented by synthetic peptides SP14, SP15 and SP31, SP32, 
SP33, respectively, were found to be immunoreactive with human sera (Figure 3.16). 
Region I reacted with EV71-positive and EV71-negative human sera whereas region 
II reacted specifically with EV71-positive human sera. In contrast, using mice 
immune sera raised the heat-inactivated EV71 whole virion, significant IgG-specific 
immunoreactivities were observed with SP55 or SP70 as coating antigens (Figure 
3.17).  Hence, the absence of human anti-SP55 and anti-SP70 IgG antibodies among 
patients who were exposed to EV71 suggests that the amino acid sequences 















Figure 3.16 Immunoreactivity of VP1 capsid protein against human sera (at 1:50 dilution) by Pepscan analysis. The IgG-based ELISA 
was carried out with EV71-negative sera (open bars) and EV71-positive sera (black bars). The vertical axis denotes the absorbance readings 
measured at 450nm and the horizontal axis denotes the synthetic peptide number. Two linear immunoreactive sites were designated as sites I and 







































Figure 3.17 Immunoreactivity of VP1 capsid protein against mice immune sera (at 1:50 dilution) by Pepscan analysis. The IgG-based 
ELISA was carried out with naïve sera (open bars) and anti-EV1 immune sera (black bars). The vertical axis denotes the absorbance readings 
measured at 450nm and the horizontal axis denotes the synthetic peptide number. The cut-off absorbance for identifying reactive peptides is 






































Previous studies have shown that the VP1 capsid protein of EV71 constitutes a 
potential subunit vaccine candidate by triggering the production of protective anti-
EV71 neutralizing antibodies in a murine model of infection (Chen et al., 2006; Chiu 
et al., 2006; Wu et al., 2001). However, these studies focused on the entire VP1 
protein without mapping the exact location of the neutralizing epitope(s). In this 
study, a Pepscan strategy was employed in which 95 overlapping synthetic peptides 
were designed according to the primary sequence of the VP1 capsid protein of EV71 
strain 41 (subgenogroup B4). The diphtheria toxoid-conjugated synthetic peptides 
were injected into adult Balb/b mice and the anti-EV71 neutralizing activities of the 
antisera were determined. This strategy allows the identification of neutralizing linear 
epitope(s) that can thus be used in various peptide vaccine designs. Two synthetic 
peptides, designated SP55 (VP1 amino acid residues 162 to 177) and SP70 (VP1 
amino acid residues 208 to 222) were shown to elicit good production of neutralizing 
antibodies against EV71. These regions are different as compared to that previously 
identified along VP1 of the prototype enterovirus (poliovirus) which suggested that 
the antigenic region (VP1 amino acid residues 89 to 100 of poliovirus type 3) 
possessed virus-neutralizing  activity (Minor et al., 1983; Minor et al., 1985; Minor et 
al., 1984). Ferguson et al. (1985) has also shown that single amino acid substitutions 
within the VP1 amino acid residues 93 to 89 of poliovirus type 3 can reduce the virus-
neutralizing activity. 
 
In this study, the anti-SP70 antiserum was found to be almost as efficient as 
the immune serum raised against the heat-inactivated homologous EV71 whole virion 
(highest dilutions preventing cytopathic effect at 1:32 and 1:64, respectively), in 
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neutralizing EV71 in an in vitro microneutralization assay. In addition, the total IgG 
response specific to EV71 whole virion measured in the anti-SP55 or anti-SP70 
antiserum was found to be as high as that measured in the immune serum raised 
against the heat-inactivated homologous EV71 strain 41. 
 
The IgG subtypes analysis of both anti-SP55 and anti-SP70 antisera showed a 
strong IgG1 specific antibody response and a very low IgG2a, IgG2b and IgG3 
antibody response which indicates a predominant Th2 immune response. These 
observations suggest that (i) both synthetic peptides SP55 and SP70 contain mainly B-
cell epitopes and (ii) the neutralizing antibodies elicited by SP55 and SP70 belong to 
the IgG1 subtype.  
 
The amino acid sequences presented by both synthetic peptides SP55 and 
SP70 lie towards the C-terminal part of the VP1 capsid protein of EV71 strain 41. The 
hydrophobicity profiles also showed that SP55 and SP70 are located within the major 
hydrophilic regions of VP1 and hence they are expected to be exposed at the surface 
of the protein. In this study, the hydrophobicity profile of VP1 using the Kyte and 
Doolittle plot was performed to further strengthen/enhance the speculations that 
regions represented by both SP55 and SP70 are hydrophilic and may be located on the 
surface of the capsid protein and hence highly immunogenic. However, it would have 
been useful to perform this profiling and identify the hydrophilic regions prior to the 
mice immunization study. This can greatly reduce the duration and the number of 
mice used for this study. In addition, both synthetic peptides map in the region (VP1 
amino acid residues 66-132) recently shown to be involved in the dimerization of VP1 
capsid protein (Lal et al., 2006).  The finding of neutralizing epitopes within this 
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region further demonstrates their involvement in virus binding and entry into host 
cells.  
 
Several genogroups and subgenogroups of EV71 have evolved since its first 
discovery in 1969, and frequent mutations of the viral genome constitute a major 
difficulty in vaccine development when using the whole viral particle as a potential 
vaccine candidate (McMinn, 2002). Many fatality cases due to EV71 were caused by 
strains from different subgenogroups and studies have shown that the EV71 
subgenogroups are constantly evolving within the community (Brown et al., 1999; 
Mizuta et al., 2005; Wang et al., 2002) which emphasizes the importance of 
identifying the location of any conserved neutralizing epitope(s). The amino acid 
sequence of synthetic peptide SP70 appears to be totally conserved amongst 25 
representative EV71 strains from different subgenogroups and this study has shown 
that the immune serum raised against SP70 was also able to neutralize heterologous 
EV71 strains comparable but lower for strains belonging to subgenogroups B2 and B5 
to that obtained with the homologous EV71 strain 41. Due to the conserved amino 
acid sequence of SP70, one would expect the neutralizing antibody titer of the anti-
SP70 immune serum to be similar when tested against both homologous and 
heterologous strains however this assumption was not observed here. Although it is 
known that VP1 contains neutralizing epitopes, which are represented by SP55 and 
SP70 in this study, but McMinn et al. (2002) discussed the possibility of numerous 
neutralizing epitopes localized among other regions of EV71 especially on capsid 
protein such as VP4. Hence, EV71 infection could still occur via different binding 
sites to host cell even though regions represented by SP55 or SP70 might be blocked 
by anti-SP55 or anti-SP70 neutralizing antibodies. 
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Although immune responses such as elevated antibody level detected soon 
after immunization may demonstrate the immunogenicity of a vaccine but they do not 
necessarily provide a reliable guide to its efficacy in priming an in vivo protective 
response. In addition, in vitro microneutralization data may not necessary correlate 
with in vivo protective potential as well. Successful protection against viral infectivity 
in animal models has long been considered as the best test to predict the efficacy of a 
vaccine. Benefits of vaccination could be derived either through active immunization 
or passive protection. In this study, EV71 infection was asymptomatic in adult Balb/c 
mice but suckling mice were susceptible to infection and hence the protective efficacy 
of the synthetic peptide SP70 was evaluated via passive immunization in newborn 
mice. Passive transfer of specific antibodies has been shown to reduce the severity of 
viral infections, including Japanese encephalitis infection (Kimura-Kuroda and Yasui, 
1988), varicella infection (Huang et al., 2001) and coxsackievirus infection (Geller 
and Condie, 1995). Here, the in vivo protective potential of EV71-neutralizing 
antibodies elicited by SP70 was tested in mice by passive transfer of immune sera and 
it was found that the anti-SP70 antisera was able to confer in vivo passive protection 
of up to 80% survival rate in suckling Balb/c mice which have been challenged with a 
lethal dose of the homologous EV71 strain 41. The level of protection conferred by 
the anti-SP70 antiserum against heterologous EV71 strains was almost similar but 
lower for strains belonging to subgenogroups C2 and C4 to that obtained against the 
homologous strain, supporting that the VP1 amino acid sequences represented by 
SP70 contain a highly conserved neutralizing linear epitope. In addition, significant 
reduction in the survival rate correlated with suckling mice receiving immune sera 
with progressively lower anti-EV71 neutralizing antibody titers indicating that the 
neutralizing titer determined in vitro correlates with the in vivo protective efficacy. 
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The cytokine profiles for EV71-challenged mice showed elevated IL-6 and IFN-γ 
levels in unprotected mice whereas significant lower levels were observed for mice 
which were protected by passively-transferred immune sera. This observation 
suggests a correlation between pro-inflammatory cytokines and the severity of EV71 
infection. 
 
Although a number of immunogens with good in vivo passive protective 
potential have been identified, the majority of EV71 vaccine candidates that have 
been studied relied mainly on whole viral particles (Wu et al., 2001; Yu et al., 2000). 
In this study, the mouse immune sera which were raised against EV71 whole virion 
did provide higher in vivo passive protection to suckling Balb/c mice against lethal 
EV71 challenge when compared with the anti-SP70 antisera. This is likely due to 
higher titers of neutralizing antibody elicited by several neutralizing epitopes located 
on the virus other than that represented by the synthetic peptide SP70 alone. The 
passively administered immune sera raised against EV71 whole virion might also 
contain antibodies which could induce lysis of the virus-infected host cells through 
activation of complement cascades or by mediating antibody-dependent cellular 
cytoxicity (ADCC) activities. Conventional vaccine preparations using the whole viral 
particle as an inactivated vaccine might be ideal since it offered good protection 
against viral infection. However, the laborious and costly procedures involved in 
EV71 production and purification as well as safety issues are of major concerns. 
Although this study has shown that the whole virion was able to elicit a high 
neutralizing antibody titer and hence conferred significant in vivo passive protection 
to suckling Balb/c mice against EV71, a mixture of both SP55 and SP70 as 
immunogen might trigger a greater neutralizing antibody response than either peptide 
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alone. Therefore, the level of in vivo protection might increase as comparable as those 
obtained with the whole virion as immunogen. 
 
 In conclusion, two independent amino acid sequences within the VP1 capsid 
protein of EV71 strain 41 which contain neutralizing linear epitopes were identified. 
These epitopes lie in the C-terminal moiety of the protein, in a hydrophilic region 
involved in VP1 dimerization. These sequences are highly conserved within the 
different subgenogroups, making them promising and attractive candidates for 
synthetic peptide-based EV71 vaccines. With high titers of anti-EV71 neutralizing 
antibody measured in human serum samples, no specific anti-SP55 or anti-SP70 IgG 
antibody was identified among those who were exposed to EV71, although anti-EV71 
immune sera raised in Balb/c mice were able to react with SP55 or SP70. This 
suggests that the VP1 amino acid sequences represented by SP55 and SP70 are not 
immunodominant linear epitope in humans. Therefore, when administered as peptide 
vaccines with appropriate adjuvant, SP70 may be able to trigger a significant antibody 
response, capable of protecting efficiently against EV71 infection. In addition, anti-
SP70 antibodies, and to a lesser extent, anti-SP55 antibodies may represent promising 
candidates for the development of therapeutic antibodies against EV71 infections. 
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CHAPTER 4 IDENTIFICATION OF IMMUNODOMINANT VP1 
LINEAR EPITOPE OF ENTEROVIRUS 71 USING 
SYNTHETIC PEPTIDES FOR DETECTING HUMAN 




Since 1997, several large epidemics of EV71 strains have been reported and 
these have caused significant mortality in the Asia-Pacific region. The common 
practice for detecting EV71 in any clinical specimen is by conventional isolation of 
the whole virus, followed by subsequent serotyping with serotype-specific antibodies 
and indirect immunofluorescence assay (IFA). This has been the practice in most 
diagnostic laboratories as the ‘gold standard’ for the identification of viral infections, 
although this method is labor-intensive and time-consuming. Another approach 
involving conventional RT-PCR is available for routine viral diagnosis. While direct 
detection of EV71 from clinical specimen is possible when the viral load is high, this 
approach is not sensitive enough to detect the virus from specimens with low viral 
load. Therefore, cell cultures were required to increase the quantity of viral particles 
(Tsao et al., 2002a) for detection. In addition, the requirement for specific and 
expensive reagents as well as equipment further restricts its use for the detection of 
EV71 infection. 
 
ELISA involves the detection of serotype-specific IgM or IgG which can 
indicate whether the patient is in the acute or convalescent phase of an infection, 
respectively. Studies on IgM-based ELISA for the diagnosis of EV71 infection were 
reported to have high sensitivity and specificity. However, this approach was too 
laborious as it involved the use of purified whole EV71 viral particle for the detection 
of EV71-specific antibody (Tano et al., 2002; Tsao et al., 2002a; Wang et al., 2004). 
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In addition, transient production of rheumatoid factor is common during the acute 
phase of many infections. Hence, with the presence of rheumatoid or antinuclear 
factor, the detection of human IgM antibodies could result in non-specific 
identification of EV71 infection (Tano et al., 2002; Tsao et al., 2002a; Wang et al., 
2004). Another study has developed a serodiagnostic tool based on Western blot by 
using a re-natured whole VP1 protein which was presented as a recombinant His-VP1 
fusion protein (Shih et al., 2000a). The VP1 antigen specifically reacted with anti-
EV71 antibodies and it was reported to show no cross immunoreactivity with anti-
CA16 antibodies. 
 
In all studies reported so far, either the whole VP1 capsid protein or the EV71 
whole virion was used as capture antigen and it poses danger to laboratory workers if 
large quantities of pathogenic viruses were cultivated and further purified. In addition, 
this study has observed that the purification of recombinant VP1 fusion protein was 
carried out with much difficulties and the final yield was low. This could be due to the 
presence of several hydrophobicity regions within VP1. Therefore, it would be an 
advantage to identify an immunodominant region within VP1 which would be easier 
to either synthesize chemically or produce efficiently as a recombinant fusion protein. 
To map the immunodominant epitope(s), an overlapping synthetic peptide library can 
be used to screen against specific antibodies in an ELISA. 
 
In this study, an IgG-specific immunodominant linear epitope on the VP1 
capsid protein of EV71 strain 41 (5865/SIN/00009) was identified by Pepscan 
analysis using overlapping synthetic peptides spanning the entire amino acid sequence 
of VP1 to screen against sera from pediatric patients containing specific anti-EV71 
CHAPTER 4 MAPPING OF IMMUNODOMINANT LINEAR EPITOPES 
___________________________________________________________________________________ 
_______________________________________________________________________________ 136
IgG antibodies. The immunodominant VP1 linear epitope represented by the synthetic 
peptide SP32 was over-expressed as a soluble recombinant GST-SP32 fusion protein 
and used as a capture antigen in Western blot analysis for the detection of human anti-
EV71 IgG antibodies. The efficacy of the purified recombinant GST-SP32 fusion 
protein, the EV71 whole virion and the recombinant GST-VP1 fusion protein used as 
























4.2.1 Mapping of the immunodominant linear epitope of VP1 capsid protein 
To identify VP1 immunodominant linear epitope in human, serum samples 
were collected from children attending a pediatric outpatient clinic at the National 
University Hospital of Singapore and screened for the presence of anti-EV71 
neutralizing antibodies by in vitro microneutralization assay. A serum neutralizing 
antibody titer of 1:8 and above was considered positive for EV71 exposure and 
designated as EV71-positive. Serum samples which failed to inhibit the virus from 
causing cytopathic effect (CPE) were designated as EV71-negative. In total, 40 
EV71-positive serum samples were pooled and tested against the 95 overlapping 
synthetic peptides in the IgG-based ELISA. These peptides were also evaluated in 
parallel against pooled EV71-negative sera from 40 serum samples. The data revealed 
two immunoreactive regions designated as regions I and II as described in chapter 3 
(Figure 3.20). The first region was represented by two overlapping synthetic peptides 
(SP14 and SP15), corresponding to VP1 amino acid residues 40 to 57 which mapped 
within or close to the N-terminal region of the VP1 capsid protein. However, the 
pooled EV71-negative sera also displayed immunoreactivities towards the same 
region which strongly suggests serological cross-reactivities. The second region spans 
VP1 amino acid residues 91 to 111 (represented by SP31 to SP33) which correspond 
to the middle region of the VP1 capsid protein (Figure 3.20). Interestingly, the pooled 
EV71-negative sera did not react with region II indicating that this region, defined by 
the core sequence ‘LEGTTNPNG’, represents the major immunodominant linear 
epitope on the VP1 capsid protein of EV71. 
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4.2.2 Expression of recombinant GST-VP1 and GST-SP32 fusion proteins 
The synthetic peptide SP32 (DLPLEGTTNPNGYAN) which contained the 
core sequence of the immunodominant VP1 linear epitope was selected as a potential 
capture antigen for human anti-EV71 IgG antibodies. Over-expression in E. coli of 
both recombinant GST-VP1 and GST-SP32 fusion proteins was achieved by IPTG 
induction and they were produced as recombinant GST-tagged fusion proteins. SDS-
PAGE analysis showed purified proteins with estimated molecular weights of 58kDa 
and 28kDa, which correspond to the sizes of the expected 58.7kDa recombinant GST-
VP1 (Figure 4.1A, lane 2) and 27.8kDa recombinant GST-SP32 fusion protein 
(Figure 4.1B, lane 2), respectively. Using commercially available mouse anti-EV71 
monoclonal antibody and anti-GST antibody, their immunoreactivities with purified 
recombinant GST-VP1 and GST-SP32 fusion proteins were evaluated in Western 
blot. A strong immunoreactivity was observed for both fusion proteins when using the 
commercially available mouse anti-EV71 monoclonal antibody as primary antibody 
(Figure 4.1C, lanes 2 and 4, respectively). In addition, using the commercially 
available mouse anti-GST antibody, similar immunoreactivity was also observed for 








































Figure 4.1 Expression of purified recombinant GST-VP1 and GST-SP32 fusion 
proteins. (A) SDS-PAGE of GST-VP1 crude and purified fractions. The lanes are as 
follows: lane M, molecular weight marker; lane 1, IPTG-induced crude cell lysate; 
lane 2, purified GST-VP1 fusion protein. (B) SDS-PAGE of GST-SP32 crude and 
purified fractions. The lanes are as follows: lane M, molecular weight marker; lane 1, 
IPTG-induced crude cell lysate; lane 2, purified GST-SP32 fusion protein. (C) 
Western blot analysis of the purified recombinant GST-VP1 and GST-SP32 fusion 
proteins. The amount of proteins loaded in each lane was 10 µg. The lanes are as 
follows: lane M, molecular weight marker; lane 1, anti-GST antibody against GST-
VP1; lane 2, anti-EV71 antibody against GST-VP1; lane 3, anti-GST antibody against 
GST-SP32; lane 4, anti-EV71 antibody against GST-SP32. Bound antibodies were 
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4.2.3 Detecting human anti-EV71 IgG antibodies using purified recombinant 
GST-VP1 and GST-SP32 fusion proteins in IgG-based ELISA and 
Western blot 
To investigate the potential of using the purified recombinant GST-SP32 
fusion protein as a capture antigen in IgG-based ELISA, its efficacy was compared to 
that of the purified recombinant GST-VP1 fusion protein and EV71 whole virion as 
capture antigens. When tested against pooled EV71-positive sera, the human anti-
EV71 IgG antibodies had strong immunoreactivities with the recombinant GST-VP1 
fusion protein and EV71 whole virion. Surprisingly, similar immunoreactivities were 
observed with both capture antigens when tested against pooled EV71-negative sera, 
suggesting cross-reactivity with human non-EV71-specific antibodies. However, there 
was no immunoreactivity for the recombinant GST-SP32 fusion protein as a capture 
antigen when tested against pooled EV71-positive or EV71-negative sera. This 
suggests that the immunodominant VP1 linear epitope represented by the synthetic 
peptide SP32 may be hidden by the larger GST protein and hence not available to 
interact with human EV71-specific IgG antibodies. The immunoreactivities of human 
anti-EV71 IgG antibodies against all three capture antigens were then tested in 
Western blot using denaturing SDS-PAGE which ensures a totally unfolded 
conformation of the proteins. As already observed in ELISA, positive 
immunoreactivities were obtained with the pooled EV71-positive and EV71-negative 
sera when using the EV71 whole virion or the recombinant GST-VP1 fusion protein 
as capture antigens (Figure 4.2). In contrast, the recombinant GST-SP32 fusion 
protein was able to react specifically with the pooled EV71-positive sera but not with 
the pooled EV71-negative sera (Figure 4.2). These results strongly indicate that the 
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purified recombinant GST-SP32 fusion protein represents an interesting capture 

































































Figure 4.2 Western blot analysis of antigen reactivity with pooled EV71-positive 
or EV71-negative sera. Capture antigens used in this assay include the EV71 whole 
virion, recombinant GST-VP1 and GST-SP32 fusion proteins, and the native GST 
protein. The amount of proteins loaded in each lane was 10 µg. The lanes are as 
follows: lane M, molecular weight marker; lane 1, immunoblotted with pooled EV71-
positive sera; lane 2, immunoblotted with pooled EV71-negative sera. Bound 
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4.2.4 Specificity of the purified recombinant GST-SP32 fusion protein as a 
capture antigen in Western blot 
The purified recombinant GST-SP32 fusion protein was tested against 
commercially available monoclonal antibodies raised against other HFMD-causing 
enteroviruses such as Coxsackie A9 and Echovirus 6. The results only showed 
significant immunoreactivity against the commercially available mouse anti-EV71 
monoclonal antibody but no cross-immunoreactivities were observed against the other 
two monoclonal antibodies. A protein–protein BLAST (blastp 2.2.17) search 
demonstrated that the amino acid sequence of the immunodominant VP1 linear 
epitope represented by the synthetic peptide SP32 was highly specific for EV71 
strains and no significant homology with other enteroviruses such as coxsackieviruses 
and echoviruses was found. The SP32 amino acid sequence was also identified to be 
conserved amongst representative EV71 strains from different genogroups and 
















Figure 4.3 Alignment of amino acid sequences represented by the synthetic peptide SP32 against heterologous EV71 strains from 

















The use of synthetic peptide(s) as capture antigen(s) in immunoassays 
represents an interesting approach for the serodiagnostic of EV71 infection as it 
would avoid the need for propagating infectious viruses. A synthetic peptide 
representing amino acid residues 42 to 55 of the VP1 capsid protein of enteroviruses 
when used as a capture antigen in an indirect IgG-based ELISA was found to be 
useful for serodiagnose a broad range of enteroviruses (Samuelson et al., 1994). 
However, this immunodiagnostic method is not specific for the detection of human 
anti-EV71 IgG antibodies and is limited by high production cost and availability of 
synthetic peptide(s). A previous study has shown that the VP1 capsid protein of EV71 
is immunogenic (Shih et al., 2000a). However, very little information is available 
regarding the location of the immunodominant epitope(s) on VP1. By expressing the 
whole VP1 protein itself and non-overlapping fragments of VP1 as recombinant His-
tagged fusion proteins in their native forms, a recent study has shown that human sera 
containing neutralizing antibodies against EV71 strain MS/7423/87 (GenBank 
accession number U22522) reacted strongly towards the N-terminal region of VP1 
which suggests the presence of immunodominant epitope(s) (Tan and Cardosa, 2007). 
 
Pepscan analysis using overlapping synthetic peptides has been widely used 
for identifying antigenic epitope(s) of viruses (Frank, 1992; Gao and Esnouf, 1996; 
He et al., 2004a, 2004b; He et al., 2005; Kramer et al., 1994; Reineke, 1996). 
Generally, epitopes can be divided into 2 broad categories defined by linear and 
discontinuous (conformational) structures (Appel et al., 1990; Barlow et al., 1986; 
Laver et al., 1990). In the present study, two IgG-specific immunoreactive linear 
regions within VP1 of EV71 strain 41 (5865/SIN/00009) have been identified using 
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the Pepscan approach. When used as capture antigen in ELISA, region I represented 
by overlapping synthetic peptides SP14 and SP15 was unable to specifically detect 
human anti-EV71 IgG antibodies as it reacted with the pooled EV71-negative sera as 
well. The second immunoreactive region was represented by overlapping synthetic 
peptides SP31, SP32 and SP33. This region in contrast, was highly specific for the 
detection of human anti-EV71 IgG antibodies and hence was identified as an IgG-
specific immunodominant linear epitope on the VP1 capsid protein of EV71. When 
tested against human sera containing neutralizing antibodies against EV71 strain 41, 
there were significant immunoreactivities towards the synthetic peptide SP32 which 
contains the core amino acid sequence ‘LEGTTNPNG’. In addition, the blast analysis 
showed that the VP1 amino acid sequence represented by SP32 was highly specific 
and conserved among EV71 strains indicating its high sensitivity as a capture antigen 
in detecting human anti-EV71 IgG antibodies. 
 
The VP1 capsid protein of prototype EV71 BrCr strain (GenBank accession 
number U00871) when produced as a recombinant His-VP1 fusion protein was highly 
insoluble which required denaturation and renaturation before it could be used as a 
capture antigen in Western blot (Shih et al., 2000a).  The insolubility could be 
attributed to several hydrophobic transmembrane regions within VP1. In this study, 
the 15-amino acid immunodominant VP1 linear epitope represented by the synthetic 
peptide SP32 was produced as a soluble recombinant GST-SP32 fusion protein at 
high yields. Based on the Kyte and Doolittle hydrophobicity profile of the entire VP1 
capsid protein of EV71 strain 41, this region (SP32) was identified to be mainly 
hydrophilic (Foo et al., 2007a). The efficacy of the purified recombinant GST-SP32 
fusion protein as a capture antigen for human anti-EV71 IgG antibodies was carried 
CHAPTER 4 MAPPING OF IMMUNODOMINANT LINEAR EPITOPES 
___________________________________________________________________________________ 
_______________________________________________________________________________ 147
out in both IgG-based ELISA and Western blot analysis. No significant 
immunoreactivity with human anti-EV71 IgG antibodies was obtained by ELISA and 
hence it was hypothesized that the antigenic site represented by SP32 may be masked 
by the much larger GST moiety, thereby inhibiting antigen-antibody interactions. 
Alternatively, the GST protein can be cleaved from the recombinant GST-SP32 fusion 
protein and the SP32 protein by itself can be used as capture antigen in ELISA. When 
the recombinant GST-SP32 fusion protein was used as a capture antigen in Western 
blot, a strong and specific immunoreactivity was obtained with human anti-EV71 IgG 
antibodies. This is likely due to the denatured state of the recombinant fusion protein 
where the steric hindrance caused by the GST protein was removed, thereby exposing 
the immunogenic region represented by SP32.  
 
When used as capture antigens, both the recombinant GST-VP1 fusion protein 
and EV71 whole virion in contrast, were not able to specifically detect human anti-
EV71 IgG antibodies. This could be attributed to the presence of numerous common 
epitopes between enteroviruses which have been shown to be present in capsid 
proteins (Cello et al., 1993; Mertens et al., 1983; Samuelson et al., 1994; Samuelson 
et al., 1993). Hence, human IgG antibodies elicited against common epitopes found 
on different viruses other than enteroviruses may display cross-reactivity when tested 
against the recombinant GST-VP1 fusion protein and EV71 whole virion. For 
example, cross-reactions were observed when using human anti-rhinovirus antisera or 
anti-cytomegalovirus antisera in immunoassays for the detection of enteroviruses 
(Couch and Knipe, 1990; Samuelson et al., 1993). Cross-reactivity may also be 
attributed to human anti-poliovirus IgG antibodies which are commonly present in 
most of the pediatric patients as a result of the National childhood immunization 
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program. Consequently, human antibodies elicited against poliovirus may cross-react 
with EV71 whole virion (Mertens et al., 1983; Tsao et al., 2002a; Wang et al., 2004). 
 
In conclusion, this study clearly showed that the purified recombinant GST-
SP32 fusion protein represents an interesting capture antigen in Western blot to detect 
specifically human anti-EV71 IgG antibodies. Therefore, the recombinant GST-SP32 
fusion protein could be further developed as a serologic reagent in the detection of 
human specific anti-EV71 IgG antibodies for the identification of EV71 infection as 
well as a confirmatory assay for previous EV71 exposure. Since Western blot is a 
multi-step process, a simpler approach such as dot blot assay may be considered as a 
detection method instead. Alternatively, the recombinant SP32 protein may be 
cleaved from the GST-SP32 fusion protein to be used as capture antigens in ELISA. 
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CHAPTER 5 IDENTIFICATION OF HUMAN CD4+ T-CELL 




EV71 epidemics with neurological, cardiac and/or pulmonary complications 
occurred worldwide with a particular surge in the Asia-Pacific region during the last 
ten years (Sanders et al., 2006). The current strategy of preventing EV71 infection 
relies on public health surveillance and good hygiene practices. Presently, there is no 
specific drug against EV71 and treatments only provide relief for fever and pain. 
Natural viral infections usually lead to the production of protective neutralizing 
antibodies. In a recent study, the cord sera from 205 individuals were tested for the 
presence of anti-EV71 neutralizing antibodies and the authors described that the N-
terminal moiety of the VP1 capsid protein is likely to harbor EV71-neutralizing 
epitopes (Tan and Cardosa, 2007). However, these epitopes have yet to be identified. 
In this study, we have identified three regions on the VP1 capsid protein of 
enterovirus 71 strain 41 (5865/SIN/00009) capable of inducing human EV71-specific 
CD4+ T cell proliferation. CD4+ T cells play a crucial and pivotal role in adaptive 
immunity, for the development of an antibody-based immunity (Collen et al., 1989; 
Collen and Doel, 1990) as well as cytotoxic T cell responses (Gao et al., 2002; Katrak 
et al., 1991; Ossendorp et al., 1998). Therefore, the identification of CD4+ T-cell 










5.2.1 Prediction of HLA-DR-restricted epitopes 
Computer-generated programs which predict MHC class II binding peptides 
are based on the identification of HLA-DR allele-specific motifs in antigenic peptides 
and on the structural definition of HLA-peptide complexes. The primary amino acid 
sequence of the VP1 capsid protein of EV71 strain 41 was analyzed using the T-cell 
epitope prediction ProPred algorithm which led to the identification of promiscuous 
regions potentially binding to HLA-DR molecules. Three regions (I to III) were 
predicted to bind more than 50% of the 51 HLA-DR alleles available in the ProPred 
database and were therefore considered as promiscuous CD4+ T-cell epitopes (Figure 
5.1). These regions map at amino acids 66 to 77, 145 to 159 and 247 to 261 of the 
VP1 protein (Table 5.1). The corresponding peptides, namely SP1, SP2 and SP3, 
respectively, were synthesized as well as a fourth peptide SP4 (scrambled), 
representing a VP1 region with poor prediction for promiscuous binding. A protein-
protein BLAST (blastp 2.2.17) search indicated that the amino acid sequences of all 
















Figure 5.1 An output of ProPred analysis of the VP1 amino acid sequence in 
HTML view II for binding to 51 HLA-DR alleles. The sequence was analyzed for 
binding to 51 HLA-DR alleles using the ProPred program at the default setting 
(threshold value of 3). The peptide sequences predicted to bind more than 50% of the 
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VP1 Amino Acid Sequences Positions 
SP1 I H - IETRCVLNSHSTAET - OH 63 – 77 
SP2 II H - EVVPQLLQYMFVPPG - OH 145 – 159 
SP3 III H - LVVRIYMRMKHVRAW - OH 247 – 261 
SP4 NA H - PTGQNTQVSSHRLDT - OH 27 – 41 
 
a peptides (SP1 to SP3) representing VP1 regions considered promiscuous for binding 
more than 25 different HLA-DR alleles. Peptide SP4 represents a scrambled peptide 
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5.2.2 HLA-DR typing and detection of anti-EV71 antibodies in human 
volunteers 
A total of twenty human volunteers were recruited and HLA-DR genotyped 
for this study. Only six displayed HLA-DR alleles which were represented in the 
ProPred database. The sera of these six volunteers were screened for the presence of 
anti-EV71 neutralizing antibodies by in vitro microneutralization assay. Among these 
six volunteers, five were sero-diagnosed positive for the presence of anti-EV71 
neutralizing antibodies with a neutralizing titer of 1:8 and above and one was 
identified as EV71-negative (Table 5.2). All volunteers were found negative for EV71 
by cultural analysis indicating that none of them were currently infected with the 
virus. Western blot analysis was subsequently performed using a recombinant GST-
VP1 fusion protein as capture antigen to detect anti-VP1 IgG antibodies in the serum 
of each volunteer. As expected, a positive signal was observed when using serum 
samples from all EV71-positive volunteers whereas no signal was detected in the 
EV71-negative volunteer, confirming previous studies which described VP1 as a 
highly immunogenic antigen (Chen et al., 2006; Chiu et al., 2006; Foo et al., 2007a; 









     Table 5.2 EV71 exposure of volunteers and predicted peptide binding efficiencies. 
 
Volunteers HLA genotypes Serum anti-EV71 
neutralizing antibody titera 
Anti-VP1 IgG 
antibodyb 
Predicted binding efficiency (%)c 
    SP1 SP2 SP3 SP4 
1 DRB1*0301    1:128 + 0 93 60 0 
2 DRB1*0301  1:64 + 0 93 60 0 
3 DRB1*0301 > 1:256 + 0 93 60 0 
4 DRB1*0405 > 1:256 + 60 60 60 0 
5 DRB1*1301  1:64 + 93 100 86 0 
6 DRB1*0301 - - 0 93 60 0 
 
a Serum anti-EV71 neutralizing titer was determined using an in vitro microneutralization assay. 
 
b Immunoblots using recombinant GST-VP1 fusion protein as capture antigen and 1:50 diluted serum sample from each volunteer as 
primary antibody. (+) represents the presence of a 58.7kDa band corresponding to the GST-VP1 fusion protein indicating the presence of 
specific anti-VP1 IgG antibody. 
 
c Predicted binding efficiency of peptides based on specific HLA-DR allele. 
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5.2.3 CD4+ T cell  proliferative responses 
CD4+ T cells isolated from EV71-positive and -negative volunteers were 
stimulated with VP1-derived peptides (SP1 to SP4) or heat-inactivated EV71 whole 
virions using autologous monocytes-derived dendritic cells (MoDCs) as professional 
antigen-presenting cells (APCs). The cellular proliferative responses were expressed 
as stimulation index (SI) which corresponds to the ratio of the counts per minute 
(cpm) in the presence of antigen over the cpm without any antigenic stimulus. As 
expected, for all EV71-positive volunteers, elevated CD4+ T cell proliferative 
responses were observed upon stimulation with EV71 whole virions (Figure 5.2). 
However, stimulation with SP4 (scrambled peptide) did not result in any significant 
proliferative response regardless of the HLA-DR alleles tested. 
 
A weak but non-negligible CD4+ T-cell proliferative response was observed 
for the EV71-negative volunteer upon stimulation with EV71 whole virions. CD4+ T 
cells isolated from EV71-positive volunteers proliferated significantly and with 
similar amplitudes upon stimulation with peptide SP2. However, the SI obtained upon 
stimulation with peptide SP1 or SP3 differ from one HLA-DR allele to another and 
was either similar or lower than the SI obtained upon SP2 stimulation (Figure 5.2). 
This data correlate with the ProPred analysis which predicted for the five EV71-
positive volunteers; a higher binding efficiency for the VP1 region II (represented by 
SP2) as compared to regions I and III (represented by SP1 or SP3) (Table 5.2). 
 
Furthermore, stimulation with SP1 failed to induce a significant CD4+ T cell 
proliferation for EV71-positive volunteers with HLA genotype DRB1*0301 
(volunteers 1 to 3) which again, correlates with the ProPred program’s predictions 
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(Table 5.2). Similarly, the SI obtained upon SP3 stimulation reflected well on the 
ProPred analysis which predicted that region III (corresponding to SP3 peptide) 
displays the highest binding efficiency for HLA genotype DRB1*1301. In addition, a 
background SI value was consistently obtained upon stimulation of CD4+ T cells 
isolated from the EV71-negative volunteer with any of the stimulating antigens, 
indicating that the proliferative responses observed for volunteers 1 to 5 resulted from 
EV71-specific CD4+ T cells (Figure 5.2). 
 
Altogether, these data indicate that the ProPred program accurately predicted 
the binding efficiency for each peptide depending on the HLA-DR allele and therefore 
represents a reliable prediction approach to identify potential CD4+ T-cell epitopes. 
The results also suggest that SP2 contains a promiscuous epitope which is able to 






















Figure 5.2 Proliferation of CD4+ T cells upon stimulation with peptides or EV71 
whole virions. Heat-inactivated EV71 whole virions, peptides (SP1 to SP4) or no 
antigen were first added to the monocyte-derived dendritic cells (MoDCs) prepared 
from each volunteer for activation before incubation with autologous CD4+ T cells. 
[methyl-3H] thymidine was added into the culture medium 24 h before counting. The 
stimulation index (SI) was calculated as the ratio of the counts per minute (cpm) in 
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5.2.4 MHC class II-blocking experiment 
To confirm that the observed CD4+ T-cell proliferation is mediated via peptide 
presentation in association with MHC class II molecules, a MHC class II-blocking 
experiment was carried out. Peptide SP2 and anti-human MHC class II monoclonal 
antibodies were incubated with immature DCs (imDCs) from EV71-positive 
volunteers and CD4+ T-cell proliferative responses were measured as described 
above. The co-incubation with anti-MHC class II antibodies resulted in a reduction of 
the SP2-induced CD4+ T-cell proliferation by more than 80% (Figure 5.3). Since, no 
antibody-specificity controls such as anti-MHC class I antibodies or isotype-matched 
control antibodies were used in this assay, this data can only suggest that SP2 is 
presented by APCs in association with MHC class II molecules to effectively induce 
EV71-specific CD4+ T cell proliferation and that SP2 may contain a MHC class II-
restricted CD4+ T-cell epitope.  
 
5.2.5 Cytokine profile upon antigenic stimulation 
To address whether antigens induce CD4+ T cell differentiation into Th1- or 
Th2-type subsets, cytokine production by proliferating CD4+ T cells was analyzed 
upon stimulation with either peptides (SP1 to SP4) or heat-inactivated EV71 whole 
virions. Significant levels of IL-2 and IFN-γ were detected in the supernatant of the 
SP1-, SP2-, SP3- and EV71-stimulated CD4+ T cells from EV71-positive volunteers 
(Table 5.3). Similar to the proliferative responses, CD4+ T cells from all EV71-
positive volunteers secreted higher levels of IL-2 and IFN-γ in response to SP2 as 
compared to SP1 and SP3. No significant differences in the production of IL-4 and 
IL-10 were observed upon stimulation with SP1 to SP4 and those without any 
antigenic stimulus (Table 5.3). However, significant levels of IL-4 were detected 
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when using EV71 whole virions as stimulants for CD4+ T cells from all EV71-
positive and -negative volunteers. Instead, a significant level of IL-10 was measured 
in EV71-stimulated CD4+ T cells from EV71-positive volunteers only. Altogether, 
these data indicate that the levels of cytokine production correlate well with the CD4+ 
T-cell proliferative responses, with SP2 triggering the highest cytokine production 
regardless of HLA-DR alleles. Significant production of IL-2 and IFN-γ by 





























Figure 5.3 Proliferation of SP2-stimulated CD4+ T cells in the presence of anti-
human MHC class II monoclonal antibodies. Peptide SP2 (20µg/ml) was added to 
the monocyte-derived dendritic cells (MoDCs) from each EV71-positive volunteer 
with or without MHC class II blocking antibodies (20µg/ml). The mixtures were then 
incubated with autologous CD4+ T cells and stimulation index (SI) was calculated as 
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Table 5.3 Antigen-specific cytokinea secretion by stimulated CD4+ T cells. 
 
 IL-2 (pg/ml) 
Volunteers SP1 SP2 SP3 SP4 EV71 No antigen 
1  4.8 (± 1.9) 42.0 (± 1.0) 13.9 (± 3.1) 4.3 (± 1.1) 102.5 (± 2.2) 2.0 (± 0.7) 
2  6.2 (± 2.9) 26.9 (± 2.1) 20.3 (± 1.5) 3.8 (± 1.3) 107.7 (± 2.8) 2.6 (± 1.1) 
3  3.3 (± 1.3) 35.4 (± 1.9) 19.8 (± 1.6) 5.4 (± 1.2) 106.2 (± 3.0) 2.7 (± 0.8) 
4 28.1 (± 4.6) 22.6 (± 2.3) 23.0 (± 1.8) 5.4 (± 2.0) 108.2 (± 1.7) 2.1 (± 1.5) 
5 38.3 (± 1.7) 33.0 (± 2.7) 34.2 (± 2.4) 6.2 (± 1.6) 106.4 (± 4.5) 2.6 (± 1.1) 
6   4.1 (± 1.7)   9.3 (± 1.7)   4.8 (± 1.1) 5.1 (± 1.3)   79.4 (± 2.7) 2.7 (± 0.8) 
 IFN-γ (ng/ml) 
Volunteers SP1 SP2 SP3 SP4 EV71 No antigen 
1 12.9 (± 1.8) 65.6 (± 3.8) 40.3 (± 3.8) 1.4 (± 1.5) 684.5 (± 3.4) 0.9 (± 0.3) 
2 13.7 (± 1.7) 48.4 (± 1.3) 31.5 (± 3.3) 1.7 (± 0.2) 236.1 (± 2.3) 1.1 (± 0.7) 
3 17.4 (± 1.2) 69.0 (± 1.2) 40.8 (± 2.2) 1.4 (± 0.6) 957.6 (± 2.1) 1.4 (± 1.1) 
4 34.4 (± 2.1) 45.5 (± 1.6) 32.0 (± 1.3) 1.6 (± 0.5) 643.8 (± 3.6) 1.1 (± 0.6) 
5 46.6 (± 2.9) 61.9 (± 3.6) 48.2 (± 1.2) 1.8 (± 0.4) 384.3 (± 2.8) 1.4 (± 1.1) 
6   0.8 (± 0.5)   1.0 (± 0.5)   0.8 (± 0.3) 0.5 (± 0.4)   38.3 (± 1.2) 0.6 (± 0.3) 
 IL-4 (pg/ml) 
Volunteers SP1 SP2 SP3 SP4 EV71 No antigen 
1   2.6 (± 1.5)   4.3 (± 4.5)   3.4 (± 0.8)  2.5 (± 1.0)  34.9 (± 1.3) 2.6 (± 1.2) 
2   3.1 (± 1.7)   3.4 (± 2.7)   3.3 (± 0.4)  2.2 (± 1.9)  26.9 (± 4.8) 2.1 (± 1.3) 
3   3.4 (± 1.2)   3.9 (± 3.3)   3.3 (± 2.0)  2.6 (± 1.4)  22.8 (± 2.1) 2.6 (± 1.3) 
4   3.0 (± 1.6)   3.1 (± 0.6)   3.9 (± 1.4)  3.2 (± 1.6)  33.1 (± 0.5) 2.7 (± 1.6) 
5   4.1 (± 4.6)   3.9 (± 3.3)   3.8 (± 4.3)  3.2 (± 1.5)  26.5 (± 2.2) 2.2 (± 0.9) 
6   2.8 (± 1.7)   2.6 (± 1.6)   2.4 (± 1.1)  2.5 (± 0.8)  19.3 (± 0.4) 2.2 (± 0.8) 
 IL-10 (ng/ml) 
Volunteers SP1 SP2 SP3 SP4 EV71 No antigen 
1   1.2 (± 0.1)   1.2 (± 0.2)   1.2 (± 0.2)   1.2 (± 0.2)  31.5 (± 0.2)  1.1 (± 0.2) 
2   1.2 (± 0.2)   1.5 (± 0.2)   1.2 (± 0.2)   1.2 (± 0.2)  22.9 (± 0.3)  1.1 (± 0.3) 
3   2.1 (± 0.2)   2.1 (± 0.2)   2.3 (± 0.3)   2.0 (± 0.3)  23.9 (± 0.8)  1.9 (± 0.1) 
4   1.6 (± 0.2)   1.9 (± 0.1)   1.8 (± 0.1)   1.1 (± 0.4)  24.4 (± 0.2)  1.1 (± 0.4) 
5   2.0 (± 0.3)   2.3 (± 0.3)   2.6 (± 0.2)   1.8 (± 0.1)  11.5 (± 0.3)  1.8 (± 0.2) 
6   1.3 (± 0.4)   1.4 (± 0.4)   1.3 (± 0.3)   1.2 (± 0.1)    3.1 (± 0.1)  1.0 (± 0.4) 
 
a Secretion of cytokines of Th1- (IL-2 and IFN-γ) and Th2- (IL-4 and IL-10) type 
subsets by CD4+ T-cells upon stimulation by autologous MoDCs in response to 
peptides, EV71 whole virions (20µg/ml) or no antigen. Values represent average of 













The host immune response developed upon any viral infection is primarily 
CD4+ T cell dependent including the induction of a cytotoxic cellular response and the 
development of an efficient antibody response. Several studies on B-cell epitopes led 
to the identification of serotype- and group-common specific B-cell epitopes on the 
VP1 capsid protein of enteroviruses (Cello et al., 1993). The functional role of 
enterovirus-specific T-cells as well as the nature and specificity of their responses 
have been less well-characterized so far. Although animal studies have been carried 
out to identify T-cell epitopes on four structural proteins (VP1 to VP4) of 
enteroviruses (Beck and Tracy, 1989; Katrak et al., 1991; Kutubuddin et al., 1992; 
Mahon et al., 1992; Wang et al., 1989), only few studies based on the VP1 capsid 
protein were carried out in humans (Graham et al., 1993; Simons et al., 1993). 
Several approaches have been reported for the identification of T-cell epitopes. 
Overlapping synthetic peptides spanning the entire sequence of the protein candidate 
can be designed and assayed for their capabilities of activating CD4+ T cells (Arend et 
al., 2000; Ravn et al., 1999; Vordermeier et al., 2001). However, such systematic 
approach is costly, time-consuming and tedious. 
 
Alternatively, prediction programs can be used to scan the protein of interest 
and predict regions likely to bind to MHC molecules. The discovery of MHC-binding 
motifs in proteins has led to the development of several computer algorithms based on 
the construction of a matrix of all possible amino acid side chain interactions for 
individual MHC-binding motifs (De Groot et al., 1997; Hammer et al., 1994). Such 
bioinformatics tools have been successfully employed to identify HLA-DR ligands 
derived from tumor antigens and endogenous proteins involved in autoimmune 
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diseases (Hammer et al., 1997; Manici et al., 1999). In addition, these programs have 
been reported to improve and accelerate the design of vaccines and diagnostic tests 
through the identification of promiscuous peptides from mycobacterial proteins 
(Panigada et al., 2002; Vordermeier et al., 2003). In this study, the ProPred program 
was employed to predict HLA-DR binding ligands within the VP1 capsid protein of 
EV71 strain 41 since HLA-DR constitutes the dominant isotype of human MHC class 
II molecules (Tsuji et al., 1992). Activation of CD4+ T cells is dependent upon the 
presentation of peptides by APCs in the context of MHC class II molecules. These 
peptides are generally of approximately 15 amino acids in length and derived from 
internalized proteins that entered the endocytotic pathway. The MHC genes are the 
most polymorphic present in the genome and the majority of the amino acid 
differences amongst the various alleles lie within the peptide-binding groove of the 
MHC class II molecules (Oftung et al., 1997). 
 
Upon analysis, numerous regions within VP1 were predicted to bind one or 
few HLA-DR alleles, but only three regions (I, II and III) were predicted to bind 50% 
or more HLA-DR alleles included in the ProPred database. These regions span amino 
acids 63 to 77, 145 to 159 and 247 to 261 of the VP1 protein, respectively. The 
corresponding peptides (SP1 to SP3) were synthesized and shown to be able to induce 
the proliferation of CD4+ T cells from EV71-positive volunteers with different HLA-
DR alleles but not from an EV71-negative volunteer, indicating that the peptides have 
stimulated EV71-specific memory CD4+ T cells. The stimulation indexes (SI) 
obtained correlated well with the binding efficiencies predicted for each peptide and 
for each HLA-DR allele. Among the three peptides tested, SP2 was identified to be 
the most capable of inducing significant CD4+ T-cell proliferative responses 
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regardless of HLA-DR alleles, and therefore corresponds to the definition of a 
promiscuous CD4+ T-cell epitope. Studies have shown that although several T-cell 
epitopes are present within the entire protein antigen, T-cells tend to focus only on a 
few immunodominant epitopes whereas discrete cryptic epitopes remain unseen by 
the host immune system (Gao et al., 1999; Novak et al., 2001). Therefore, SP2 most 
likely contains an immunodominant CD4+ T-cell epitope. In addition, using anti-
MHC class II antibody, we have demonstrated that SP2 suggests to be a MHC class 
II-restricted CD4+ T-cell epitope. 
 
 An ideal synthetic peptide-based vaccine should contain both B-cell epitope(s) 
and T-cell epitope(s) that are able to induce a protective antibody response as well as 
a cytotoxic T-cell response important for killing infected host cells. The first 
generation of peptide vaccines which includes both B- and T-cell epitopes has been 
reported and shown to have a very good protective efficacy (Tam, 1996). In addition, 
antigen-specific CD4+ T-cells producing IFN-γ have been shown to be essential for 
activation and maintenance of CD8+ T-cell-mediated immune responses and for B-cell 
differentiation (Gao et al., 2002; Ossendorp et al., 1998). A previous study on the 
identification of enterovirus cross-reactive T-cell epitopes suggested that IFN-γ 
release may be used as an indicator for specific T-cell activation (Cello et al., 1996). 
However, a poor correlation between the degree of antigen-specific T-cell 
proliferation and IFN-γ production has been previously reported, suggesting that 
proliferating and IFN-γ-producing T cells may belong to functionally different subsets 
(Cello et al., 1996). Instead, our results showed that the levels of IFN-γ secreted by 
peptide-stimulated CD4+ T cells correlated well with the respective proliferative 
responses. In addition, the significant production of IL-2 and IFN-γ upon stimulation 
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with SP1 to SP3 clearly indicates a Th1-subtype differentiation. Instead, the cytokine 
production profile observed when stimulating with EV71 whole virions suggested a 
mixed Th1-Th2 response, as evidenced by the production of significant levels of IFN-
γ, IL-2, IL-4 and IL-10. Interestingly, a weak but significant proliferative response 
and cytokine production were observed by EV71-stimulated CD4+ T cells from the 
EV71-negative volunteer. However, neither anti-EV71 neutralizing activity nor anti-
VP1 antibodies were detected in the serum. It is likely that this volunteer might have 
been exposed to cross-reactive enteroviruses such as coxsackievirus 16 (CA16) or 
poliovirus as a result of the National childhood immunization program. 
   
In conclusion, we have identified three promiscuous CD4+ T-cell epitopes 
within the VP1 capsid protein of EV71. We have shown that the ProPred program has 
accurately predicted the presence of these epitopes and their binding efficiencies to 
three different HLA-DR alleles. However, to confirm the promiscuous feature of 
these epitopes, more HLA-DR alleles should be tested. Among these three epitopes, 
one spanning amino acids 145 to 159 of VP1 appeared to be the most promiscuous, 
inducing high proliferation of, and cytokine production by, EV71-specific CD4+ T 
cells. We believe that the identification of CD4+ T-cell epitopes within VP1, the major 
immunogenic and protective antigen, will contribute to a better understanding of the 
immune correlates of protection against EV71 infections and will help in developing 
more effective immuno-therapeutic and immuno-prophylactic strategies. 
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CHAPTER 6  CONCLUSIONS 
 
 
Enterovirus 71 (EV71) has been increasingly recognized as a major etiological 
agent for Hand, foot and mouth disease (HFMD) which has been associated with 
significant mortality in young children and infants during large scale outbreaks in the 
Asia-Pacific region over the last few years. Unlike CA16 which has limited 
pathogenicity, EV71 can give rise to major complications involving the central 
nervous system and this has raised public concern. At present, the only successful 
approach to prevent and control the spread of EV71 is by public health surveillance 
and quarantine. There are several promising therapeutic drugs with antiviral 
properties targeting enteroviruses but they are still undergoing clinical trials. 
However, a major obstacle to the successful use of these drugs in EV71-associated 
encephalitis is that most children may have already suffered irreversible brain damage 
due to the high viral load before diagnosis and treatment. Although the drugs may 
have successful antiviral activities against EV71, it is not likely that much clinical 
improvement can be expected after treatment. Hence, major research efforts are 
required to emphasize on the prevention of EV71 infection instead of therapy and this 
can be carried out via the development of effective vaccines. Vaccination is one of the 
most successful public health initiatives ever achieved. However, for some diseases, 
vaccine designs is a challenge. Several strategies have been devised to deliver specific 
and immunogenic vaccine components to the immune system in the hope of eliciting 
a therapeutic or prophylactic immune response. One such beneficial strategy is to 
select particular protein antigens from the microorganism for inclusion into 
recombinant vaccines. The most precise selection of vaccine component exists in 
epitope-based peptide vaccines.  
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6.1 Synthetic peptides as candidates to elicit protective antibodies 
In this study, the characterization of linear neutralization epitopes on the VP1 
capsid protein of the EV71 strain 5865/SIN/00009 (designated as Strain 41) was 
undertaken by analysis of Balb/c mice antisera raised against 95 diphtheria toxoid-
conjugated synthetic peptides spanning the entire VP1 region. Two synthetic peptides, 
designated SP55 and SP70, successfully elicited high titers of neutralizing antibodies 
against EV71. As neutralizing response plays a protective role against viral 
infectivity, EV71-neutralizing antibodies elicited by synthetic peptides SP55 and 
SP70 were characterized based on their specificities and functional roles in the 
neutralization process. These peptide epitopes represent the minimal immunogenic 
region of VP1 protein antigen, and allow for precise direction of immune responses. 
The in vivo protective potential of EV71-neutralizing antibodies elicited by SP70 was 
also evaluated in mice by passive transfer of immune sera which demonstrated that 
the anti-SP70 antisera was able to confer in vivo passive protection of up to 80% 
survival rate in suckling Balb/c mice which have been challenged with either the 
homologous or heterologous EV71 strains. The protective efficacy induced by SP70 
was comparable to the heat-inactivated EV71 whole virion as particulate antigen. 
Traditionally, vaccines have consisted of either live attenuated microorganisms or 
inactivated microorganisms delivered via injection. However, many pathogenic 
microorganisms are difficult to culture in vitro, and therefore production of live 
attenuated or inactivated vaccines of these pathogens is impractical. In addition, 
features of even attenuated microorganisms may result in detrimental immune 
responses, or the pathogen may contain material that initiates unwanted host 
responses. Hence, although the use of whole virion has been commonly 
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acknowledged as a good vaccine candidate, this study has shown that synthetic 
peptides can also be used to elicit good immune responses. 
 
Compared with conventional vaccines, synthetic peptide offers several 
advantages over other forms of vaccines, particularly with regards to safety and ease 
of production. There is no risk of reversion or formation of adverse reassortants that 
can lead to virulence, which is a potential problem with live attenuated vaccine 
preparations. As compared to DNA vaccines, peptide-based vaccine has no risk of 
genetic integration or recombination. In addition, the advantage of a peptide-based 
strategy focus on the short amino acid sequence used to elicit protective immune 
responses which result in the production of antibodies against specific sites on the 
antigen. Therefore, considering the differences in genomic sequence between various 
EV71 strains due to mutations, only minor alteration to the synthetic peptide sequence 
is needed and hence newly synthesized peptides can be manufactured. However, easy 
as it may seems, peptide-based vaccine depends upon a short amino acid sequence to 
confer protection and antibodies raised against a specific region may not neutralize 
other EV71 strains especially if mutations occur within neutralizing epitopes. 
Different peptide candidates have to be designed according to identified neutralizing 
region(s) of different EV71 strains. Hence, due to several fatality cases caused by 
infections from EV71 strains belonging to different subgenogroups and the rapid 
evolution of the virus within the community, this emphasizes the importance of 
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6.2 Improvements to synthetic peptide-based prophylactic strategy 
Although previous studies have shown that the entire VP1 protein may elicit a 
significant immune response (Chen et al., 2006; Wu et al., 2001), the use of longer 
peptide precursors is not always desirable as tissue-specific processing and the 
frequent non-concordance of processing of longer exogenous peptides compared with 
endogenous antigens can result in unwanted immune responses. In this study, when 
all 95 synthetic peptides were screened against sera from human who have been 
exposed to EV71, SP70 was not identified to be reactive in the IgG-based ELISA. 
This suggests that during exposure to the whole virion, the neutralizing epitope 
represented by SP70 may not be presented by antigen-presenting cells (APCs) to elicit 
antibodies or the titer of anti-SP70 antibody present in the serum samples is lower 
than the detection limit. Nevertheless, this study has shown that SP70 contains the 
linear VP1 neutralizing epitope and anti-SP70 antibodies raised against the peptide 
are able to neutralize EV71 and hence confer good in vitro and in vivo protection 
against EV71 infectivity. Therefore, considering the use of SP70 as a potential 
peptide-based vaccine candidate, further improvement will be required especially on 
its mode of delivery. It is known that some drawbacks of peptide-based vaccine 
include the need to potently enhance the immunogenicity of the simple peptide, to 
stimulate T cells and to elicit immunological memory responses (Aguilar and 
Rodriguez, 2007; Brown and Jackson, 2005). Adjuvant science, lipopeptide 
conjugation and direct delivery to dendritic cells (DCs) are some of the approaches 
currently used to overcome these problems (Brown and Jackson, 2005). The covalent 
and non-covalent attachment of peptides to proteins that generally have some role in 
the innate immune response or target the proteins to receptors on APCs can be 
investigated as a mode of delivery and as an adjuvant for bound peptides (Aguilar and 
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Rodriguez, 2007; Brown and Jackson, 2005). Considering that peptide-based 
immunogens may be poor inducers of T-cell response, another approach to enhance 
the induction of T cells upon vaccination is to use protein transduction domains 
(PTDs) coupled to the protein immunogens to enhance their uptake by DCs and hence 
mediate their presentation to T cells. However, a recent study has demonstrated the 
successful use of human cytomegalovirus tegument protein pp65 as an alternative 
protein carrier to PTDs with a higher uptake efficiency by DCs and hence making 
pp65 a promising delivery system to induce significant immune responses for peptide-
based vaccine (Scheller et al., 2008). 
 
One of the goals for vaccination is to induce immunity by selectively 
stimulating antigen-specific B cells and T cells, and hence a good vaccine should 
contain two antigenic epitopes which will induce both T-helper cell and B cell. 
However, the use of epitope-based vaccines is restricted to human of a given HLA 
haplotype, and as such need to be tailored to accommodate the natural variation in 
HLA genes. Epitope prediction remains a popular first-screening approach to identify 
candidate T cell determinants for subsequent biological validation. In this study, the 
identification focused on the use of a CD4+ T-cell epitope prediction program, 
ProPred, to predict HLA-DR binding ligands within VP1. Since predictive algorithms 
are frequently combined with in vitro MHC-binding assays to confirm that the 
predicted ligands bind to the targeted MHC molecule (Buus, 1999), the predicted 
peptides in this study have shown to be capable of specifically inducing the 
proliferation of CD4+ T cells from humans who have been exposed to EV71, 
indicating that the peptides have indeed stimulated EV71-specific memory CD4+ T 
cells. 
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As the induction of B-cell response is generally dependent on the additional 
stimulation of CD4+ T-helper cell, an alternative approach to peptide-epitope vaccine 
design is to covalently couple the B-cell epitope to one or two immunodominant 
CD4+ T-cell epitope(s) that are selected from the numerous potential MHC class II 
ligands or to carrier protein which will provide a good source of T-cell epitopes. In 
this study, diphtheria toxoid was conjugated to the synthetic peptides as a carrier 
protein to enhance the immunogenicity of these peptides. However, in a clinical 
setting, the provision of T-cell help can be more readily achieved using defined T-cell 
epitopes that are matched to the haplotype of patients (Purcell et al., 2003). In this 
study, the identification of human CD4+ T-cell epitopes within VP1 will help in the 
development of a more effective immuno-prophylactic strategy when coupled with 
SP70 as the B-cell epitope, thereby enhancing the recruitment of T cells as well as the 
production of cytokines necessary for B-cell activation and differentiation into plasma 
cells. 
 
6.3 Alternative diagnostic strategy 
Beside vaccine development, the use of synthetic peptide instead of the whole 
virion as an alternative source of capture antigen in immunoassays may be an 
interesting approach for the serodiagnostic of EV71 infection. Pepscan analysis using 
overlapping synthetic peptides has been widely used for identifying antigenic 
epitope(s) of viruses and this study focused on the use of overlapping synthetic 
peptides to identify the major human immunodominant VP1 linear epitope of EV71. 
This epitope, represented by SP32, was produced as a soluble recombinant GST-SP32 
fusion protein at high yields and when used as capture antigen in Western blot, a 
strong and specific immunoreactivity was obtained with human anti-EV71 IgG 
CHAPTER 6 CONCLUSIONS 
___________________________________________________________________________________ 
_______________________________________________________________________________ 172
antibodies. Compared with the use of EV71 whole virion, SP32 has a higher 
serological specificity and sensitivity as a capture antigen. Moreover, it has the 
additional advantage of reduced time of antigen production when compared with the 
laborious and expensive propagation of EV71 in the laboratory. However, it is 
noteworthy that such approach may be improved by the inclusion of other peptides, 
representing immunodominant linear epitopes identified within other capsid proteins. 
Nevertheless, this study suggests that SP32 could be further developed as a serologic 
reagent for the detection of human anti-EV71 IgG antibodies and the assay described 
here may constitute an important tool for the diagnosis of EV71 or a confirmatory 
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Media for Bacterial Culture 
 
 
LB (Luria-Bertani) Medium, per liter (Miller, 1972) 
 
NaCl    10 g 
Trytone   10 g 
Yeast extract     5 g 
 
For agar preparation, 15 g of Oxoid Agar Technical No. 3 was added before 











































Materials for Tissue Culture 
 
 
10x Minimum Essential Medium (MEM) Powder (Gibco BRL) 
 
The powdered medium is supplemented with Earle’s salt, L-glutamate, non-essential 
amino acids, without sodium bicarbonate. The MEM medium was prepared by 




MEM Growth Media 
 
1x MEM     90.5 ml 
1x Penicillin/Streptomycin     1.0 ml 
Fetal Calf Serum (FCS)     5.0 ml 
1.0 M HEPES Buffer      2.0 ml 
7% Sodium Bicarbonate     1.5 ml 
 
The media was stored at 4oC until used. 
 
 
MEM Reviving Media 
 
1x MEM     85.5 ml 
1x Penicillin/Streptomycin     1.0 ml 
Fetal Calf Serum (FCS)   10.0 ml 
1.0 M HEPES Buffer      2.0 ml 
7% Sodium Bicarbonate     1.5 ml 
 
The media was stored at 4oC until used. 
 
 
MEM Freezing Media 
 
1x MEM     89.5 ml 
1x Penicillin/Streptomycin     1.0 ml 
Fetal Calf Serum (FCS)     5.0 ml 
1.0 M HEPES Buffer      2.0 ml 
7% Sodium Bicarbonate     1.5 ml 
Dimethyl sulphoxide (DMSO)    1.0 ml 
 
The media was prepared fresh before carrying out the procedure for cell freezing. 








TN Buffer, per litre 
 
Tris-HCL     50 mM 
NaCl      50 mM 
 
The pH was adjusted to 7.8 and the volume was prepared up to 1 L with sterile 
distilled water before further sterilization by membrane filtration. 
 
 
30% Sucrose Gradient Cushion, per litre 
 
A. Solution I 
 
Tris-Acetate    20 mM 
NaCl          1 M 
 
The volume was prepared up to 600 ml with sterile distilled water. 
 
B. Solution II 
 
Sucrose      300 g 
 
The volume was prepared up to 400 ml with sterile distilled water. 
 
For a final 1 L preparation, both solutions I and II were added together before further 






































No. of wells 
showing CPE 



















10-3 4/4 9 0 9/9 100 
10-4 3/4 5 1 5/6 83 
10-5 2/4 2 3 2/5 40 
10-6 0/4 0 7 0/7 0 
 
TCID50 was calculated using the Reed using and Muench formula. 
 
1. The cumulative number of infected wells was obtained by adding all the 
wells which showed CPE at every dilution. 
(e.g. at dilution 10-5, 2 wells showed CPE. At dilution 10-4, 3 wells 
showed CPE. Hence, the total number of wells which were showed CPE 
up to dilution factor 10-4 was 2 + 3 = 5) 
 
2. The cumulative number of wells which were not infected with the virus 
was obtained by subtracting the number of wells which showed CPE from 
the number of wells inoculated. 
(e.g. at dilution 10-4, 1 well did not show CPE. At dilution 10-5, 2 wells did 
not show CPE. Hence, the total number of wells which did not show CPE 
up to the dilution factor 10-5 was 1 + 2 = 3) 
 
3. The percentage of infectivity was calculated by dividing the total sum of 
the wells which showed CPE and those did not show CPE by the 
cumulative number of wells which showed CPE. 
(e.g. at dilution 10-4, 5/5+1 = 0.83 = 83%) 
 
4. The proportionate distance between the two dilutions, 10-4 and 10-5 , where 
50% lies: 
 
Infectivity above 50% - 50%    83 - 50 
         =          =    
0.7 
Infectivity above 50 % - Infectivity below 50%   83 - 40 
 
5. TCID50 end point calculation: The negative logarithm of the dilution factor 
which was the closet to 50% was -4. Hence, the TCID50 end point = -4.0 + 





6. Interpretation of TCID50 titer: A virus suspension with a TCID50 of 10-4.7 
per 0.1 ml represents one TCID50: at such dilution, 50% of the cultures 
inoculated with the virus will be infected. A dilution of 10-2.7 will contain 

























































 5% Separating Gel 
(10 ml total) 
12% Stacking Gel 
(10 ml total) 
 
30% acrylamide / 0.8% N,N`-methylene 
bisacrylamide 
4,000 μl 1,700 μl 
1.5 M Tris-HCl, pH 8.8 2,500 μl  - 
1.0 M Tris-HCl, pH 6.8 - 1,250 μl 
10% SDS    100 μl    100 μl 
10% Ammonium persulphate    100 μl    100 μl 
TEMED        5 μl      10 μl 
dH20 3,295 μl 6,840 μl 
 
 
6x SDS Gel Loading Dye 
 
Tris-HCl     0.35 M 
SDS    10.28 % 
Glycerol     36.0 % 
Dithiothreitol (DTT)      0.6 M 
Bromophenol Blue  0.012 % 
 
The pH was adjusted to 6.8 and stored at -20oC until used. 
 
 
SDS Running Buffer 
 
Tris-BASE     25 mM 
Glycine   192 mM 
SDS        0.1 % 
 




SDS Staining Solution 
 
Ethanol    40 % 
Acetic acid    10 % 
Coomassie Brilliant Blue 0.1 % 
Distilled water    50 % 
 





SDS Destaining Solution 
 
Ethanol   40 % 
Acetic acid   10 % 
Distilled water   50 % 
 

















































Materials for Western Blot 
 
 
Western Transfer Buffer 
 
Tris-HCL   3.03 g 
Glycine   1.44 g 
Methanol    200 ml 
 
The volume was prepared up to 1 L with distilled water and stored at 4oC until used. 
 
 
Western Blocking Buffer 
 
Tris-HCL     20 mM 
NaCl    150 mM 
Tween 20     0.05 % 
Bovine Serum Albumin (BSA)      1 % 
 
 
Western Washing Buffer 
 
Tris-HCL     20 mM 
NaCl    150 mM 
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bstract
Enterovirus 71 (EV71) is the main causative agent of Hand, foot and mouth disease (HFMD) and has been associated with severe neurological dis-
ases resulting in high mortalities. Currently, there is no vaccine available and treatment is limited to palliative care. In this study, antisera were raised
n mice against 95 overlapping synthetic peptides spanning the VP1 capsid protein of EV71. Two peptides, SP55 and SP70, containing amino acid
63–177 and 208–222 of VP1, respectively, are capable of eliciting neutralizing antibodies against EV71 in the in vitro microneutralization assay.
P70 was identified to be particularly potent in eliciting a neutralizing antibody titer comparable to that obtained with a whole virion-immune serum.
mmunization of mice with either SP55 or SP70 triggered an EV71-specific IgG response as high as that obtained with the whole virion as immuno-
en. The IgG sub-typing revealed that the neutralizing antibodies elicited by both synthetic peptides are likely belonging to the IgG1 sub-type. Align-
ent with databases showed that the amino acid residues of SP70 are highly conserved amongst the VP1 sequences of EV71 strains from various sub-
enogroups. Altogether, these data indicate that SP70 represents a promising candidate for an effective synthetic peptide-based vaccine against EV71.













teywords: Enterovirus 71; VP1 capsid protein; Synthetic peptides; Neutralizin
. Introduction
Enterovirus 71 (EV71) was first reported in 1974 (Schmidt
t al., 1974) and in recent years, it has caused large outbreaks
ith significant mortality in the Asia Pacific region. EV71
as been associated with an array of clinical diseases, ranging
rom mild exanthemas such as herpangina to aseptic menin-
itis, encephalitis and pulmonary edema. EV71 is also one of
he main etiological agents of Hand, foot, and mouth disease
HFMD) (Hagiwara et al., 1978). In 1998, a HFMD outbreak
aused by EV71 affected more than 100,000 young children
n Taiwan and resulted in 78 deaths (Ho et al., 1999; Liu
t al., 2000). During the period from September to October
000, an outbreak of HFMD occurred in Singapore, affect-
ng mostly children below 6 years of age and resulted in four
atal cases. The most recent epidemic occurring in Sarawak in
∗ Corresponding author. Tel.: +65 6516 3674; fax: +65 6776 6872.
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ebruary 2006 involved 8117 HFMD cases and caused nine
eaths.
Currently, the only means of preventing and controlling the
pread of EV71 during outbreaks is by public health surveillance
nd quarantine. A number of promising antiviral agents with
ctivity against enteroviruses are still undergoing clinical trials.
mong them, the ‘WIN’ group of compounds such as pleconaril
s the most promising of these agents. Their antiviral activity is
hought to be mediated by stabilization of the viral capsid and
ence preventing the virus from uncoating upon receptor binding
Pevear et al., 1999). However, one major obstacle to the success-
ul use of any antiviral agents in EV71-associated encephalitis is
hat most children may have already suffered irreversible brain
amage due to the high viral load before treatment. Although
he antiviral agent may have high level of activity against EV71,
t is unlikely that much clinical improvement can be expected
fter treatment. Consequently, major research efforts are needed
o emphasize on prevention of EV71 infection instead of ther-
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Synthetic peptides are considered promising candidates for
ew-generation vaccines as large quantities of peptides can
e chemically synthesized readily and safely. Other benefits
f using peptide vaccines for immunization are the ability to
mmunize with a minimal structure, consisting of a well-defined
mmunogenic and protective epitope in order to stimulate an
ffective and specific protective immune response while avoid-
ng potential undesirable effects. A peptide vaccine containing
neutralizing epitope can serve as an ideal vaccine as it is capa-
le of inducing specific antibodies that can inhibit the interaction
etween the viral capsid protein and its cellular receptor.
EV71 is a small, non-enveloped, positive single-stranded
NA virus with four capsid proteins VP1, VP2, VP3 and VP4
here VP1 is composed of 297 amino acids and has been shown
o be immunogenic. Immunization using a recombinant VP1
rotein of EV71 was shown to confer protection against lethal
V71 infection in newborn mice, indicating that VP1 contains
mportant antigenic sites that contribute to the neutralization of
he virus (Wu et al., 2001).
In this study, characterization of the linear neutralization epi-
opes on the VP1 capsid protein of the Enterovirus 71 strain
1 (5865/SIN/00009) (belonging to genogroup B4 and isolated
rom a fatal case) was undertaken by the analysis of mice anti-
era raised against 95 diphtheria toxoid-conjugated synthetic
eptides spanning the entire VP1 region. We tested the neutral-
zing abilities of the antisera elicited by the conjugated synthetic
eptides and reported here two of them, designated SP55 and
P70, which successfully elicited high titers of neutralizing anti-
ody against EV71.
. Materials and methods
.1. Design and synthesis of synthetic peptides
A set of 95 overlapping synthetic peptides spanning the entire
equence of the VP1 capsid protein of Enterovirus 71 strain
1 (Genbank accession no. AF316321) were synthesized at
imotopes Pty Ltd. (Clayton Victoria, Australia). Each peptide
ontains 15 amino acid residues with 12 residues overlapping
ith the adjacent peptides. A cysteine residue was added at the
-terminal end for conjugation. Each peptide was chemically
inked to the carrier protein, Diphtheria toxoid (DKP), through
linker, Maleimidocaproyl-N-hydroxysuccinimide.
.2. Virus growth and puriﬁcation
Enterovirus 71 strain 41 (5865/SIN/00009) as the homol-
gous strain and representative EV71 strains from sub-
enogroups B2, B5, C2 and C4 as heterologous strains were
ropagated in rhabdomyosarcoma (RD) cells using minimum
ssential medium (Gibco, USA) supplemented with 5% fetal
alf serum, 1% sodium pyruvate and 1.5% sodium bicarbonate.
he infected cells were harvested and completely lysed by three
ycles of freeze–thaw. The virus from the tissue culture was
urified by precipitation with 7% polyethylene glycol 8000 and
hen centrifuged on a 30% sucrose cushion at 25,000 × g for 4 h.
he virus titer was determined as TCID50 on RD cells based on
2
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typical cytopathic effect (CPE) produced by viral infection.
efore being administered to mice, the homologous virus strain
as inactivated by heating at 56 ◦C for 30 min. The amount of
irion protein was quantified by the Bradford method (Bio-Rad
aboratories, USA).
.3. Mice immunization
Groups of 5 adult (6 weeks old) female Balb/c mice were
ntraperitoneally immunized in a 50% emulsion of Freund’s
omplete adjuvant with either 50g of conjugated synthetic
eptides or heat-inactivated EV71 strain 41 (10g total protein).
wo booster doses in 50% emulsion with Freund’s incomplete
djuvant were given at 3 weeks intervals. Immune sera were
ollected 7 days after the last immunization.
.4. Antibody detection
The levels of antibody to each synthetic peptide were mea-
ured by enzyme-linked immunosorbent assay (ELISA). The
6-well microtiter plates were coated overnight at 4 ◦C with
0l of 0.1 M carbonate buffer (pH 9.6) containing 10g/ml of
nconjugated synthetic peptides or purified virions (EV71 strain
1). After blocking with 2% bovine serum albumin (BSA), plates
ere incubated with 50l of anti-serum at the indicated dilu-
ions at 37 ◦C for 1 h and then washed three times with phosphate
uffered saline (PBS) containing 0.1% Tween 20. Detection was
erformed using secondary horseradish peroxidase-conjugated
oat anti-mouse IgG (H + L) antibody (Bio-Rad Laboratories,
SA) at 37 ◦C for 1 h, followed by three washes. The reaction
as revealed by the addition of the o-phenylenediamine dihy-
rochloride substrate (Sigma Aldrich, USA) and the absorbance
t 450 nm was measured by an ELISA plate reader (Tecan
unrise, USA). Each assay was performed three times indepen-
ently.
The profiles of specific IgG sub-types in the mice anti-sera
ere determined by a commercially available mouse sub-type
sotyping kit (Zymed Laboratories Inc., USA) according to
he manufacturer’s instructions using 10g/ml purified virions
EV71 strain 41) to coat the 96-well microtiter plates. The assay
as performed three times independently.
.5. Western blot
The total proteins of EV71 strain 41 were used to study
he immunoreactivity of the mice hyperimmune sera. Briefly,
iral proteins were transferred onto nitrocellulose membranes,
locked in 1% BSA-PBS and then incubated with the hyper-
mmune sera. A secondary alkaline phosphatase-conjugated
oat anti-mouse IgG (H + L) antibody was used for detection
sing the WesternBreeze® chromogenic immunodetection sys-
em (Invitrogen, USA)..6. Neutralizing antibody assay
The presence of neutralizing antibodies was assayed in an
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amples were incubated at 56 ◦C for 30 min to inactivate the
omplement. Briefly, 25l of two-fold serial serum dilutions
ere mixed with equal volumes of 103 TCID50 of virus in a
6-well microtiter plate and RD cell suspensions (final concen-
ration 5 × 104 cells) were added 2 h later. After incubation for
8 h at 37 ◦C, the neutralizing antibody titer was read as the
ighest dilution of serum that inhibited virus growth. The assay
as performed three times independently.
.7. Computational analysis
The protein sequence of VP1 was analyzed for hydrophobic
nd hydrophilic regions using the Kyte and Doolittle method.
he amino acid sequences of the synthetic peptides were used
s query sequences in a protein–protein BLAST (blastp 2.2.14)





ig. 1. Neutralization assay using antisera from mice immunized with heat-inactiv
ncubated together with the virus and RD cells, and survival of cells was observed 48arch 125 (2007) 61–68 63
ion database. Alignment of the amino acid sequences was
lso undertaken by using the Clustal method of DNASTAR
egAlign.
. Results
.1. Identiﬁcation of neutralizing synthetic peptide antisera
A set of 95 diphtheria toxoid-conjugated synthetic peptides
onsisting of 15 amino acids in length spanning the entire VP1
apsid protein of EV71 strain 41 were individually injected into
roups of two mice. The antisera raised against each peptide
ere analyzed in an in vitro microneutralization assay. Two dis-
inct antisera, obtained from mice immunized with synthetic
eptides SP55 (amino acid residues 162–177) and SP70 (amino
cid residues 208–222), showed significant neutralizing activi-
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ies against infectivity of the homologous EV71 strain (data not
hown).
To confirm the results obtained from this screening, groups of
ve mice were immunized with either the conjugated synthetic
eptides SP55, SP70, SP12 or the heat-inactivated EV71, where
P12 (amino acid residues 34–48) and heat-inactivated EV71
epresented negative and positive control groups, respectively.
The neutralizing activities of the antisera obtained from
he SP55-, SP70-, SP12- or heat-inactivated EV71-immunized
ice were analyzed in an in vitro microneutralization assay,
sing RD cells infected with 103 TCID50 of EV71 strain 41.
omplete protection of RD cells from CPE was observed
ith dilutions ranging from neat to 1:32 of the antiserum
btained from the SP70-immunized mice. The antiserum from
he SP55-immunized mice also showed a neutralizing activity
ith complete protection from CPE at dilutions from neat to 1:8
hereas the heat-inactivated EV71-antiserum gave a complete
rotection from CPE at dilutions up to 1:64 (Fig. 1). Antis-
ra from the naive and SP12-immunized mice did not confer
ny protection to RD cells from CPE (data not shown). Hence,
hese data demonstrated that the immune sera obtained from the
P70- and, to a lesser extent, the SP55-immunized mice con-
ained neutralizing antibodies which suggest that neutralizing
inear epitopes were present in both synthetic peptides SP70
nd SP55.
.2. Immunoreactivity of SP12, SP55 and SP70 antisera
The immunoreactivity of the antisera obtained from mice
mmunized with synthetic peptides SP12, SP55 or SP70 was
ssayed against viral total proteins by Western blot. For each
ntiserum tested, a single band was revealed at an apparent
olecular weight (MW) of 32 kDa (Fig. 2). This band very
ig. 2. Western blot analysis using the synthetic peptide-antisera against EV71
otal proteins. The amount of viral proteins loaded in each lane was 10g. The
anes are as follows: lane M, molecular weight marker; lane 1, antiserum against
ynthetic peptide SP12; lane 2, antiserum against synthetic peptide SP55; lane
, antiserum against synthetic peptide SP70. Arrow indicates the presence of
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ikely corresponds to the VP1 monomer whose apparent MW is
2.7 kDa, indicating that the mice antisera raised against SP12,
P55 and SP70 contained specific VP1 antibodies that do not
ross-react with other viral proteins.
The immuno-specificity of all three antisera towards the
5 synthetic peptides was also assayed by ELISA where the
ynthetic peptides were individually coated onto the 96-well
icrotiter plates. A strong positive signal was obtained when
ntisera were incubated with the corresponding peptide used for
mmunization (homologous peptide). Furthermore, a positive
ignal was also obtained when antisera were incubated with the
eptides whose amino acid sequences overlap the sequence of
he homologous peptide (overlapping peptides). Interestingly,
oth the anti-SP12 and anti-SP55 antisera showed reactivity
gainst the synthetic peptides SP19, SP20, SP21 and SP40, sug-
esting that SP12 and SP55 share common epitopes with SP19,
P20, SP21 and SP40 (Table 1).
.3. Analysis of IgG responses elicited by synthetic peptides
To further characterize the antibody response raised upon
mmunization with the synthetic peptides SP12, SP55 or SP70,
he total IgG response against the whole virion was measured by
LISA. The antibody levels elicited by the synthetic peptides
ere found to be as high as those obtained upon immuniza-
ion with the heat-inactivated EV71 strain 41 (Table 2A). In
ddition, examination of the IgG sub-types revealed that IgG1
ntibodies are predominantly produced in antisera elicited by
he three respective synthetic peptides, and at levels compara-
le to the IgG1 level measured in the antiserum obtained from
V71-immunized mice. In contrast, the levels of IgG2a, IgG2b
nd IgG3 measured in the antisera from mice immunized with
ynthetic peptides were significantly lower than those obtained
n the antiserum from EV71-immunized mice (Table 2B).
hese data indicate that the conjugated synthetic peptides
P12, SP55 and SP70 elicited mainly a Th2 immune response
hereas the heat-inactivated EV71 triggered a mixed Th1/Th2
esponse.
.4. In silico analysis of SP55 and SP70 amino acid
equences
The Kyte and Doolittle hydrophobicity profile of the VP1
apsid protein indicated that both synthetic peptides SP55 and
P70 contained amino acid sequences which are located within
he major hydrophilic regions of the protein (Fig. 3), therefore,
n regions likely to be exposed on the surface of VP1.
A protein–protein BLAST (blastp 2.2.14) search demon-
trated that the amino acid sequences of SP55 and SP70 were
ighly specific for EV71 strains and no significant homol-
gy with other enteroviruses such as coxsackieviruses and
choviruses was found (data not shown). Alignment using
he Clustal method of MegAlign (DNASTAR program) also
ndicated that the amino acid sequence of SP70 was found
o be totally conserved amongst 25 other EV71 strains from
ub-genogroups A to C4 whereas SP55 showed 80% iden-
ity with the genogroup A strain, BrCr-CA-70, from US and
D.G.W. Foo et al. / Virus Research 125 (2007) 61–68 65
Table 1












SP12 34–48 AC – VSSHRLDTGEVPALQC – DKP +++ SP10, SP11, SP13, SP14, SP15 SP19, SP20, SP21, SP40
SP55 163–177 AC – PESRESLAWQTATNPC – DKP +++ SP54, SP56 SP19, SP20, SP21, SP40
SP70 208–222 AC – YPTFGEHKQEKDLEYC – DKP +++ SP68, SP69, SP71, SP72 –
a AC denotes an acetyl group attached to the amino (N)-terminal end and DKP denotes the carrier protein (Diphtheria toxoid) conjugated at the carboxy (C)-terminal
end.
b Peptide specificities were based on ELISA readings at 450 nm. The data represents the average of three independent experiments.
Table 2
Total and IgG sub-type responses in SP12-, SP55- and SP70-immune sera
Immunogen OD450 nm




Heat-inactivated virus 0.98 (0.01)
Naı¨ve 0.17 (0.02)
Immunogen OD450 nm
IgG1 IgG2a IgG2b IgG3
(B) IgG sub-type response
SP55 0.47 (0.04) 0.10 (0.02) 0.09 (0.02) 0.11 (0.04)
SP70 0.80 (0.02) 0.18 (0.01) 0.14 (0.03) 0.12 (0.01)
SP12 0.72 (0.02) 0.11 (0.01) 0.10 (0.01) 0.17 (0.03)
Heat-inactivated virus 0.83 (0.03) 0.73 (0.01) 0.78 (0.01) 0.80 (0.02)
Naı¨ve 0.08 (0.02) 0.09 (0.02) 0.08 (0.01) 0.07 (0.01)
(A) ELISA was carried out using individual sera at a dilution of 1:50. The 96-well microtiter plates were coated with purified virions (10g/ml). OD450 nm readings
are expressed as the average of five antisera per group. Standard deviation of OD readings is in parenthesis.
(B) ELISA was carried out using pooled sera (n = 5) at a dilution of 1:50. Wells of the 96-well microtiter plates were coated with the corresponding unconjugated
synthetic peptide (10g/ml). The data represents the average of three separate experiments. Standard deviation of OD readings at 450 nm is in parenthesis.
Fig. 3. Kyte and Doolittle hydrophobicity profiles of the VP1 capsid protein of EV71. The horizontal axis represents the amino acid position in VP1 and the vertical
axis represents the hydropathy scores. Positive scores indicate hydrophobicity while negative scores indicate hydrophilicity. SP70 (amino acid residues 208–222)
and SP55 (amino acid residues 163–177) are indicated on the plot.












































aig. 4. Alignment of amino acid sequences represented by the synthetic peptid
ased on the VP1 amino acid sequences.
5–100% homology with the other representative strains from
ub-genogroups B1 to C4 (Fig. 4).
.5. In vitro protection afforded by antisera from mice
mmunized with SP55, SP70 and heat-inactivated EV71
train 41 against homologous and heterologous EV71
trains
To test that SP55- and SP70-antisera have neutralizing
ctivities against heterologous strains of EV71, the mice anti-
era raised against each peptide were analyzed in an in
itro microneutralization assay, using RD cells infected with
03 TCID50 of representative EV71 strains from other sub-
enogroups such as B2, B5, C2 and C4. Antiserum from mice
mmunized with the heat-inactivated virion served as the positive
ontrol.
Complete protection of RD cells from CPE was observed with
ntiserum from mice immunized with the whole virion at a neu-
ralizing titer of 1:64. The antiserum from the SP70-immunized
ice showed neutralizing activities against homologous and het-
rologous EV71 strains with significant neutralizing antibody
iter of 1:32 whereas the SP55-antiserum has a lower neutralizing
ntibody titer of 1:8 (Table 3). Hence, the data demonstrated the
able 3
eutralizing antibody titers elicited by SP55, SP70 and heat-inactivated virion
n mice against homologous and heterologous EV71 strains
mmunogen Sub-genogroups of EV71
B2a B4b B5a C2a C4a
hole virionc 1:32 1:64 1:64 1:64 1:64
P55 1:8 1:8 1:8 1:8 1:8
P70 1:16 1:32 1:16 1:32 1:32
a Heterologous EV71 strain.
b Homologous EV71 strains.
















d5 and SP70 against heterologous EV71 strains from different sub-genogroups
rotective potential of SP70 and, to a lesser extend, SP55 against
eterologous EV71 strains. This suggests that the neutraliz-
ng linear epitopes present in both SP70 and SP55 are highly
onserved amongst representative EV71 strains from different
ub-genogroups.
. Discussion
Previous studies have shown that the VP1 capsid protein of
V71 constitutes a good sub-unit vaccine candidate by trig-
ering the production of protective neutralizing antibodies in
murine model of infection (Wu et al., 2001; Chen et al.,
006; Chiu et al., 2006). However, the location of the protec-
ive neutralizing epitopes within the VP1 protein has not been
stablished yet.
To approach this, we have used a Pepscan strategy in which
5 overlapping synthetic peptides were designed according to
he primary sequence of the VP1 capsid protein. The diphthe-
ia toxoid-conjugated synthetic peptides were injected into mice
nd the neutralizing activity of the antisera was determined. This
trategy allows the identification of conformation-independent
eutralizing linear epitope(s) that can thus be used in various
accine designs. Two synthetic peptides, designated SP55 and
P70, were shown to elicit the production of neutralizing anti-
odies against EV71. The anti-SP70 antiserum was found to be
lmost as efficient as the heat-inactivated EV71 antiserum (high-
st dilutions preventing CPE at 1:32 and 1:64, respectively), in
eutralizing the virus in an in vitro microneutralization assay.
oreover, the total IgG response specific to the whole virion
hich was measured in the antisera elicited by SP55 and SP70
as found to be as high as that measured in the EV71-immune
erum. Previous studies have shown that whole virus particles
ffer the most effective protection against EV71 (Yu et al., 2000;
u et al., 2001). Altogether, these data strongly suggest that syn-
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An ideal synthetic peptide-based vaccine should contain both
-cell epitope(s) and T-cell epitope(s) that are able to induce
protective antibody response as well as a cytotoxic T-cell
esponse important for killing infected host cells. The first gen-
ration of peptide vaccines which includes both B-cell and T-cell
pitopes has been reported and shown to have a very good pro-
ective efficacy (Tam, 1996). In our study, the IgG sub-types
nalysis of the SP55- and SP70-antisera showed a strong IgG1
pecific antibody response and a very low IgG2a, IgG2b and
gG3 antibody response which indicates a predominant Th2
mmune response. These observations suggest that (i) both syn-
hetic peptides SP55 and SP70 contain mainly B-cell epitopes
nd (ii) the neutralizing antibodies elicited by SP55 and SP70
elong to the IgG1 sub-type. The identification of T-cell epi-
ope(s) within the VP1 capsid protein might be advantageous
o further develop an effective synthetic peptide-based EV71
accine. This work is currently in progress.
In a recent study, the N-terminal moiety of the VP1 capsid
rotein was found to be the most immunogenic (Sivasamugham
t al., 2006). However, both synthetic peptides SP55 and SP70
equences are not located within the N-terminal moiety of VP1
ut lie instead more towards the C-terminal part of the pro-
ein. The hydrophobicity profiles showed that SP55 and SP70
re located within the major hydrophilic regions of VP1 and
ence they are expected to be exposed at the surface of the
rotein. Moreover, both synthetic peptides map in the region
amino acid residues 66–132) recently shown to be involved
n the dimerization of VP1 capsid protein (Lal et al., 2006).
he finding of neutralizing epitopes within this region further
emonstrates their involvement in virus binding and entry into
ost cells. Our data also suggest that the N-terminal moiety
f VP1 capsid protein may not be the best choice for sub-unit
accine candidate.
Although the immunoreactivity of SP12-antiserum was
hown to be as good as the SP55- and SP70-antisera, it does
ot contain any neutralizing antibodies. This suggests that the
mino acid region of the VP1 capsid protein represented by
ynthetic peptide SP12 does not contain any functional domain
nvolved in the virus binding and entry into host cells.
Several genogroups and sub-genogroups of EV71 have
volved since its first discovery in 1969, and frequent muta-
ions of the viral genome constitute a major difficulty in vaccine
evelopment when using the whole viral particle as a potential
accine candidate (McMinn, 2002). Many fatality cases due to
V71 were caused by strains from different sub-genogroups and
tudies have shown that the EV71 sub-genogroups are constantly
volving within the community (Brown et al., 1999; Mizuta et
l., 2005; Wang et al., 2002) which emphasizes the importance of
dentifying the location of any conserved neutralizing epitope(s).
ur blast search has shown that the amino acid sequence of
ynthetic peptide SP70 is totally conserved amongst 25 represen-
ative EV71 strains from different sub-genogroups and we have
hown that the antisera raised against SP70 were able to neu-
ralize heterologous EV71 strains, indicating cross-protection
gainst EV71 infectivity.
A study has shown the changes in the survival rate of suckling
ice upon in vivo EV71 challenge followed by administering
H
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ntraperitoneally with mouse anti-EV71 serum containing dif-
erent titers of neutralizing antibody (Yu et al., 2000). With
eference to the multiplicity of infection (MOI), our study has a
OI value of 0.02 as compared to theirs with a lower MOI value
f 0.0125. Based on their in vivo protection studies, they reported
100% survival rate for suckling mice which received mouse
nti-EV71 serum with a neutralizing antibody titer of 1:128 and
60% survival rate for those which received mouse anti-EV71
erum with a lower neutralizing antibody titer of 1:64. Since their
OI value is approximately two-fold lower, their neutralizing
ntibody titers should decrease sequentially by two-fold when
ompared with our data. Therefore, for a 60% survival rate, the
eutralizing antibody titer should decrease to 1:32 which cor-
esponds to our neutralizing titer for antibody against synthetic
eptide SP70. From extrapolation, this suggests that we should
btain a similar 60% survival rate for our suckling mice born
o dams immunized with SP70 upon EV71 challenge. Another
tudy has discussed on the discrepancy between levels of in
itro microneutralization activity and in vivo protection efficacy
hich suggests that in vivo functions of antibody, which cannot
e measured and compared with the in vitro microneutralization
ssay, contribute significantly to protection that includes activa-
ion of complement cascades and mediating antibody-dependent
ytotoxicity (Wu et al., 2001). Hence, demonstrating the in vivo
rotective efficacy of the synthetic peptide SP70 is necessary to
urther demonstrate its potential as a promising peptide vaccine
andidate.
In conclusion, we have successfully identified two inde-
endent amino acid sequences within the VP1 capsid protein
f EV71 strain 41 which contain neutralizing linear epitopes.
hese epitopes lie in the C-terminal moiety of the protein, in a
egion involved in VP1 dimerization. These sequences are highly
onserved within the different sub-genogroups, making them
romising and attractive candidates for synthetic peptide-based
V71 vaccines.
cknowledgements
The authors wish to thank Miss Jasmine Chua Xin Jun for
er experimental help throughout the course of this study. This
esearch was supported by a Microbiology Vaccine Initiative
rant number R182-008-067-731 awarded to C.L. Poh.
eferences
rown, A.B., Oberste, M.S., Alexander Jr., J.P., Margery, L.K., Mark, A.P., 1999.
Molecular epidemiology and evolution of Enterovirus 71 strains isolated
from 1970 to 1998. J. Virol. 73, 9969–9975.
hen, H.F., Chang, M.H., Chiang, B.L., Jeng, S.T., 2006. Oral immunization of
mice using transgenic tomato fruit expressing VP1 protein from Enterovirus
71. Vaccine 24, 2944–2951.
hiu, C.H., Chu, C., He, C.C., Lin, T.Y., 2006. Protection of neonatal mice from
lethal Enterovirus 71 infection by maternal immunization with attenuated
Salmonella enterica serovar Typhimurium expressing VP1 of Enterovirus
71. Microb. Infect. [Epub ahead of print].agiwara, A., Tagaya, I., Yoneyama, T., 1978. Epidemic of hand, foot and mouth
disease associated with Enterovirus 71 infection. Intervirology 9, 60–63.
o, M., Chen, E.R., Hsu, K.H., Twu, S.J., Chen, K.T., Tsai, S.F., et al., 1999. An
epidemic of enterovirus infection in Taiwan. Taiwan Enterovirus Epidemic











W8 D.G.W. Foo et al. / Virus
al, S.K., Kumar, P., Yeo, W.M., Kar-Roy, A., Chow, V.T., 2006. The VP1 protein
of human Enterovirus 71 self-associates via an interaction domain spanning
amino acids 66–297. J. Med. Virol. 78, 582–590.
iu, C.C., Tseng, H.W., Wang, S.M., Wang, J.R., Su, I.J., 2000. An outbreak
of Enterovirus 71 infection in Taiwan, 1998; epidemiologic and clinical
manifestations. J. Clin. Virol. 17, 23–30.
cMinn, P.C., 2002. An overview of the evolution of Enterovirus 71 and
its clinical and public health significance. FEMS Microbiol. Rev. 26,
91–107.
izuta, K., Abiko, C., Murata, T., Matsuzaki, Y., Itagaki, T., Sanjoh, K.,
Sakamoto, M., Hongo, S., Murayama, S., Hayasaka, K., 2005. Frequent
importation of Enterovirus 71 from surrounding countries into the local
community of Yamagata, Japan, between 1998 and 2003. J. Clin. Microbiol.
43, 6171–6175.
evear, D.C., Tull, T.M., Seipel, M.E., Groarke, J.M., 1999. Activity of Ple-
conaril against enteroviruses. Antimicrob. Agents Chemother. 43, 2109–
2115.
Yarch 125 (2007) 61–68
chmidt, N.J., Lennette, E.H., Ho, H.H., 1974. An apparently new enterovirus
isolated from patients with disease of the central nervous system. J. Infect.
Dis. 129, 304–309.
ivasamugham, L.A., Cardosa, M.J., Tan, W.S., Yusoff, K., 2006. Recombinant
newcastle disease virus capsids displaying Enterovirus 71 VP1 fragment
induce a strong immune response in rabbits. J. Med. Virol. 78, 1096–1104.
am, J.P., 1996. Recent advances in multiple antigen peptides. J. Immunol. Meth.
196, 17–32.
ang, J.R., Tuan, Y.C., Tsai, H.P., Yan, J.J., Liu, C.C., Su, I.J., 2002. Change
of major genotype of Enterovirus 71 in outbreaks of hand-foot-and-mouth
disease in Taiwan between 1998 and 2000. J. Clin. Microbiol. 40, 10–15.
u, C.N., Lin, Y.C., Fann, C., Liao, N.S., Shih, S.R., Ho, M.S., 2001. Protection
against Enterovirus 71 infection in newborn mice by passive immunization
with subunit VP1 vaccines and inactivated virus. Vaccine 20, 895–904.
u, C.K., Chen, C.C., Chen, C.L., Wang, J.R., Liu, C.C., Yan, J.J., Su, I.J., 2000.
Neutralizing antibody provided protection against enterovirus type 71 lethal
challenge in neonatal mice. J. Biomed. Sci. 7, 523–528.
Microbes and Infection 9 (2007) 1299e1306
www.elsevier.com/locate/micinfOriginal article
Passive protection against lethal enterovirus 71 infection in newborn
mice by neutralizing antibodies elicited by a synthetic peptide
Damian Guang Wei Foo, Sylvie Alonso, Vincent Tak Kwong Chow, Chit Laa Poh*
Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, MD4A, 5 Science Drive 2, Singapore 117597, Singapore
Received 27 March 2007; accepted 5 June 2007
Available online 10 June 2007
Abstract
Enterovirus 71 (EV71) infections could lead to high mortalities and neither vaccine nor therapeutic treatment is available. We investigated
vaccination with a synthetic peptide SP70 representing a neutralizing linear VP1 epitope of EV71 strain 41 (subgenogroup B4) and passive trans-
fer of anti-SP70 antibodies to protect suckling Balb/c mice against EV71 infectivity. When the mouse anti-SP70 antisera with a neutralizing
antibody titer of 1:32 were passively administered to one-day-old suckling mice which had been challenged with a lethal dose of 1000
TCID50 per mouse, the neutralizing anti-SP70 antibodies were able to confer 80% in vivo protection. In contrast, suckling mice which did
not receive any anti-SP70 antisera did not survive the viral challenge at day 21 postinfection. Histological examination and real-time RT-
PCR assays revealed viral infiltration in small intestines of EV71-infected mice. Interestingly, anti-SP70 antibodies play a major role in the in-
hibition of EV71 replication in vivo and significantly reduced the viral titer. In conclusion, EV71-neutralizing antibodies elicited by the synthetic
peptide SP70 were able to confer good in vivo passive protection against homologous and heterologous EV71 strains in suckling Balb/c mice.
 2007 Elsevier Masson SAS. All rights reserved.
Keywords: Enterovirus 71; VP1 capsid protein; Synthetic peptide; Passive protection1. Introduction
Enterovirus 71 (EV71) is a viral pathogen within the Picor-
naviridae family that causes clinical diseases in humans with
manifestations such as herpangina, aseptic meningitis, enceph-
alitis, pulmonary edema and hand, foot, and mouth disease
(HFMD). EV71-infected children can develop severe neuro-
logical complications that lead to rapid clinical deteriorations
and even death [1e5]. A significant increase in EV71 epi-
demics with high mortalities has been observed throughout
the Asia-Pacific region since 1997. In 1998, an epidemic of
EV71 infection affected more than 100,000 young children
in Taiwan and approximately 400 children were hospitalized
for pulmonary edema and neurogenic shock which resulted
in 78 deaths [6e8]. In October 2000, an outbreak of HFMD
* Corresponding author. Tel.: þ65 6516 3674; fax: þ65 6776 6872.
E-mail address: micpohcl@nus.edu.sg (C.L. Poh).1286-4579/$ - see front matter  2007 Elsevier Masson SAS. All rights reserved
doi:10.1016/j.micinf.2007.06.002caused by EV71 occurred in Singapore, affecting mostly chil-
dren below 6 years of age and there were four fatalities. At
present, there are no specific effective antiviral drugs available
and only palliative care is provided. Preventive and control
measures during EV71 outbreaks are limited to public health
surveillance and isolation of infected children as there is no
available vaccine against EV71.
EV71 contains a positive-stranded RNA which is enclosed
by capsid proteins VP1, VP2, VP3, and VP4. These proteins
are presumed to be similar to the picornaviral prototype capsid
which is made up of the four structural proteins arranged in 60
repeating protomeric units of an icosahedron [9,10]. In addi-
tion to protecting the viral RNA from nuclease cleavage, the
capsid recognizes the receptors on the surface of host cells
[11e13] and displays antigenicity [14,15]. Newborn ICR
mice born to dams which were immunized with the forma-
lin-inactivated EV71 whole virion were protected against le-
thal viral challenge [16]. However, this strategy involves the
use of whole viral particles which may implicate safety issues.
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shown that the whole VP1 capsid protein is a potential vaccine
candidate when it was able to confer protection against EV71
infection in suckling ICR mice, suggesting the presence of
neutralizing epitope(s) within VP1 [17]. However, the neutral-
izing epitope(s) remained undefined. In our previous study,
a synthetic peptide SP70 representing a neutralizing linear
VP1 epitope of EV71 strain 41 (5865/SIN/00009) was suc-
cessfully identified in eliciting high titers of neutralizing anti-
bodies in Balb/c mice based on in vitro microneutralization
assays [18]. However, passive protection of suckling Balb/c
mice by anti-SP70 antibodies in an in vivo EV71 challenge
study has not been reported. In this study, we demonstrated
the in vivo protective efficacy of mouse antisera raised against
the synthetic peptide SP70 which harbors a neutralizing linear
epitope of the VP1 capsid protein of EV71 strain 41. We com-
pared the efficacy with in vivo passive protection afforded by
antisera raised against the heat-inactivated homologous EV71
strain and the synthetic peptide SP12 which represents an im-
munogenic but non-neutralizing linear VP1 epitope.
2. Materials and methods
2.1. Viruses
EV71 strain 41 (5865/SIN/00009) from the subgenogroup
B4 was presented as the homologous strain in mice immuniza-
tion and challenge studies. Representative EV71 strains
(EV71/MS/7423/87) from the subgenogroup B2; 2933-Yama-
gata-03 from the subgenogroup B5; 1585-Yamagata-01 from
the subgenogroup C2; and 75-Yamagata-03 from the subge-
nogroup C4 were presented as heterologous strains in chal-
lenge studies [1]. Viruses were grown in rhabdomyosarcoma
(RD) cells at 37 C in minimum essential medium (MEM)
(Gibco, USA) supplemented with 5% fetal bovine serum,
1% sodium pyruvate and 1.5% sodium bicarbonate. Once
the cells displayed cytopathic effect (CPE), they were har-
vested and completely lysed by three freezeethaw cycles. Cel-
lular debris was removed by centrifugation at 10,000 g for
30 min. The virus was purified by precipitation with 7% poly-
ethylene glycol 8000 (PEG 8000) and then subjected to centri-
fugation on a 30% sucrose cushion at 25,000 g for 4 h. The
50% tissue culture infective dose (TCID50) was determined in
RD cells using the Reed and Muench formula [19]. Before be-
ing administered as an immunogen, the homologous EV71
strain was inactivated by heating at 56 C for 30 min and the
amount of virion protein was quantified by the Bradford assay
(Bio-Rad Laboratories, USA). Viability of viruses after heat
inactivation was carried out by introducing viral preparations
into fresh medium containing RD cells to check for CPE.
2.2. Synthetic peptides
Diphtheria toxoid-conjugated synthetic peptides represent-
ing the amino acid sequence of SP12 or SP70 were synthe-
sized by Mimotopes Pty Ltd (Clayton, Victoria, Australia) as
described previously [18].2.3. Mice
Inbred Balb/c mice were obtained from the Centre for An-
imal Resources of the National University of Singapore. All
institutional guidelines for animal care and use were strictly
followed throughout the experiments. Groups of mice
(n¼ 6) at different age groups, ranging from one-day-old to
two-week-old, were inoculated intraperitoneally with 100 ml
of the homologous EV71 strain (1000 TCID50). In another ex-
periment, groups of mice (n¼ 6) at day 1 after birth were
given different doses of the homologous EV71 strain (ranging
from 1 TCID50 to 1000 TCID50 per mouse) via the intraperi-
toneal route. Mice (n¼ 6) in the control group were given
100 ml of phosphate buffered saline (PBS). Mice were moni-
tored for the occurrence of mortality until three weeks postin-
fection. For immunization, groups of six-week-old female
mice (n¼ 5) were intraperitoneally immunized with a 50%
emulsion of Freund’s complete adjuvant containing either
50 mg of conjugated synthetic peptides or the heat-inactivated
EV71 strain 41 (10 mg total protein). Two booster doses in
50% emulsions with Freund’s incomplete adjuvant were given
at three weekly intervals. Sera were collected seven days after
the final booster and checked for the presence of EV71-neu-
tralizing antibodies using the in vitro microneutralization as-
say. Sera containing neutralizing antibodies were pooled and
stored at 80 C until use. For passive protection study,
groups of mice (n¼ 6) at day 1 after birth were injected intra-
peritoneally with 100 ml of EV71 (1000 TCID50 per mouse),
followed by 100 ml of heat-treated (56 C, 30 min) mice im-
mune sera 24 h later. Suckling mice (n¼ 6) from control
groups were either given naive sera or not given any antisera
at all. Mice were monitored for body weight gain/loss and
the occurrence of mortality until three weeks postinfection.
2.4. In vitro microneutralization assay
EV71-neutralizing antibodies were identified using the in
vitro microneutralization assay as described previously [18].
The assay was carried out in triplicates.
2.5. Reverse transcription polymerase
chain reaction (RT-PCR)
Organs from mice were aseptically harvested in MEM and
were homogenized for total RNA extraction using the RNeasy
extraction kit (Qiagen, USA) according to the manufacturers’
instructions. The extracted RNA was then analyzed for the
presence of EV71 using real-time Hybridization Probe RT-
PCR for the detection of EV71 RNA as described previously
[20]. Each assay was carried out in triplicates.
2.6. Immunohistochemical analysis
Cryosections with a thickness of 4 mm were made from fro-
zen tissues and fixed on poly-L-lysine glass slides. Permeabili-
zation of the fixed tissue sections was carried out by
incubating with 0.2% Triton at room temperature for 10 min
1301D.G.W. Foo et al. / Microbes and Infection 9 (2007) 1299e1306followed by the addition of mouse anti-EV71 monoclonal an-
tibody (Chemicon International, USA) and further incubation
for 30 min. Slides were washed three times with PBS and
bound antibodies were detected using secondary biotinylated
anti-mouse IgG (Zymed Laboratories, USA). The reaction
was visualized by the addition of aminoethyl carbazole sub-
strate (Zymed Laboratories, USA) to give a red colored perox-
idase stain and the slide was counterstained with haematoxylin
(Zymed Laboratories, USA) to generate a blue background.
3. Results
3.1. Age of mice and viral dosage
EV71 infection was characterized by hairless skin lesions
and paralysis of limbs in infected Balb/c mice. Both clinical
manifestations persisted throughout the observation period
(Fig. 1). Suckling Balb/c mice from different age groups
were infected intraperitoneally with the homologous EV71
strain at a dose of 1000 TCID50 per mouse. Mice which
were infected at day 1 after birth did not survive by day 11
postinfection. With mice infected at day 4 after birth, death
was delayed but all mice died by day 16 postinfection. Mice
which were infected at day 7 or day 10 after birth had higher
survival rates of 60% and 90%, respectively, by day 21 post-
infection. All mice which were infected at day 14 after birth
survived throughout the experimental period (data not shown).
To determine the lethal viral dosage, groups of mice at day 1
after birth were infected intraperitoneally with different doses
of viruses, ranging from 1 TCID50 to 1000 TCID50 per mouse.
With an infective dose of 1000 TCID50 virus, all mice died by
day 11 postinfection whereas a 30% survival rate was ob-
served for those which were infected with a reduced dosage
(1 TCID50 per mouse). Mice which were not infected didnot show any sign of distress and all of them survived
(Fig. 2A).
3.2. Passive protection against lethal homologous EV71
strain challenge in suckling mice
To assess the efficacy of passive protection by antisera
raised against the homologous EV71 whole virion (anti-
EV71) and the synthetic peptide SP70 (anti-SP70), suckling
Balb/c mice born to naive dams were administered with the
respective antisera one day after lethal challenge with the ho-
mologous EV71 strain (1000 TCID50 per mouse). Groups of
mice that received the anti-EV71 antisera with neutralizing
antibody titers of 1:64 or 1:32 survived throughout the ex-
perimental period. The anti-SP70 antisera with a neutralizing
antibody titer of 1:32 provided 80% protection whereas
EV71-infected suckling mice which did not receive any anti-
sera and those which received antisera either from SP12-
immunized (anti-SP12) or naive mice did not survive by
day 12 postinfection (Fig. 2B). The body weight of mice
that were protected against EV71 infectivity rose steadily
up to an average of approximately 12 g at day 21 postinfec-
tion. At day 9 postinfection, they weighed approximately 8 g
on average when compared to unprotected mice that had an
average body weight of approximately 3 g before they died
from EV71 infection (Fig. 2C). When the neutralizing anti-
body titer of anti-EV71 antisera was reduced to 1:16, the sur-
vival rate of EV71-infected suckling mice dropped to 70%
and subsequently to 50% when the neutralizing antibody titer
was further reduced to 1:8 (Fig. 3A). Approximately 80% of
suckling mice survived when they were given the anti-SP70
antisera with a neutralizing antibody titer of 1:32 and
a 50% survival rate was observed with the antisera at reduced
titer of 1:16. With a reduced neutralizing antibody titer ofFig. 1. Viral infection of suckling Balb/c mice with a lethal EV71 dose (1000 TCID50 per mouse). (A) Mice at day 3 postinfection are shown. The mouse on the
right side is a non-infected age-matched control. (B) Mice at day 9 postinfection are shown. The mouse on the left side is a non-infected age-matched control. Limb
paralysis is represented by * and skin lesion is represented by **.
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Fig. 2. In vivo infectivity of EV71. (A) Dose dependency of EV71-induced death. Groups of Balb/c mice (n¼ 6) at day 1 after birth were intraperitoneally infected
with increasing doses of the homologous EV71 strain (ranging from 1 TCID50 to 1000 TCID50 per mouse). Mice in the control group were given 100 ml of PBS.
Death was monitored daily until 21 days postinfection. (B) In vivo passive protection of suckling Balb/c mice after challenged with the homologous EV71 strain.
Groups of mice (n¼ 6) at day 1 after birth were intraperitoneally infected with a lethal dose of 1000 TCID50 per mouse. One day after infection, suckling mice
were administered with antisera from EV71-, SP70- or SP12-immunized mice via the similar route. Mice in control groups were given naive sera or not admin-
istered with any antisera. Death was monitored daily until 21 days postinfection. (C) Monitoring of body weight gain/loss in suckling Balb/c mice after EV71
challenge. Body weights were recorded for all surviving mice every three days until 21 days postinfection.1:8, the anti-SP70 antisera were still able to confer 20% pro-
tection (Fig. 3B).
3.3. Histological examination in EV71-infected
suckling mice
Histological examinations revealed EV71 infiltration in
small intestines of suckling Balb/c mice infected with the
homologous EV71 strain. The presence of the virus was
detected with the anti-EV71 monoclonal antibody. From
micrographs of the cryosections, infected mice had intesti-
nal structures which were damaged, thus indicating exten-
sive viral replications. Mice which received the anti-EV71
or anti-SP70 antisera had intact intestinal structures and
were protected against EV71 infectivity. However, micewhich received the anti-SP12 antisera showed signs of tis-
sue damage in their small intestines. The red colored per-
oxidase stain indicated EV71 infiltration of intestinal tissues
(Fig. 4).
3.4. Detection of EV71 by real-time RT-PCR
hybridization probe assay
Organs were harvested from Balb/c mice after challenge
studies and RNA was extracted from homogenized tissues for
the detection of EV71. The amplicons generated from the
real-time RT-PCR assay were based on 204 base pairs PCR
product of the VP1 region. Quantification analysis showed
that the positive control has a Ct value of 13 which represents
5 108 EV71 copies and every 3.3 Ct value difference
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Fig. 3. In vivo passive protection study conferred by different EV71-neutralizing antibody titers. Groups of Balb/c mice (n¼ 6) at day 1 after birth were infected
with the homologous EV71 strain (1000 TCID50 per mouse) via the intraperitoneal route. One day after infection, suckling mice were intraperitoneally adminis-
tered with serially diluted pooled antisera from (A) EV71-immunized mice or (B) SP70-immunized mice. Mice in control groups were not administered with any
antisera. Death was monitored until 21 days postinfection.represents a 10-fold difference in viral copies. Viral RNA sam-
ples from suckling mice which did not receive any antisera and
those which received the anti-SP12 antisera or naive sera indi-
cated a Ct value of 33. This represents the presence of 50 EV71copies in the three respective samples. However, suckling mice
which received either the anti-EV71 or anti-SP70 antisera had
RNA transcripts with a higher Ct value of 37, representing ap-
proximately five EV71 copies (Fig. 5).Fig. 4. Detection of EV71 infection in small intestines of suckling Balb/c mice after being challenged with the homologous EV71 strain (1000 TCID50 per mouse).
Intestinal structures from: (A) non-infected mice as the negative control; (B) EV71-infected mice as the positive control; (C) mice receiving the anti-EV71 antisera;
(D) mice receiving the anti-SP70 antisera; and (E) mice receiving the anti-SP12 antisera. Cryosections of intestinal tissues were prepared and EV71 was detected
with mouse anti-EV71 monoclonal antibody and biotinylated anti-mouse IgG before visualizing with aminoethyl carbazole substrate to give a red colored perox-
idase stain as positive detection and haematoxylin to give a blue background.
1304 D.G.W. Foo et al. / Microbes and Infection 9 (2007) 1299e1306Fig. 5. Detection of EV71 by real-time RT-PCR hybridization probe assay in suckling Balb/c mice after challenge studies. (A) EV71 RNA transcript as the positive
control with a Ct value of 13 representing 5 108 viral copies. (B) RNA transcripts from groups of suckling mice receiving pooled antisera from SP12-immunized
mice (n¼ 5), pooled sera from non-immunized mice (n¼ 5) or no sera with a Ct value of 33 representing 50 viral copies. (C) RNA transcripts from groups of
suckling mice receiving pooled antisera from EV71 whole virion- or SP70-immunized mice (n¼ 5) with a higher Ct value of 37 representing five viral copies. (D)
The negative control includes all reagents without any RNA template.3.5. Passive protection afforded by the anti-EV71 or
anti-SP70 antisera against heterologous EV71 strains
Groups of suckling Balb/c mice born to naive dams were
challenged with heterologous EV71 strains (1000 TCID50
per mouse) and antisera raised against the homologous
EV71 whole virion or synthetic peptide SP70 were adminis-
tered at day 2 after infection. When EV71-infected suckling
mice were administered with the anti-EV71 antisera at a neu-
tralizing antibody titer of 1:32, all of them survived. Mice in-
fected with EV71 strains from the subgenogroup B2 or B5 had
80% survival rates when they were administered with the anti-
SP70 antisera with a neutralizing antibody titer of 1:32. Upon
lethal challenge with EV71 strains from the subgenogroup C2
or C4, the anti-SP70 antisera protected 70% of infected
suckling mice (Table 1).
Table 1
Survival rates of suckling mice from challenge with homologous or heterolo-
gous EV71 strains











a One day after EV71 challenge (1000 TCID50 per mouse), suckling mice
were administered with antisera from mice immunized with the heat-inacti-
vated EV71 strain 41 (anti-EV71) or synthetic peptide SP70 (anti-SP70) and
monitored until 21 days postinfection. Each group contained six mice.
b Homologous EV71 strain.
c Heterologous EV71 strains.4. Discussion
Although immune responses such as elevated antibody
level detected soon after immunization may demonstrate the
immunogenicity of a vaccine, they do not necessarily provide
a reliable guide to its efficacy in priming an in vivo protective
response. Successful protection against viral infectivity in an-
imal models has long been regarded as the best test for the ef-
ficacy of any vaccine. Benefits of vaccination could be derived
either through active immunization or passive protection. Pas-
sive transfer of specific antibodies has been shown to reduce
the severity of viral infections, including Japanese encephalitis
infection [21], varicella infection [22] and coxsackievirus
infection [23]. We have previously identified a neutralizing
linear VP1 epitope, denoted as SP70 within the VP1 capsid
protein of EV71 strain 41, which was able to elicit high titers
of mouse EV71-neutralizing antibodies against the homolo-
gous EV71 strain and five heterologous EV71 strains from
subgenogroups B2, B5, C2 and C4 [18]. In the present study,
we have tested the in vivo functional potential of EV71-
neutralizing antibodies elicited by the synthetic peptide SP70
in mice and have shown that the anti-SP70 antisera were
able to confer in vivo passive protection of up to 80% survival
rate in suckling Balb/c mice which have been challenged with
a lethal dose of the homologous EV71 strain. Our previous
study has shown that the amino acid sequence represented
by SP70 was totally conserved amongst 25 EV71 strains
from subgenogroups A, B1eB5 and C1eC4, which suggested
possible cross-protection against infectivity of all EV71 strains
[18]. Here, we have demonstrated that the anti-SP70 antisera
with a neutralizing antibody titer of 1:32 were able to confer
up to 80% in vivo passive protection in suckling Balb/c mice
challenged with several heterologous EV71 strains. It is inter-
esting to note that the level of protection was almost similar to
that obtained against the homologous strain. This reflects the
efficacy of in vivo protection conferred by passively trans-
ferred EV71-neutralizing antibodies elicited by SP70. We
1305D.G.W. Foo et al. / Microbes and Infection 9 (2007) 1299e1306have also shown that the neutralizing antibody titer plays a de-
cisive role in the in vivo passive protection against EV71 infec-
tivity. A significant reduction in the survival rate was
correlated with suckling mice receiving antisera with progres-
sively lower EV71-neutralizing antibody titers.
Natural viral infections commonly lead to the production of
protective neutralizing antibodies recognizing both linear and
conformational epitopes of viruses. A screening study based
on ELISA has shown that human sera with high titers of neu-
tralizing antibodies against EV71 strain MS/7423/87 reacted
strongly with neutralizing conformational epitopes located at
the N-terminal region of VP1 but exact locations of these epi-
topes were not well-defined [24]. The in vivo protective effi-
cacy of these neutralizing antibodies has not been established
as well. The neutralizing linear VP1 epitope (SP70) we have
previously identified was located more towards the C-terminal
part of the protein and mapped in the region involving VP1 di-
merization [18]. In this study, we have demonstrated that the
mouse antisera raised against this neutralizing linear VP1 epi-
tope were able to confer good in vivo passive protection to
suckling Balb/c mice against EV71 infectivity.
Antisera with a neutralizing antibody titer of 1:64 from
mice immunized with formalin-inactivated EV71 strain
Tainan/5079/98 were able to confer 65% passive protection
to suckling ICR mice following challenge with the same viral
strain [16]. Subsequently, another study reported that the pas-
sive administration of antisera raised against EV71 whole
virions via the intraperitoneal route also offered 70%
protection to newborn ICR mice against EV71 infectivity
[17]. Although a number of immunogens with good in vivo
passive protective potential have been identified, the majority
of candidates that have been tested experimentally relied
mainly on whole viral particles. In our study, the mouse anti-
sera which were raised against EV71 whole virions did pro-
vide higher in vivo passive protection to suckling mice
against lethal EV71 challenge when compared with the anti-
SP70 antisera. This might be due to higher titers of neutraliz-
ing antibodies elicited by several neutralizing epitopes located
on the virus other than that represented by the synthetic pep-
tide SP70 alone. Unlike SP70, the immunogenic but non-
neutralizing linear VP1 epitope represented by the synthetic
peptide SP12 elicited antibodies which were unable to neutral-
ize EV71 infectivity and hence infected suckling mice were
not protected. The passively administered antisera raised
against EV71 whole virions might also contain antibodies
which could induce lysis of the virus-infected host cells
through activation of complement cascades or by mediating
antibody-dependent cellular cytoxicity (ADCC) activities.
Conventional vaccine preparations using the whole virion as
an inactivated vaccine might be ideal since it offered good pro-
tection against viral infection. However, the laborious and
costly procedures involved in EV71 cultivation and purifica-
tion as well as safety issues are of major concerns.
It is likely that different vaccine delivery systems can pres-
ent the antigen differently. It is clear, however, that the deliv-
ery system must be considered carefully when assessing the
immunogenicity and protective efficacy of any vaccinecandidate. In a recent study, a vaccine strategy using live-at-
tenuated Salmonella enterica serovar Typhimurium strains to
express and deliver the VP1 protein of EV71 strain 2272
was shown to protect newborn ICR mice against infection
caused by the same viral strain but immunization with live-
attenuated vaccines has the problem of possible reversions to
wild-type virulence [25]. The use of a synthetic peptide, how-
ever, has advantages of defined chemical composition, stabil-
ity, safety and reduces the complexity of manufacturing. In
this study, the synthetic peptide SP70 with its highly con-
served amino acid sequence was able to elicit high titers of
EV71-neutralizing antibodies that confer broad immunity
against homologous and heterologous EV71 strains. Due to
its small size, the synthetic peptide by itself may be poorly im-
munogenic. To increase the immunogenicity of a synthetic
peptide, it could be linked to a larger carrier protein or by
forming multiple antigenic peptides [26]. The use of either
natural or artificial adjuvants has been found to enhance the
immunogenicity of a synthetic peptide by promoting its uptake
and activating dendritic cells (DCs) to initiate the immune re-
sponse [27]. In the present study, the synthetic peptide SP70
was conjugated with a diphtheria toxoid which serves as a car-
rier protein and may help to prolong the half-life of SP70. The
addition of a 50% emulsion of Freund’s adjuvant to SP70
could have further enhanced its immunogenicity as well.
The immunogenicity of a synthetic peptide could also be en-
hanced by designing a chimeric peptide construct incorporat-
ing both B-cell and T-cell epitopes. The neutralizing linear
VP1 epitope represented by SP70 when linked to a T-helper
cell epitope could be further explored as a chimeric peptide
to raise antisera for in vivo protective efficacy evaluation.
In the absence of a vaccine for EV71, this study has demon-
strated that the in vivo passive protection of suckling Balb/c
mice by antisera raised against the synthetic peptide SP70 of-
fers a potential therapeutic treatment for EV71 infections.
The Fab region of the mouse anti-SP70 antibody which will
recognize and bind to the neutralizing linear VP1 epitope can
be selected as a potential candidate for humanized antibody
production. Humanized monoclonal antibodies conferring
good passive protection have been developed against the Ven-
ezuelan equine encephalomyelitis virus [28] and the respiratory
syncytial virus [29]. A humanized monoclonal antibody which
has specificity, avidity and neutralizing activity might be a via-
ble treatment option against EV71 infection in humans.
Acknowledgements
Heterologous EV71 strains used in this study were gifts of
Dr Katsumi Mizuta, Yamagata Prefectural Institute of Public
Health, Yamagata, Japan. This investigation was supported
by a Microbiology Vaccine Initiative Grant (R182-008-
067-731) awarded to C.L. Poh.
References
[1] K. Mizuta, C. Abiko, T. Murata, Y. Matsuzaki, T. Itagaki, K. Sanjoh,
M. Sakamoto, S. Hongo, S. Murayama, K. Hayasaka, Frequent
1306 D.G.W. Foo et al. / Microbes and Infection 9 (2007) 1299e1306importation of enterovirus 71 from surrounding countries into the local
community of Yamagata, Japan, between 1998 and 2003, J. Clin. Micro-
biol. 43 (2005) 6171e6175.
[2] K.T. Wong, L.C. Lum, S.K. Lam, Enterovirus 71 infection and neuro-
logic complications, N. Engl. J. Med 342 (2000) 356e358.
[3] L.C. Lum, K.T. Wong, S.K. Lam, K.B. Chua, A.Y. Goh, W.L. Lim,
B.B. Ong, G. Paul, S. AbuBakar, M. Lambert, Fatal enterovirus 71 en-
cephalomyelitis, J. Pediatr. 133 (1998) 795e798.
[4] L.Y. Chang, C.Y. Lee, C.L. Kao, T.Y. Fang, C.Y. Lu, P.I. Lee,
L.M. Huang, Hand, foot and mouth disease complicated with central
nervous system involvement in Taiwan in 1980e1981, J. Formos.
Med. Assoc. 106 (2007) 173e176.
[5] P.C. McMinn, An overview of the evolution of enterovirus 71 and its
clinical and public health significance, FEMS. Microbiol. Rev. 26
(2002) 91e107.
[6] L.Y. Chang, T.Y. Lin, Y.C. Huang, Fulminant neurogenic pulmonary oe-
dema with hand, foot and mouth disease, Lancet 352 (1998) 367e368.
[7] M. Ho, E.R. Chen, K.H. Hsu, S.J. Twu, K.T. Chen, S.F. Tsai, J.R. Wang,
S.R. Shih, An epidemic of enterovirus 71 infection in Taiwan, N. Engl. J.
Med. 341 (1999) 929e935.
[8] S.M. Wang, C.C. Liu, H.W. Tseng, J.R. Wang, C.C. Huang, Y.J. Chen,
Y.J. Yang, S.J. Lin, T.F. Yeh, Clinical spectrum of enterovirus 71 infec-
tion in children in southern Taiwan, with an emphasis on neurological
complications, Clin. Infect. Dis. 29 (1999) 184e190.
[9] M.G. Mateu, Antibody recognition of picornaviruses and escape from
neutralization: a structural view, Virus Res. 38 (1995) 1e24.
[10] R.R. Ruekert, in: B.N. Fields, D.M. Knipe, P.M. Howley, et al. (Eds.),
Picornaviridae: The Viruses and Their Replication, third ed., Fields Vi-
rology Lippincott-Raven Publishers, Philadelphia, 1996, pp. 609e640.
[11] C. Mendelsohn, E. Wimmer, V.R. Racaniello, Cellular receptors for po-
liovirus: molecular cloning, nucleotide sequence and expression of a new
member of the immunoglobulin super family, Cell 56 (1989) 855e865.
[12] J.M. Bergelson, M.P. Sepley, B.M.C. Chan, M.E. Heinler, R.N. Finberg,
Identification of the antigen VLA-2 as a receptor for echovirus 1, Science
255 (1992) 1718e1720.
[13] J.M. Greve, G. Davis, A.M. Meyer, C.P. Forte, S.C. Yost, C.W. Marlor,
M.E. Kamarck, A. McClelland, The major human rhinovirus receptor
is ICAM-1, Cell 56 (1989) 839e847.
[14] A.L. Van Wezel, P. Van der Marel, T.G. Hazendonk, V. Boer Bak,
M.A. Henneke, Antigenicity and immunogenicity of poliovirus capsid
proteins, Dev. Biol. Stand. 55 (1983) 209e215.
[15] D.M. Moore, K.M. Cowan, Effect of trypsin and chymotrypsin on the
polypeptides of large and small plaque variants of foot-and-mouth dis-
ease virus: relationship to specific antigenicity and infectivity, J. Gen.
Virol. 41 (1978) 549e562.[16] C.K. Yu, C.C. Cheng, C.L. Cheng, J.R. Wang, C.C. Liu, J.J. Yan,
I.J. Su, Neutralizing antibody provided protection against enterovirus
type 71 lethal challenge in neonatal mice, J. Biomed. Sci. 7 (2000)
523e528.
[17] C.N. Wu, Y.C. Lin, C. Fann, N.S. Liao, S.R. Shih, M.S. Ho, Protection
against enterovirus 71 infection in newborn mice by passive immuniza-
tion with subunit VP1 vaccines and inactivated virus, Vaccine 20
(2001) 895e904.
[18] D.G.W. Foo, S. Alonso, M.C. Phoon, N.P. Ramachandran, V.T.K. Chow,
C.L. Poh, Identification of neutralizing linear epitopes from the VP1 cap-
sid protein of enterovirus 71 using synthetic peptides, Virus Res. 125
(2007) 61e68.
[19] L.J. Reed, H. Muench, A simple method of estimating fifty percent end-
points, Am. J. Hyg. 27 (1938) 4931e4937.
[20] E.L. Tan, V.T.K. Chow, G. Kumarasinghe, R.P.L. Tze, I.M. MacKay,
T.P. Sloots, C.L. Poh, Specific detection of enterovirus 71 directly
from clinical specimens using real-time RT-PCR hybridization probe as-
say, Mol. Cell. Probes 20 (2006) 135e140.
[21] J. Kimura-Kuroda, K. Yasui, Protection of mice against Japanese enceph-
alitis virus by passive administration with monoclonal antibodies, J. Im-
munol. 141 (1988) 3606e3610.
[22] Y.C. Huang, T.Y. Lin, Y.J. Lin, R.I. Lien, Y.H. Chou, Prophylaxis of in-
travenous immunoglobulin and acyclovir in perinatal varicella, Eur. J.
Pediatr. 160 (2001) 91e94.
[23] T.J. Geller, D. Condie, A case of protracted coxsackie virus meningoen-
cephalitis in a marginally immunodeficient child treated successfully
with intravenous immunoglobulin, J. Neurol. Sci. 129 (1995) 131e133.
[24] C.S. Tan, M.J. Cardosa, High-titred neutralizing antibodies to human en-
terovirus 71 preferentially bind to the N-terminal portion of the capsid
protein VP1, Arch. Virol. (2007).
[25] C.H. Chiu, C. Chu, C.C. He, T.Y. Lin, Protection of neonatal mice from
lethal enterovirus 71 infection by maternal immunization with attenuated
Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus
71, Microbes Infect. 8 (2006) 1e8.
[26] I. Haro, M.J. Gomara, Design of synthetic peptide constructs for the vac-
cine development against viral infections, Curr. Protein Pept. Sci. 5
(2004) 425e433.
[27] K.S. Rosenthal, D.H. Zimmerman, Vaccines: all things considered, Clin.
Vaccine Immunol. 13 (2006) 821e829.
[28] A.R. Hunt, S. Frederickson, C. Hinkel, K.S. Bowdish, J.T. Roehrig, A hu-
manized murine monoclonal antibody protects mice either before or after
challenge with virulent Venezuelan equine encephalomyelitis virus,
J. Gen. Virol. 87 (2006) 2467e2476.
[29] H. Fuller, C. Del Mar, Immunoglobulin treatment for respiratory syncy-
tial virus infection, Cochrane Database Syst. Rev. 4 (2006) CD004883.
RESEARCH NOTE 10.1111/j.1469-0691.2007.01904.x
Identification of immunodominant VP1
linear epitope of enterovirus 71 (EV71)
using synthetic peptides for detecting
human anti-EV71 IgG antibodies in western
blots
D. G. W. Foo1, R. X. Ang1, S. Alonso1,
V. T. K. Chow1, S. H. Quak2 and C. L. Poh1,3
1Department of Microbiology, Yong Loo Lin
School of Medicine, National University of
Singapore, 2Department of Pediatrics, Children’s
Medical Institute, National University Hospital,
Singapore and 3Faculty of Life and Social
Sciences, Swinburne University of Technology,
Australia
ABSTRACT
A major IgG-specific immunodominant VP1
linear epitope of enterovirus 71 (EV71) strain 41
(5865 ⁄ SIN ⁄ 00009), defined by the core sequence
LEGTTNPNG, was identified by Pepscan analy-
sis. Oligonucleotides corresponding to the amino-
acid sequence of synthetic peptide SP32 were
cloned and over-expressed in Escherichia coli as
a recombinant glutathione-S-transferase (GST)–
SP32 fusion protein. In ELISAs, this protein did
not react with human anti-EV71 IgG antibodies,
but there was significant immunoreactivity
according to western blot analysis. The amino-
acid sequence of SP32 was highly specific for
detecting EV71 strains in western blot analysis,
and showed no immunoreactivity with monoclo-
nal antibodies raised against other enteroviruses,
e.g., CA9 and Echo 6.
Keywords Detection, enterovirus 71, immunodomi-
nant linear epitope, pepscan analysis, recombinant
GST–SP32 fusion protein, synthetic peptide
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Enterovirus 71 (EV71) is a single positive-
stranded RNA virus [1], with infection often
manifesting as hand, foot and mouth disease [2],
characterised by ulcerating vesicles on the palate
and vesicular lesions on the hands, feet and
buttocks. The usual method for detecting EV71
in any clinical specimen involves viral isolation,
followed by serotyping with serotype-specific
antibodies and indirect immunofluorescence
assays. An IgM-based ELISA for EV71 diagnosis
has been reported to have high sensitivity and
specificity. However, this approach is too labo-
rious, as it involves the use of purified whole
EV71 virions for detecting anti-EV71 antibodies
[3–5]. Synthetic peptides corresponding to the
VP1 protein of enteroviruses are broadly reactive
in an IgG-based ELISA using sera from patients
infected with enteroviruses, and this approach
has the potential for serodiagnosis of a wide
range of enterovirus serotypes [6]. To detect an
enterovirus of unknown serotype, an assay with
broad reactivity would be useful, but this would
not help to identify a specific enterovirus.
In the present study, 95 overlapping synthetic
peptides, designated SP1–SP95, that spanned the
entire VP1 sequence of EV71 strain 41
(5865 ⁄ SIN ⁄ 00009) (GenBank accession no.
AF316321) were synthesised by Mimotopes
(Clayton, Australia). EV71 was propagated in
RD cells using minimum essential medium
(Gibco, Rockville, MD, USA), based on cyto-
pathic effects produced as a result of virus
infection. Serum samples were collected from
children attending a paediatric outpatient clinic
at the National University Hospital of Singapore,
and these were screened for the presence of anti-
EV71-neutralising antibodies using an in-vitro
microneutralisation assay. A serum-neutralising
titre of ‡1:8 was considered to be positive for
EV71 exposure. Sera containing anti-EV71-
neutralising antibodies (n = 40) were pooled
and designated as EV71-positive sera. Sera with-
out anti-EV71-neutralising antibodies (n = 40)
were pooled and designated as EV71-negative
sera. For assigning linear epitope(s) in ELISAs,
the mean OD obtained from EV71-negative sera
plus twice the standard deviation of the respec-
tive mean was used as the cut-off value.
Two IgG-specific immunoreactive VP1 linear
regions were identified, designated as sites I
and II. The first region, represented by
synthetic peptides SP14 and SP15 (amino-acid
residues 40–57), was not specific for detecting
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human anti-EV71 IgG, as both peptides also
reacted with EV71-negative sera, perhaps
because of the presence of non-specific IgG
elicited previously against other enteroviruses
that might harbour similar antigenic determi-
nants. The second immunoreactive region was
represented by synthetic peptides SP31, SP32
and SP33 (amino-acid residues 91–111), and
these were highly specific for detecting human
anti-EV71 IgG. This region, defined by the core
sequence LEGTTNPNG, represents the major
immunodominant VP1 linear epitope of EV71.
When SP32 (DLPLEGTTNPNGYAN) was tested
against EV71-positive sera, there was significant
immunoreactivity towards SP32, which con-
tained the core sequence.
The VP1 protein of the prototype EV71 BrCr
strain (GenBank accession no. U00871), when
produced as a recombinant His–VP1 fusion
protein, was highly insoluble and therefore
required denaturation and renaturation before
it could be used as a capture antigen in western
blots [7]. This insolubility could be attributed to
several hydrophobic transmembrane regions
within VP1. When a smaller peptide without
these regions was used, the immunodominant
VP1 linear epitope represented by SP32 was
over-expressed as a soluble recombinant gluta-
thione-S-transferase (GST)–SP32 fusion protein.
Based on the Kyte and Doolittle hydrophobicity
profile [8], this region (SP32) was shown to be
mainly hydrophilic. Using a protein–protein
BLAST search (blastp v.2.2.14; http://www.
ncbi.nlm.nih.gov), the amino-acid sequence of
SP32 was revealed to be highly homologous to
EV71 strains, indicating its probable high sensi-
tivity as a capture antigen for detecting human
anti-EV71 IgG. Hence, a pair of positive- and
negative-sense oligonucleotides was designed,
based on the nucleotide sequence of SP32
(nucleotides 280–324 of the VP1 gene). For
annealing, both oligonucleotides were heated at
90C for 3 min, and then incubated at 37C for
15 min. Primers flanking the VP1 gene (nucle-
otides 2442–3332 of the complete genome of
EV71 strain 41) were also constructed: GST–
VP1F, 5¢-TGGATCCGGAGATAGAGTGGCAG
(the BamH1 restriction site is underlined) and
GST–VP1R, 5¢-GCCGAAGTCGACTCAAAGGG
TAG (the SalI restriction site is underlined).
The vector pGEX-6p-1 (GE Healthcare Life
Sciences, Little Chalfont, UK) was used to
construct recombinant GST–SP32 and GST–VP1
fusion proteins, following the procedure recom-
mended by the manufacturer.
The efficacy of the recombinant GST–SP32
fusion protein as a capture antigen for human
anti-EV71 IgG was evaluated in IgG-based ELISA
and western blot assays. No significant immuno-
reactivity was detected by ELISA, but because of
its native state, the antigenic site represented by
SP32 could have been masked by the larger GST
protein moiety, thereby hindering antigen–anti-
body interactions. However, the fusion protein
was immunoreactive against human anti-EV71
IgG in western blots, probably because of its
denatured state, in which the steric hindrance
caused by the GST protein would have been
removed, thereby exposing the immunogenic
region represented by SP32. Before being used
as a capture antigen, EV71 was heat-inactivated at
56C and the amount of viral protein was quan-
tified using the Bradford protein assay (Bio-Rad
Laboratories, Hercules, CA, USA). Both the
recombinant GST–VP1 fusion protein and the
whole EV71 virion were non-specific when used
as capture antigens in western blots for detecting
human anti-EV71 IgG. This was attributed to the
presence of numerous common linear epitopes
among enteroviruses [6,9–11]. It is believed that
the cross-reactivity may be attributed to human
anti-poliovirus IgG, present in most paediatric
patients as a result of the national childhood
immunisation programme.
In conclusion, the recombinant GST–SP32
fusion protein, harbouring the immunodominant
VP1 linear epitope of EV71, demonstrated high
specificity and sensitivity, and was a better cap-
ture antigen in western blots than the recombinant
GST–VP1 fusion protein and the whole EV71
virion. This suggests that the recombinant GST–
SP32 fusion protein could be further developed as
a serological reagent for the detection of human
anti-EV71 IgG, and could be used as a tool for
identifying EV71 infection and as a confirmatory
assay for recognising previous EV71 exposure.
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Identification of Human CD4 T-Cell Epitopes 
on the VP1 Capsid Protein of Enterovirus 71
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ABSTRACT
The identification of human CD4 T-cell epitopes within a protein vaccine candidate is of great in-
terest, as it provides a better understanding of the mechanisms involved in protective immunity and
may therefore help in the design of effective vaccines and diagnostic tools. The entire amino acid
sequence of the VP1 capsid protein from enterovirus 71 (EV71) strain 41 was submitted to analy-
sis by the ProPred algorithm for the identification of potential promiscuous human CD4 T-cell
epitopes. Three regions spanning amino acids 66–77, 145–159, and 247–261 of VP1 were predicted
to bind more than 25 HLA-DR alleles. The corresponding synthetic peptides (SP1 to SP3) were then
tested for their abilities to induce proliferation of CD4 T cells isolated from five human volunteers
screened positive for previous EV71 exposure and one EV71-negative volunteer. Upon stimulation
with either peptide, CD4 T-cell proliferative responses were observed for all EV71-positive vol-
unteers, indicating the presence of EV71-specific memory CD4 T cells. The amplitude of the pro-
liferative responses was peptide- and HLA-DR–dependent, and correlated well with the ProPred
predicted binding efficiencies. Moreover, CD4 T cells from EV71-positive volunteers produced sig-
nificant levels of IL-2 and IFN- upon stimulation, indicative of a T-cell differentiation into Th-1-
type subset. Among the three peptides, SP2 induced the highest proliferative response and cytokine
production. Moreover, SP2-induced proliferative response could be inhibited with anti–major his-
tocompatibility complex (MHC) class II antibody, indicating that SP2 represents a MHC class II–re-
stricted CD4 T-cell epitope. This study demonstrates that the ProPred algorithm can accurately
predict the presence of human CD4 T-cell epitopes within the VP1 capsid protein of EV71, and
therefore represents a useful tool for the design of subunit vaccines against EV71.
1
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INTRODUCTION
ENTEROVIRUS 71 (EV71) IS AN EMERGING AGENT of in-fectious disease and belongs to the enterovirus A
species (33). In 1969, EV71 was first isolated in Cali-
fornia (37), and its association with hand, foot, and mouth
disease (HFMD) was made in 1973 during the small epi-
demics in Sweden (5) and Japan (19). In 1975, the neu-
rovirulence of EV71 was first reported in Bulgaria, where
44 people died of a polio-like disease (10). EV71 epi-
demics with neurological, cardiac, and/or pulmonary
complications subsequently occurred worldwide, with a
particular surge in the Asia-Pacific region during the last
10 years (36).
The current strategy for preventing EV71 infection re-
lies on public health surveillance and good hygiene prac-
tices. Presently, there is no specific drug against EV71
and treatments remain symptomatic only, providing re-
lief from fever and pain. The “WIN” group of compounds
is the most promising drug class so far, but it is rather
ineffective in disease regression (2). Other anti-viral
agents are currently being developed, including synthetic
compounds like pyridazinyl oxime ethers (3) and the use
of RNA interference (RNAi) technology (26). Natural
products like allophycocyanin (38) and lactoferrin (25)
have also been shown to exhibit anti-EV71 properties.
Therapeutic antibodies against EV71 might be an inter-
esting alternative to conventional drug treatments. We
have recently described anti-EV71 neutralizing antibod-
ies capable of effectively protecting suckling mice
against homologous and heterologous EV71 challenges
(14). However, a major concern with such therapeutic
treatments is that they may be administered too late to
the patient, after the virus has caused substantial and ir-
reversible damage. Hence, the need for an effective vac-
cine against EV71 is urgent.
Natural viral infections usually lead to the production
of protective neutralizing antibodies. Inactivated whole
virions and subunit vaccines have been reported to ef-
fectively protect suckling mice against EV71 infection in
passive experiments (14,46,47) or through maternally-
transferred antibodies (9,46). In particular, the VP1 cap-
sid protein has been shown to trigger the production of
protective antibodies against EV71, highlighting VP1 as
a promising vaccine candidate (8,9,14,46). In a recent
study, the cord sera from 205 individuals were tested for
the presence of anti-EV71 neutralizing antibodies, and
the authors described that the N-terminal moiety of VP1
is likely to harbor EV71-neutralizing conformational epi-
topes (41). However, the mapping and the characteriza-
tion of these regions have not been carried out.
Here we have identified three regions on the VP1 cap-
sid protein of enterovirus 71 strain 41 (5865/SIN/00009)
capable of inducing human EV71-specific CD4 T-cell
proliferation. CD4 T cells play a crucial and pivotal role
in adaptive immunity, for the development of an anti-
body-based immunity (11,12,40), as well as cytotoxic T-
cell responses (17,22,32). Therefore the identification of
CD4 T-cell epitopes is of great interest and might help
to design more effective subunit vaccines.
MATERIALS AND METHODS
T-cell epitope prediction
The VP1 amino acid sequence of enterovirus 71 strain
41 (5865/SIN/00009) (Genbank accession no. AF316321)
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was loaded into the ProPred prediction software using 
the server (http://www.imtech.res.in/raghava/propred) to
predict promiscuous epitopes. This server analyzes pro-
tein regions for their ability to bind to a total of 51 alle-
les belonging to 9 serologically defined HLA-DR mole-
cules that are encoded by DRB1 and DRB5 genes. The
quantitative matrices used in this prediction method in-
clude HLA-DR1 (2 alleles), HLA-DR3 (7 alleles), HLA-
DR4 (9 alleles), HLA-DR7 (2 alleles), HLA-DR8 (6 al-
leles), HLA-DR11 (9 alleles), HLA-DR13 (11 alleles),
HLA-DR15 (3 alleles), and HLA-DR51 (2 alleles). The
server analyzed the amino acid sequence using each of
the alleles independently and computed the binding
strength of all the peptides. The prediction threshold was
set at 3% and peptides predicted to bind at least 50% of
the major histocompatibility complex (MHC) class II
molecules were considered promiscuous for binding.
Virus propagation
Enterovirus 71 strain 41 (belonging to genogroup B4
and isolated from a fatal HFMD case in Singapore) was
propagated in rhabdomyosarcoma (RD) cells as described
previously (15). The cultured virus was purified with 7%
polyethylene glycol 8000 followed by 30% sucrose gra-
dient (15). The virus titer was determined as 50% tissue
culture infective doses (TCID50) in RD cells based on a
typical cytopathic effect as a result of viral infection. In-
fected cells were seen to cluster, shrank and became
pyknotic, and eventually degenerated and fell off of the
surface (24) The virus was inactivated by heating at 56°C
for 30 min, and the amount of viral protein was quanti-
fied by the Bradford assay (Bio-Rad Laboratories, Cali-
fornia, USA) according to the manufacturer’s instructions.
Peptide synthesis
Synthetic peptides (SP1 to SP4) were synthesized by
Mimotopes Pty Ltd (Clayton, Victoria, Australia). Pep-
tides were 90% in purity as assessed by high-perfor-
mance liquid chromatography and were used without
further purification. Approximately 1.7 mg of the pep-
tide was dissolved in 340 L dimethylsulfoxide (Sigma
Chemical Co., St. Louis, USA) to obtain a 5 mM working
concentration. For computational analysis, the amino acid
sequences of the synthetic peptides were used as query
sequences in a protein-protein BLAST (blastp 2.2.17)




Blood samples from 20 volunteers of both genders,
25–31 y of age, were collected in tubes containing 4%
2
sodium citrate as an anticoagulant. Genomic and sero-
logical typing was performed by the WHO Immunology
and Training Research Centre, Singapore, as a kind gift
from the director, Professor Chan SH.
In vitro microneutralization assay
Human anti-EV71 neutralizing antibodies were iden-
tified using an in vitro microneutralization assay with RD
cells as described previously (15). Human serum samples
were incubated at 56°C for 30 min to heat-inactivate the
complement before the assay. The assay was carried out
in triplicate.
Isolation of peripheral blood mononuclear cells
Blood cells were subjected to separation by Ficoll-Hy-
paque gradient centrifugation at 400 g for 40 min. The
buffy coats thus separated were diluted with phosphate-
buffered saline (pH 7.2), supplemented with 2 mM EDTA
(PBS/EDTA), and centrifuged at 300 g for 10 min. For
removal of platelets, resuspended cells were centrifuged
at 200 g for 15 min and the washing step was repeated
once. After washing, peripheral blood mononuclear cells
(PBMCs) were counted prior to magnetic labeling.
Culture and activation of monocyte-derived
dendritic cells
PBMCs were resuspended in 80 L of PBS/EDTA per
107 total cells, followed by incubation with CD14 Mi-
croBeads (Miltenyi Biotec Inc., California, USA) for 15
min at 4°C. The suspension was then centrifuged at 300
g for 10 min and the pellet was resuspended at 108 cells
in 500 L of PBS/EDTA, followed by magnetic separa-
tion using LS columns (Miltenyi Biotec Inc., California,
USA). Briefly, cell suspensions were applied to the top
of the column and the unbound cells were passed through
with 3  3 mL of PBS/EDTA supplemented with 0.5%
bovine serum albumin (column buffer). CD14 cells were
eluted with 5 mL column buffer. The cells were cultured
for 6 d at 37°C in RPMI 1640 media supplemented with
human interleukin 4 (IL-4) and granulocyte-macrophage
colony-stimulating factor (GM-CSF) (each at 20 ng/mL)
to generate immature DCs (imDCs). To activate the
imDCs, the cells were stimulated with peptides or EV71
whole virions (20 g/mL) in the presence of LPS (0.5
g/mL). When indicated, monoclonal anti-human MHC
class II (HLA-DP, -DQ, and -DR) antibodies (Ancell Co.,
Minnesota, USA) were also added at 20 g/mL.
T-cell proliferation assay
PBMCs were resuspended in 80 L of PBS/EDTA per
107 total cells followed by incubation with CD4 Mi-
croBeads (Miltenyi Biotec Inc.) for 15 min at 4°C. The
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isolation steps are similar to those for isolation of DCs
as described above. CD4 T cells were resuspended in
AIM-V® media (Invitrogen, Carlsbad, CA) supplemented
with 10% autologous serum and were incubated in flat-
bottomed 96-well plates for 7 d at 37°C in 5% CO2 in
air in the presence or absence of stimulated or non-stim-
ulated DCs. The stimulator:responder cell ratio was 1:10.
At 24 h before the end of incubation, the cells were pulsed
with 0.5 Ci per well of [methyl-3H] thymidine. After
washing, the cells were harvested and counted on a liq-
uid scintillation counter. Their radioactivity was ex-
pressed as the mean counts per min (cpm) of triplicate
determinations. The stimulation index (SI) was calculated
as the mean number of counts of cell-associated [3H]
thymidine per minute recovered from wells containing
activated DCs divided by the mean number of counts of
cell-associated [3H] thymidine per minute recovered from
wells containing imDCs.
Cytokine analysis
CD4 T-cell culture supernatants were collected at 96
h for cytokine measurement using the Bio-Plex™ sus-
pension array system (Bio-Rad Laboratories) according
to the manufacturer’s instructions. The multiplex sus-
pension bead array immunoassay was performed using
the human 6-Plex kit (Bio-Rad Laboratories) to specifi-
cally evaluate cytokines of Th-1-type (IL-2 and IFN-)
and Th-2-type (IL-4 and IL-10) subsets according to the
manufacturer’s protocol. The assay was carried out in
triplicate.
RESULTS
Prediction of HLA-DR-restricted epitopes
Computer-generated algorithms that predict MHC
class II binding peptides are based on the identification
of HLA-DR allele-specific motifs in antigenic peptides
and on the structural definition of HLA-peptide com-
plexes. The primary amino acid sequence of the VP1 cap-
sid protein of EV71 strain 41 was analyzed using the T-
cell epitope prediction ProPred algorithm, which led to
the identification of promiscuous regions potentially
binding to HLA-DR molecules. Three regions (I, II, and
III) were predicted to bind more than 50% of the 51 HLA-
DR alleles available in the ProPred database, and were
therefore considered as promiscuous CD4 T-cell epi-
topes by the program (Fig. 1). These regions map at
amino acids 66–77, 145–159, and 247–261 of the VP1
protein (Table 1). The corresponding peptides, namely
SP1, SP2, and SP3, respectively, were synthesized, as
well as a fourth peptide SP4 (scrambled), representing a
VP1 region with poor predictability for promiscuous
3
binding (Table 1). A protein-protein BLAST (blastp
2.2.17) search indicated that the amino acid sequences of
all four peptides were highly specific for EV71 strains
and no significant homology with other enteroviruses was
found (data not shown).
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HLA-DR typing and detection of anti-EV71
antibodies in human volunteers
Of the 20 human volunteers recruited for this study,
only six displayed HLA-DR alleles that were repre-
sented in the ProPred database. Among these six vol-
unteers, five were sero-diagnosed positive for the pres-
ence of anti-EV71 neutralizing antibodies, with a
neutralizing titer of 1:8 and above (Table 2). One vol-
unteer was identified as EV71-negative (Table 2). All
six volunteers were found to be negative for EV71 by
cultural analysis, indicating that none of them were cur-
rently infected with EV71 (data not shown). In addi-
tion, Western blot analysis was performed using a re-
combinant GST-VP1 fusion protein as capture antigen
to detect anti-VP1 IgG antibodies in the serum from
each volunteer. As expected, a positive signal was ob-
served when using serum samples from the five EV71-
positive volunteers, whereas no signal was detected in
the EV71-negative volunteer, demonstrating the pres-
ence of circulating anti-VP1 IgG antibodies in the
EV71-positive volunteers, and confirming results of
previous studies that described VP1 as a highly im-
munogenic antigen (8,9,14,15,46,47) (data not shown).
CD4 T-cell proliferative responses
CD4 T cells isolated from the EV71-positive and
EV71-negative volunteers were stimulated with VP1-de-
rived peptides (SP1–SP4) or with heat-inactivated EV71
whole virions using autologous monocyte-derived den-
dritic cells as professional antigen-presenting cells
(APCs). The cellular proliferative responses were ex-
pressed as a stimulation index (SI), which corresponds
to the ratio of the counts per minute (cpm) in the pres-
ence of antigen over the cpm without any antigenic stim-
ulus. As expected, for the five EV71-positive volunteers,
elevated CD4 T-cell proliferative responses were ob-
served upon stimulation with EV71 whole virions (Fig.












































































































































































































FIG. 1. An output of ProPred analysis of the VP1 amino
acid sequence in HTML view II. The sequence was analyzed
for binding to 51 HLA-DR alleles using the ProPred program
at the default setting (threshold value of 3%). The peptide se-
quences predicted to bind more than 50% of the HLA-DR al-
leles available in the database are underlined.
TABLE 1. SEQUENCES AND LOCATIONS WITHIN VP1 OF
PREDICTED PROMISCUOUS CD4T-CELL EPITOPES
Peptide Predicted region VP1 amino acid sequence Position
SP1 I H-IETRCVLNSHSTAET-OH 66–77
SP2 II H-EVVPQLLQYMFVPPG-OH 145–159
SP3 III H-LVVRIYMRMKHVRAW-OH 247–261
SP4 NA H-PTGQNTQVSSHRLDT-OH 27–41
aPeptides (SP1 to SP3) representing VP1 regions considered promiscuous for binding more than
25 different HLA-DR alleles. Peptide SP4 represents a scrambled peptide with poor predictability of
promiscuous binding.
Abbreviation: NA, not applicable.
did not result in any significant proliferative response re-
gardless of the HLA-DR allele tested. A weak but de-
tectable CD4 T-cell proliferative response was ob-
served for the EV71-negative volunteer upon stimulation
with EV71 whole virions. CD4 T cells isolated from
the EV71-positive volunteers proliferated significantly
and with similar amplitudes upon stimulation with pep-
tide SP2 (Fig. 2). However, the stimulation indices ob-
tained upon stimulation with peptide SP1 or SP3 differ
from one HLA-DR allele to another, and was either sim-
ilar to or lower than the SI obtained upon SP2 stimula-
tion. These data correlate with the ProPred analysis,
which predicted for the five EV71-positive volunteers a
higher binding efficiency for the VP1 region II (repre-
sented by SP2) as compared to regions I and III (repre-
sented by SP1 and SP3, respectively) (Table 2). Fur-
thermore, stimulation with SP1 failed to induce
significant CD4 T-cell proliferation for the EV71-pos-
itive volunteers with HLA genotype DRB1*0301 (vol-
unteers 1–3), which again correlates with ProPred’s pre-
dictions (Table 2). Similarly, the SI obtained upon SP3
stimulation correlated well with the ProPred analysis,
which predicted that region III (corresponding to SP3
peptide) displays the highest binding efficiency for HLA
genotype DRB1*1301. In addition, a background SI
value was consistently obtained upon stimulation of
CD4 T cells isolated from the EV71-negative volun-
teer with any of the stimulating antigens, indicating that
the proliferative responses observed for volunteers 1–5
likely resulted from EV71-specific CD4 T cells (Fig.
2). Altogether, these data indicate that the ProPred pro-
gram accurately predicted the binding efficiency for each
peptide depending on the HLA-DR allele, and therefore
represents a reliable approach to prediction and identi-
fication of potential human CD4 T-cell epitopes.
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MHC class II-blocking experiment
To confirm that the observed CD4 T-cell prolifera-
tion was mediated by peptide presentation in association
with MHC class II molecules, a MHC class II–blocking
experiment was carried out using SP2 as the stimulating
antigen. SP2 and anti-human MHC class II monoclonal
antibodies were incubated with immature DCs (imDCs)
from the five EV71-positive volunteers, and CD4 T-cell
proliferative responses were measured as described
above. The data showed that co-incubation with anti-
5
TABLE 2. EV71 EXPOSURE OF VOLUNTEERS AND PREDICTED PEPTIDE BINDING EFFICIENCIES
Serum anti-EV71 Anti-VP1 IgG
Volunteer HLA genotype neutralizing antibody titera antibodyb SP1 SP2 SP3 SP4
1 DRB1*0301 1128  0 93 60 0
2 DRB1*0301 1648  0 93 60 0
3 DRB1*0301 1256  0 93 60 0
4 DRB1*0405 1256  60 60 60 0
5 DRB1*1301 1648  93 100 86 0
6 DRB1*0301 —  0 93 60 0
aSerum anti-EV71 neutralizing titer was determined using an in vitro microneutralization assay.
bImmunoblots using recombinant GST-VP1 fusion protein as capture antigen and 150 diluted serum sample from each volunteer
as primary antibody. Plus signs represent the presence of a 58.7-kDa band corresponding to the GST-VP1 fusion protein, indicating
the presence of specific anti-VP1 IgG antibody.
cPredicted binding efficiency of peptides based on a specific HLA-DR allele.































FIG. 2. Proliferation of CD4 T cells upon stimulation
with peptides or EV71 whole virions. Heat-inactivated EV71
whole virions, peptides (SP1–SP4), or no antigen were first
added to the monocyte-derived dendritic cells prepared from
each volunteer before incubation with autologous CD4 T cells.
[3H] thymidine was added to the culture medium 24 h prior to
counting. The stimulation index (SI) was calculated as the ra-
tio of the mean cpm in the presence of activated DCs over the
mean cpm in the presence of immature DCs (imDCs).
MHC class II antibodies resulted in a reduction of SP2-
induced CD4 T-cell proliferation by more than 80%
(Fig. 3). Therefore, this observation suggests that SP2 has
to be presented by APCs in association with MHC class
II molecules to effectively induce EV71-specific CD4
T-cell proliferation, thereby indicating that SP2 contains
an MHC class II–restricted CD4 T-cell epitope.
Cytokine profile upon antigenic stimulation
To address whether the SP-induced stimulation of
CD4 T-cells drives their differentiation into Th-1-type
or Th-2-type subsets, the cytokine profile was deter-
mined. CD4 T cells from the six volunteers were co-in-
cubated with autologous DCs primed with either peptides
(SP1–SP4) or with heat-inactivated EV71 whole virions
as described above, and the production of interleukins
(IL)-2, IL-4, and IL-10, and interferon gamma (IFN-)
was measured in the culture supernatants. Significant lev-
els of IL-2 and IFN- were detected in the supernatant
of the SP1-, SP2-, SP3-, and EV71-stimulated CD4 T
cells from EV71-positive volunteers (Table 3). Similar to
the proliferative responses, CD4 T cells from all EV71-
positive volunteers secreted significantly (p  0.05)
higher levels of IL-2 and IFN- in response to SP2 as
compared to SP1 and SP3. No significant differences in
the production of IL-4 and IL-10 were observed upon
stimulation with SP1–SP4 and in those with no antigenic
stimulus (Table 3). Instead, significant but rather low lev-
els of IL-4 were detected when using EV71 whole viri-
ons as stimulants for CD4 T cells from all EV71-posi-
tive, but also from EV71-negative, volunteers. Instead, a
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significant level of IL-10 was measured in EV71-stimu-
lated CD4 T cells from EV71-positive volunteers only.
Altogether, these data indicate that the levels of cytokine
production correlate well with the CD4 T-cell prolifer-
ative responses, with SP2 triggering the highest cytokine
production regardless of which HLA-DR allele is used.
Significant production of IL-2 and IFN- by proliferat-
ing CD4 T cells also suggests their differentiation into
a Th-1-type subset.
DISCUSSION
The host immune response developed upon any viral
infection is primarily CD4 T-cell dependent, including
the induction of a cytotoxic cellular response and the
development of an efficient antibody response. Several
studies of B-cell epitopes led to the identification of
serotype- and group-common specific B-cell epitopes on
the VP1 capsid protein of enteroviruses (6). The func-
tional role of enterovirus-specific T cells, as well as 
the nature and specificity of their responses, have 
been less well-characterized so far. Although animal
studies have been carried out to identify T-cell epitopes
on four structural proteins (VP1–VP4) of enteroviruses
(4,22,23,27,29,45), only a few studies based on the VP1
capsid protein have been carried out in humans (18,39).
Several approaches have been reported for the identi-
fication of T-cell epitopes. Overlapping synthetic pep-
tides spanning the entire sequence of the protein candi-
date can be designed and assayed for their capability to
activate CD4 T cells (1,35,43). However, such a sys-
tematic approach is costly, time-consuming, and tedious.
Alternatively, computer programs can be employed to
scan the protein of interest and predict regions likely to
bind to MHC molecules. The discovery of MHC-binding
motifs in proteins has led to the development of several
algorithms based on the construction of a matrix of all
possible amino acid side chain interactions for individ-
ual MHC-binding motifs (13,20). Such bioinformatics
tools have been successfully employed to identify HLA-
DR ligands derived from tumor antigens and endogenous
proteins involved in autoimmune diseases (21,28). In ad-
dition, these programs have been reported to improve and
accelerate the design of vaccines and diagnostic tests
through the identification of promiscuous peptides in my-
cobacterial proteins (34,44).
In this study, the ProPred program was employed to
predict HLA-DR binding ligands within the VP1 capsid
protein of EV71 strain 41, since HLA-DR constitutes the
dominant isotype of human MHC class II molecules (42).
Activation of CD4 T cells is dependent upon the pre-
sentation of peptides by APCs in the context of MHC

















FIG. 3. Proliferation of SP2-stimulated CD4 T cells in
the presence of anti-human MHC class II monoclonal antibod-
ies. Peptide SP2 (20 g/mL) was added to the monocyte-de-
rived dendritic cells from each EV71-positive volunteer with or
without MHC class II blocking antibodies (20 g/mL). The
mixtures were then incubated with autologous CD4 T cells
and the stimulation index (SI) was calculated as previously de-
scribed.
imately 15 amino acids in length and are derived from
internalized proteins that entered the endocytotic path-
way. The MHC genes are the most polymorphic genes
present in the genome, and the majority of the amino acid
differences among the various alleles lie within the pep-
tide-binding groove of the MHC class II molecules (31).
Upon analysis, numerous regions within VP1 were pre-
dicted to bind one or more HLA-DR alleles, but only
three regions (I, II, and III) were predicted to bind 50%
or more HLA-DR alleles included in the ProPred data-
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base. These regions span amino acids 66–77, 145–159,
and 247–261 of the VP1 protein, respectively. The cor-
responding peptides (SP1–SP3) were synthesized and
shown to be able to induce the proliferation of CD4 T
cells from five EV71-positive volunteers with different
HLA-DR alleles, but not from an EV71-negative volun-
teer, indicating that the peptides have stimulated EV71-
specific memory CD4 T cells. The stimulation indices
obtained correlated well with the binding efficiencies pre-
dicted for each peptide and for each HLA-DR allele.
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TABLE 3. ANTIGEN-SPECIFIC CYTOKINE SECRETION BY STIMULATED CD4T CELLS
IL-2 (pg/mL)
Volunteer SP1 SP2 SP3 SP4 EV71 No antigen
1 4.8 (1.9) 42.0 (1.0) 13.9 (3.1) 4.3 (1.1) 102.5 (2.2) 2.0 (0.7)
2 6.2 (2.9) 26.9 (2.1) 20.3 (1.5) 3.8 (1.3) 107.7 (2.8) 2.6 (1.1)
3 3.3 (1.3) 35.4 (1.9) 19.8 (1.6) 5.4 (1.2) 106.2 (3.0) 2.7 (0.8)
4 28.1 (4.6) 22.6 (2.3) 23.0 (1.8) 5.4 (2.0) 108.2 (1.7) 2.1 (1.5)
5 38.3 (1.7) 33.0 (2.7) 34.2 (2.4) 6.2 (1.6) 106.4 (4.5) 2.6 (1.1)
6 4.1 (1.7) 9.3 (1.7) 4.8 (1.1) 5.1 (1.3) 79.4 (2.7) 2.7 (0.8)
IFN- (ng/mL)
Volunteer SP1 SP2 SP3 SP4 EV71 No antigen
1 12.9 (1.8) 65.6 (3.8) 40.3 (3.8) 1.4 (1.5) 684.5 (3.4) 0.9 (0.3)
2 13.7 (1.7) 48.4 (1.3) 31.5 (3.3) 1.7 (0.2) 236.1 (2.3) 1.1 (0.7)
3 17.4 (1.2) 69.0 (1.2) 40.8 (2.2) 1.4 (0.6) 957.6 (2.1) 1.4 (1.1)
4 34.4 (2.1) 45.5 (1.6) 32.0 (1.3) 1.6 (0.5) 643.8 (3.6) 1.1 (0.6)
5 46.4 (2.9) 61.9 (3.6) 48.2 (1.2) 1.8 (0.4) 384.3 (2.8) 1.4 (1.1)
6 0.8 (0.5) 1.0 (0.5) 0.8 (0.3) 0.5 (0.4) 38.3 (1.2) 0.6 (0.3)
IL-4 (pg/mL)
Volunteer SP1 SP2 SP3 SP4 EV71 No antigen
1 2.6 (1.5) 4.3 (4.5) 3.4 (0.8) 2.5 (1.0) 34.9 (1.3) 2.6 (1.2)
2 3.1 (1.7) 3.4 (2.7) 3.3 (0.4) 2.2 (1.9) 26.9 (4.8) 2.1 (1.3)
3 3.4 (1.2) 3.9 (3.3) 3.3 (2.0) 2.6 (1.4) 22.8 (2.1) 2.6 (1.3)
4 3.0 (1.6) 3.1 (0.6) 3.9 (1.4) 3.2 (1.6) 33.1 (0.5) 2.7 (1.6)
5 4.1 (4.6) 3.9 (3.3) 3.8 (4.3) 3.2 (1.5) 26.5 (2.2) 2.2 (0.9)
6 2.8 (1.7) 2.6 (1.6) 2.4 (1.1) 2.5 (0.8) 19.3 (0.4) 2.2 (0.8)
IL-10 (ng/mL)
Volunteer SP1 SP2 SP3 SP4 EV71 No antigen
1 1.2 (0.1) 1.2 (0.2) 1.2 (0.2) 1.2 (0.2) 31.5 (0.2) 1.1 (0.2)
2 1.2 (0.2) 1.5 (0.2) 1.2 (0.2) 1.2 (0.2) 22.9 (0.3) 1.1 (0.3)
3 2.1 (0.2) 2.1 (0.2) 2.3 (0.3) 2.0 (0.3) 23.9 (0.8) 1.9 (0.1)
4 1.6 (0.2) 1.9 (0.1) 1.8 (0.1) 1.1 (0.4) 24.4 (0.2) 1.1 (0.4)
5 2.0 (0.3) 2.3 (0.3) 2.6 (0.2) 1.8 (0.1) 11.5 (0.3) 1.8 (0.2)
6 1.3 (0.4) 1.4 (0.4) 1.3 (0.3) 1.2 (0.1) 3.1 (0.1) 1.0 (0.4)
Secretion of cytokines of Th-1-type (IL-2 and IFN-) and Th-2-type (IL-4 and IL-10) subsets by CD4 T cells upon stimulation
by autologous monocyte-derived dendritic cells in response to peptides, EV71 whole virions (20 g/mL), or no antigen. Values 
represent averages of data obtained from triplicate assays. Standard deviations are in parentheses.
Among the three peptides tested, SP2 was identified to
be the most capable of inducing significant CD4 T-cell
proliferative responses among the five EV71-positive
volunteers. Studies have shown that although several T-
cell epitopes are present within the entire protein antigen,
T cells tend to focus on only a few immunodominant epi-
topes, whereas discrete cryptic epitopes remain unseen
by the host immune system (16,30). Therefore, SP2 most
likely contains an immunodominant CD4 T-cell epi-
tope. In addition, using anti-MHC class II antibody, we
have demonstrated that SP2 is an MHC class II-restricted
CD4 T-cell epitope.
Antigen-specific CD4 T cells producing IFN- have
been shown to be essential for activation and maintenance
of CD8 T-cell–mediated immune responses and for B-
cell differentiation (17,32). A previous study on the iden-
tification of enterovirus cross-reactive T-cell epitopes
suggested that IFN- release may be used as an indica-
tor for specific T-cell activation (7). However, a poor cor-
relation between the degree of antigen-specific T-cell
proliferation and IFN- production has been previously
reported, suggesting that proliferating and IFN-–pro-
ducing T cells may belong to functionally different sub-
sets (7). Instead, our results showed that the levels of
IFN- secreted by peptide-stimulated CD4 T cells cor-
related well with their respective proliferative responses.
In addition, the significant production of IL-2 and IFN-
 upon stimulation with SP1–SP3 clearly indicates a Th-
1-subtype differentiation. Interestingly, a weak but sig-
nificant proliferative response and cytokine production
were observed by EV71-stimulated CD4 T cells from
the EV71-negative volunteer. However, neither anti-
EV71 neutralizing activity nor anti-VP1 antibodies were
detected in the serum. It is likely that this volunteer might
have been exposed to cross-reactive enteroviruses such
as coxsackievirus 16 (CA16) or poliovirus as a result of
the national childhood immunization program.
CONCLUSION
In conclusion, we have identified three potential hu-
man CD4 T-cell epitopes within the VP1 capsid pro-
tein of EV71. We have shown that the ProPred program
has accurately predicted the presence of these epitopes
and their binding efficiencies to three different HLA-DR
alleles. Among these three epitopes, the one spanning
amino acids 145–159 of VP1 appeared to be the best at
inducing a high proliferation response of, and high cy-
tokine levels by, CD4 T cells from the five EV71-pos-
itive human volunteers. However, to further demonstrate
the promiscuous nature of this epitope, a larger number
of human volunteers should be tested whose HLA-DR
alleles are available in the ProPred database. In addition,
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to confirm that the antigenic stimulation induces prolif-
eration of, and cytokine production by, EV71-specific
CD4 T cells, more EV71 sero-negative volunteers
should be tested. Because EV71 infection is endemic in
Singapore, the proportion of sero-negative individuals is
extremely low. This study is a first step toward the iden-
tification of promiscuous human CD4 T-cell epitopes
within VP1, the major immunogenic and protective anti-
gen against EV71. We believe that this approach will con-
tribute to a better understanding of the immune correlates
of protection against EV71 infection, and will help in de-
veloping more effective immuno-therapeutic and im-
muno-prophylactic strategies.
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Bordetella pertussis, the causative agent of whooping cough, is a promising and attractive candidate for
vaccine delivery via the nasal route, provided that suitable attenuation of this pathogen has been obtained.
Recently, the highly attenuated B. pertussis BPZE1 strain has been described as a potential live pertussis
vaccine for humans. We investigated here the use of BPZE1 as a live vehicle for heterologous vaccine
candidates. Previous studies have reported the filamentous hemagglutinin (FHA), a major B. pertussis adhesin,
as a carrier to express foreign antigens in B. pertussis. In this study, we also examined the BrkA autotransporter
as a surface display system. Three copies of the neutralizing peptide SP70 from enterovirus 71 (EV71) were
fused to FHA or in the passenger domain of BrkA, and each chimera was expressed in BPZE1. The FHA-
(SP70)3 and BrkA-(SP70)3 chimeras were successfully secreted and exposed at the bacterial surface, respec-
tively. Nasal administration of the live recombinant strains triggered a strong and sustained systemic anti-
SP70 antibody response in mice, although the titers and neutralizing activities against EV71 were significantly
higher in the sera of mice immunized with the BrkA-(SP70)3-producing strain. These data indicate that the
highly attenuated BPZE1 strain is a potential candidate for vaccine delivery via the nasal route with the BrkA
autotransporter as an alternative to FHA for the presentation of the heterologous vaccine antigens.
Live recombinant bacteria adapted to the respiratory tract
appear to be attractive and promising vehicles for the presen-
tation of vaccine antigens to the respiratory mucosa. Bordetella
pertussis, the etiological agent of whooping cough, colonizes
the human respiratory tract very efficiently and induces strong
and protective local and systemic immune responses after a
single nasal administration (39, 40, 49), with induction of im-
munity even at distant mucosal sites, such as the urogenital
tract (41).
Consequently, B. pertussis has been successfully used as a
live bacterial vector for the presentation of foreign antigens to
the respiratory mucosa in mouse models (33, 38). However,
suitable attenuation is mandatory in order to use B. pertussis as
a live recombinant vector of vaccination. Recently, the highly
attenuated B. pertussis BPZE1 strain was described (40). Miel-
carek et al. reported markedly reduced lung inflammation in
mice nasally infected with BPZE1, while the ability to colonize
and induce protective immunity against pertussis infection was
maintained. Furthermore, BPZE1 was found to induce protec-
tion in infant mice that was superior to the protection provided
by the current acellular pertussis vaccines. These features
make the B. pertussis BPZE1 strain an attractive live pertussis
vaccine candidate and also a potential vehicle for vaccine de-
livery via the nasal route. The expression of heterologous an-
tigens in BPZE1 and the ability of this strain to induce specific
immune responses upon nasal administration of live recombi-
nant bacteria have not been described previously.
Several heterologous antigens have been produced in re-
combinant B. pertussis, including the Schistosoma mansoni 28-
kDa glutathione S-transferase (42), fragment C of tetanus
toxin (50), transferrin-binding protein B (TbpB) from Neis-
seiria meningitidis (15), and HtrA from Haemophilus influenzae
(3). These antigens have been fused to the filamentous hem-
agglutinin (FHA), a major adhesin of B. pertussis (34). FHA is
a 220-kDa monomeric protein that is both surface exposed and
secreted into the extracellular milieu (16, 29). It is highly im-
munogenic (2, 8, 52) and displays adjuvant properties (47),
prompting its use as a carrier to present heterologous antigens
to the respiratory mucosa. However, efficient secretion of FHA
chimeras across the outer membrane requires a totally un-
folded conformation of the passenger (24, 50), which limits the
use of FHA as a carrier.
Autotransporters have been successfully used in Salmonella
and Escherichia coli to present heterologous antigens at the
bacterial surface (31, 32, 62), and they are able to translocate
folded protein domains across the outer membrane (58). Au-
totransporters are large, secreted, often virulence-associated
proteins of gram-negative bacteria (25). They display a char-
acteristic domain structure that includes (i) a signal peptide at
the N terminus; (i) a passenger domain, which encodes the
functional part of the protein, and (iii) a C-terminal translo-
cation unit, which is conserved in the autotransporter family.
The latter domain consists of a beta barrel that is embedded in
the outer membrane and through which the passenger domain
is translocated to the cell surface (26). Most autotransporters
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are proteolytically processed, releasing an -domain which
comprises most of the passenger domain.
The B. pertussis BrkA autotransporter confers serum resis-
tance by inhibiting the classical pathway of complement acti-
vation (6, 20) and plays a role in B. pertussis adhesion to and
invasion of the host cells (19, 20). It is expressed as a 103-kDa
precursor and is processed during secretion, which yields a
73-kDa N-terminal passenger domain and a 30-kDa C-termi-
nal translocation unit (53). Following translocation, the
cleaved passenger domain remains tightly associated with the
bacterial surface (44). A truncated version of BrkA with a large
deletion within its passenger domain has been reported and
shown to be efficiently translocated across the outer membrane
(45). We therefore hypothesized that this domain may be per-
missive for replacement at least in part by heterologous anti-
gens.
Here, we report the expression of the neutralizing SP70
peptide from enterovirus 71 (EV71) in the highly attenuated B.
pertussis BPZE1 strain using FHA or BrkA as a carrier. EV71
is a major causative agent of hand, foot, and mouth disease and
has a propensity to cause severe neurological complications
leading to significant morbidity and mortality in infants and
children (36, 46). Since 1997, several outbreaks of EV71 infec-
tion have been reported in East and Southeast Asia, including
Singapore and Japan, and its epidemic activity has been on the
rise in the Asia-Pacific region (10, 12, 27). Several reports have
indicated that the EV71 VP1 capsid protein is protective in
animal models (13, 14, 55, 59) and is highly immunogenic in
humans (57). We have recently shown that the SP70 peptide,
spanning amino acids 208 to 222 of VP1, contains a neutraliz-
ing (23) and protective (22) B-cell epitope and is highly con-
served among the EV71 subgenogroups.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains used in this
study are listed in Table 1. BPSY13.1, BPSY1, and BPSQ5 were derived from B.
pertussis BPZE1, a streptomycin-resistant Tohama I derivative producing inac-
tivated pertussis toxin, no dermonecrotic toxin, and background levels of tracheal
cytotoxin (40). All B. pertussis strains were grown at 37°C for 72 h on Bordet-
Gengou (BG) agar (Difco, Detroit, MI) supplemented with 1% glycerol, 10%
defibrinated sheep blood, and 100 g/ml streptomycin (Sigma Chemical Co., St
Louis, MO). Liquid cultures were grown as described previously (37) in Stainer-
Scholte medium containing 1 g/liter heptakis(2,6-di-o-methyl)--cyclodextrin
(Sigma).
All DNA manipulations were carried out with chemically competent Esche-
richia coli One-Shot TOP10 (Invitrogen). The bacteria were grown at 37°C
overnight on Luria-Bertani agar or in Luria-Bertani broth with vigorous shaking.
When appropriate, 100 g/ml ampicillin, 50 g/ml ampicillin, or 10 g/ml gen-
tamicin was added to select for antibiotic-resistant strains.
Virus growth and purification. EV71 strain 5865/SIN/00009 (GenBank acces-
sion no. AF316321) was propagated in rhabdomyosarcoma (RD) cells using
minimum essential medium (Gibco, United States) supplemented with 5% fetal
calf serum, 1% sodium pyruvate, and 1.5% sodium bicarbonate. The virus par-
ticles were purified as described previously (23). Briefly, infected cells were lysed
by subjecting them to freeze-thaw cycles. The virus particles were precipitated in
7% polyethylene glycol 8000 by centrifugation on a 30% sucrose cushion at
25,000  g for 4 h. The virus titer was expressed as the 50% tissue culture
infective dose with RD cells based on typical cytopathic effects (CPE) produced
by viral infection. Before injection into mice, the virus suspension was heat
inactivated at 56°C for 30 min. The amount of virion protein was quantified by
the Bradford method (Bio-Rad Laboratories, United States).
Oligonucleotides, peptides, and antibodies. To circumvent any problems in
protein translation due to poor codon usage (28), the original sp70 DNA se-
quence was optimized to B. pertussis codon usage preference. To generate the
FHA-(SP70)3 construct, the upper and lower DNA strands of optimized sp70
(5-GATCGGCTACCCGACCTTCGGCGAGCACAAGCAGGAGAAGGAC
CTGGAGTACGA-3 and 5-GATCTCGTACTCCAGGTCCTTCTCCTGCTT
GTGCTCGCCGAAGGTCGGGTAGCC-3) were chemically synthesized and
annealed, generating cohesive BglII-compatible ends. To generate the BrkA-
(SP70)3 construct, the upper and lower DNA strands of optimized sp70 (5-GA
TCTGTACCCGACCTTCGGCGAGCACAAGCAGGAGAAGGACCTGGA
GTACTG-3 and 5-GATCCAGTACTCCAGGTCCTTCTCCTGCTTGTGCT
CGCCGAAGGTCGGGTACA-3) were chemically synthesized and annealed,
generating cohesive BamHI-compatible ends.
Unconjugated SP70 peptide (22) was chemically synthesized at Mimotopes
Pty. Ltd. (Clayton Victoria, Australia).
Rabbit anti-BrkA polyclonal antibodies were a kind gift from Rachel Fernan-
dez (University of British Columbia, Canada).
Construction of recombinant B. pertussis strains. To construct the recombi-
nant B. pertussis BPSY13.1 strain producing the FHA-(SP70)3 chimera, a
1,620-bp HindIII PCR fragment was amplified from the BPZE1 chromosomal
DNA using primers 5-TTAAGCTTGCGAACGCGCTGCTGTGGG-3 and 5-
TTAAGCTTCGCATCGGCGCTGCCCAGC-3 (HindIII sites are underlined)
and cloned into HindIII-opened plasmid pBR322 (7), yielding pBRSY0. The
PCR fragment corresponded to nucleotides (nt) 5221 to 6840 of the fhaB open
reading frame (ORF) and contained its unique BglII site. Three copies of the
sp70 DNA sequence were inserted in tandem and sequentially into the unique
BglII site of pBRSY0. Insertion of one copy of sp70 DNA into BglII-digested
pBRSY0 restored a BglII site only at the 3 end of the sp70 DNA fragment,
allowing insertion of a second sp70 copy and then a third sp70 copy, finally
yielding pBRSY3. The 1,755-bp HindIII fragment from pBRSY3 was then
cloned into HindIII-opened suicide plasmid pJQmp200rpsL18 (48), yielding
pJQSY3. BPZE1 was electroporated with pJQSY3, allowing the fha-(sp70)3
construct to integrate into the chromosomal DNA by allelic exchange (56) at the
fhaB locus.
To construct the recombinant B. pertussis BPSQ5 strain, which express the
BrkA-(SP70)3 chimera, a 1-kb SalI-BamHI PCR fragment and a 945-bp BamHI-
HindIII PCR fragment were cloned into pUC19 (60) using the corresponding
restriction sites, yielding pUCSY2. Both PCR fragments were amplified from
BPZE1 chromosomal DNA. The 1-kb SalI-BamHI PCR fragment was amplified
using primers 5-TTGTCGACGTAGTATCCCTTGGCCGCGC-3 and 5-TTG
GATCCTGCGCATGCGGCGCGCC-3 (SalI and BamHI sites are underlined)
and encompassed the 5 end of the brkA ORF (nt 1 to 151), its promoter region,
and the first 529 nt of the adjacent brkB ORF, which is transcribed in the
opposite direction. A 945-bp BamHI-HindIII PCR fragment was obtained using
primers 5-TTGGATCCACGCCGGCCAGGACGGCAA-3 and 5-TTAAGC
TTCACGACCCAGGTTCCGCCC-3 (BamHI and HindIII sites are under-
lined) and corresponded to nt 789 to 1735 of the brkA ORF. Three copies of the
sp70 gene fragment were then inserted in tandem and sequentially into BamHI-
digested pUCSY2. Insertion of one copy of sp70 DNA into BamHI-digested
pUCSY2 restored a BamHI site only at the 3 end of the sp70 DNA fragment,
which allowed insertion of a second copy and a third copy of sp70, finally yielding
pUCSQ2. The 2,125-bp HindIII fragment from pUCSQ2 was finally cloned into
HindIII-opened pJQmp200rpsL18, yielding pJQSQ1. BPZE1 was electropo-
rated with pJQSQ1, which allowed the brkA-(sp70)3 construct to integrate into
the chromosomal DNA by allelic exchange at the brkA locus.
To construct the brkA knockout strain BPSY1, the 1,963-bp HindIII fragment
from pUCSY2, which contained both the 1-kb SalI-BamHI and 945-bp BamHI-
HindIII PCR fragments described above, was inserted into HindIII-opened
pJQmp200rpsL18, yielding pJQSY1. BPZE1 was then electroporated with
TABLE 1. B. pertussis strains used in this study
Strain Relevant feature(s) Reference
BPZE1 Attenuated Smr BPSM derivative
lacking the dnt gene and
producing inactive pertussis
toxin and reduced tracheal
cytotoxin
40
BPSQ5 BPZE1 derivative producing
BrkA-(SP70)3
This study
BPSY13.1 BPZE1 derivative producing
FHA-(SP70)3
This study
BPSY1 brkA knockout BPZE1 derivative This study
112 HO ET AL. INFECT. IMMUN.
pJQSY1, which allowed allelic exchange at the brkA chromosomal locus and
resulted in deletion of nt 151 to 789 in the brkA ORF. BPSY1 therefore produced
a truncated BrkA protein consisting of 103 amino acids.
Whole-cell extract preparation and supernatant concentration. Ten milliliters
of mid- to late-exponential-phase bacteria in SSAB medium was centrifuged at
7,000 rpm for 15 min at room temperature. The supernatant was concentrated
10-fold using a 30-kDa-cutoff Ultra-4 centrifugal filter device (Amicon) accord-
ing to the manufacturer’s protocol. The bacterial pellet was resuspended in 500
l of ultrapure water. An equal volume of 2 loading buffer was added before
the preparation was heated at 95°C for 10 min. The chromosomal DNA was
sheared by passing the suspension 10 times through a 27-gauge needle; this was
followed by heating at 95°C for 15 min before 30 l was loaded onto a sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gel for Western blot analysis.
Immunodetection of FHA-(SP70)3 and BrkA-(SP70)3 chimeras. Concentrated
(10) culture supernatants or whole-cell extracts of the B. pertussis strains were
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 8 or
12% polyacrylamide gels. The proteins were electrotransferred onto nitrocellu-
lose membranes and incubated with mouse anti-SP70 polyclonal antibodies (23)
diluted 1:100, mouse anti-FHA monoclonal antibodies diluted 1:250 (49), or
rabbit anti-BrkA polyclonal antibodies diluted 1:30,000 (45) in Tris-buffered
saline containing 0.1% Tween 20 and 2% bovine serum albumin. Alkaline phos-
phatase-conjugated goat anti-mouse or anti-rabbit immunoglobulin G (IgG)
secondary antibodies (Sigma), both diluted 1:3,000, were used for chromogenic
detection of the proteins after addition of the alkaline phosphatase substrate
(nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate reagents;
Sigma).
FACS. B. pertussis strains grown on BG agar were washed three times with
sterile phosphate-buffered saline (PBS) supplemented with 5% glycerol. Fluo-
rescence-activated cell sorting (FACS) was then conducted with the intact B.
pertussis cells using a Coulter Epics machine (Beckman Coulter, Palo Alto, CA).
Intact bacteria were incubated with rabbit anti-BrkA polyclonal antibodies (45)
diluted 1:200 and then with Cy2-conjugated goat anti-rabbit IgG (Jackson Lab-
oratories, West Grove, PA) diluted 1:100. Samples were analyzed with laser
excitation at 488 nm, and the data were acquired using the EXPO version 2.0
software (Applied Cytometry Systems, Sheffield, United Kingdom) and analyzed
with the WinMDI-2.8 software. The assay was performed two times indepen-
dently.
Immunofluorescence. Intact B. pertussis cells were prepared as described
above for FACS and spotted onto glass slides pretreated with 100 l of 0.1%
poly-L-lysine. The samples were examined with blue light excitation (488 nm)
using an epifluorescence microscope (BX40; Olympus, Japan) at a magnification
of 1,000.
i.n. infection. The mice were kept under specific-pathogen-free conditions in
individual ventilated cages, and all the experiments were carried out using the
guidelines of the National University of Singapore animal study board. For
colonization studies, 9-week-old outbred CD1 mice (Biopolis Research Center,
Singapore) were each infected intranasally (i.n.) with 5  106 CFU of the
different B. pertussis strains in 20 l as described previously (1). At the indicated
time points, four mice per group were sacrificed, and their lungs were aseptically
removed and homogenized in PBS. Serial dilutions from individual lung homog-
enates were plated onto BG agar, and the total numbers of CFU per lung were
determined after 4 to 5 days of incubation at 37°C. For immunization studies,
groups of six 5-week-old BALB/c mice (Biopolis Research Center, Singapore)
were infected i.n. twice at a 4-week interval with 5  106 CFU of the different B.
pertussis strains in 20 l. An additional group of six mice was inoculated intra-
peritoneally (i.p.) twice at a 4-week interval with 10 g of heat-inactivated EV71
in a 50% emulsion of complete and incomplete Freund’s adjuvant. At the
indicated time points, the mice were bled at the retroorbital sinus.
Antibody detection. The levels of antibodies to SP70 and B. pertussis were
measured by an enzyme-linked immunosorbent assay (ELISA). The 96-well
microtiter plates (COSTAR; Corning) were coated overnight at 4°C with 50 l
of 0.1 M carbonate buffer (pH 9.6) containing 10 g/ml of unconjugated SP70
peptide or total B. pertussis BPZE1 cell lysate. After blocking with 2% bovine
serum albumin in PBS containing 0.1% Tween 20, 50 l of serum diluted 1:50
(for anti-SP70 detection) or 1:800 (for anti-B. pertussis detection) was added to
the wells. The plates were incubated at 37°C for 1 h, rinsed in PBS-0.1% Tween
20, and incubated at 37°C for 1 h with 50 l of horseradish peroxidase-conjugated
goat anti-mouse IgG(HL) secondary antibodies (Sigma) at a 1:3,000 dilution.
To detect the various IgG subtypes, horseradish peroxidase-conjugated goat
anti-mouse IgG1, IgG2a, IgG2b, and IgG3 secondary antibodies (Jackson Lab-
oratories) were used at a 1:5,000 dilution. The reaction was then developed using
o-phenylenediamine dihydrochloride substrate (Sigma) at room temperature for
30 min in the dark and stopped by addition of 1 M sulfuric acid. The absorbance
at 490 nm was determined with an ELISA plate reader (Tecan Sunrise, United
States).
EV71 neutralization assay. The presence of neutralizing antibodies against
EV71 was determined by an in vitro microneutralization assay using RD cells, as
described previously (23). Mouse serum samples were first incubated at 56°C for
30 min to inactivate complement activity. Briefly, 25 l of twofold serial dilutions
of heat-treated serum was coincubated with equal volumes containing 103 50%
tissue culture infective doses of virus in a 96-well microtiter plate. Two hours
later, 5  104 RD cells were added to each well and incubated at 37°C for 48 h.
The cells were examined for CPE, and the neutralizing antibody titer was defined
as the highest dilution of serum that inhibited virus growth by 100%, thereby
preventing CPE. The assay was performed three times independently.
Statistical analysis. The results were analyzed using the unpaired Student t
test. Differences were considered significant if the P value was 0.05.
RESULTS
Production of FHA-(SP70)3 and BrkA-(SP70)3 chimeras by
B. pertussis. Up to 85% of the passenger domain of BrkA can
be deleted without affecting the efficacy of translocation of the
protein across the outer membrane (45). However, the passen-
ger domain of BrkA has recently been found to possess adju-
vant properties and immunogenic activities (9), which may be
important when BrkA is used as a carrier for the display of
vaccine candidates. We therefore decided to truncate the BrkA
protein from amino acid A52 to H263, corresponding to a
deletion of 32% of the passenger domain. Three copies of the
15-amino-acid SP70 neutralizing peptide from EV71 were then
fused in tandem in the truncated passenger domain of BrkA.
Three copies of SP70 were also inserted in tandem into full-
length FHA. The chimeric proteins were designated BrkA-
(SP70)3 and FHA-(SP70)3, respectively. The corresponding
DNA constructs were introduced by allelic exchange into the
brkA and fhaB chromosomal loci, respectively, of attenuated B.
pertussis BPZE1, resulting in strains BPSQ5 and BPSY13.1,
respectively.
The production of the FHA-(SP70)3 and BrkA-(SP70)3 chi-
meras by the recombinant strains was analyzed by immuno-
blotting using anti-SP70 and anti-FHA or anti-BrkA antibod-
ies. A 225-kDa band corresponding to the predicted size of
FHA-(SP70)3 was detected in the culture supernatant of
BPSY13.1 using anti-FHA and anti-SP70 antibodies (Fig. 1A
and B, respectively). Two bands at 103 and 73 kDa, corre-
sponding to full-length wild-type BrkA and its passenger do-
main, respectively, were detected in the whole-cell extract of
BPZE1 using anti-BrkA antibodies (Fig. 1C). Similarly, two
bands at 85 and 55 kDa, corresponding to the predicted sizes
of full-length BrkA-(SP70)3 and its passenger domain, respec-
tively, were detected in the whole-cell extract of BPSQ5 using
FIG. 1. Detection of FHA-(SP70)3 and BrkA-(SP70)3 chimeras by
immunoblotting. Tenfold-concentrated culture supernatants from
BPZE1 and BPSY13.1 cultures (A and B) or whole-cell extracts from
BPZE1, BPSQ5, and BPSY1 cultures (C and D) were assayed by
immunoblotting using anti-SP70 polyclonal antibodies (B and D), anti-
FHA monoclonal antibodies (A), and anti-BrkA polyclonal antibodies
(C). Fifty microliters of supernatant or 10 l of cell extract was loaded.
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anti-BrkA and anti-SP70 antibodies (Fig. 1C and D, respec-
tively). No bands were detected in the brkA knockout BPSY1
strain using either antibody (Fig. 1C and D). FHA and BrkA
were not detected by anti-SP70 antibodies (Fig. 1B and D,
respectively).
These data demonstrate that FHA-(SP70)3 and BrkA-
(SP70)3 were successfully produced by BPSY13.1 and BPSQ5,
respectively. Moreover, they indicate that FHA-(SP70)3 was
efficiently secreted by BPSY13.1 into the extracellular milieu.
In contrast and as expected, BrkA-(SP70)3 was not secreted by
BPSQ5 at an appreciable level (data not shown).
Cell surface exposure of the BrkA-(SP70)3 chimera. To as-
sess whether BrkA-(SP70)3 was exposed at the bacterial sur-
face of BPSQ5, FACS was performed with intact (nonperme-
abilized) BPSQ5 cells using anti-BrkA antibodies. The
parental BPZE1 and brkA knockout BPSY1 strains were used
as positive and negative controls, respectively. As shown in Fig.
2, 100% of the parental BPZE1 cells exhibited surface expo-
sure of BrkA. Similarly, the majority of BPSQ5 cells were
found to be positive, and the difference from the parental
strain was not statistically significant (P  0.21) (Fig. 2B). As
expected, the BPSY1 strain did not display any significant
fluorescence.
The surface exposure of BrkA-(SP70)3 was further con-
firmed by immunofluorescence analysis using anti-BrkA anti-
bodies on intact BPSQ5, BPZE1, and BPSY1 cells. As shown
in Fig. 3, BPZE1 and BPSQ5 cells displayed strong and com-
parable fluorescence signals (Fig. 3G and H, respectively),
while no significant fluorescence emission was detected with
the BPSY1 strain (Fig. 3F).
Due to a high background value, the anti-SP70 immune
serum could not be used as the primary antibody in FACS and
immunofluorescence studies to confirm the data obtained with
the anti-BrkA immune serum (data not shown).
These results demonstrate that BrkA-(SP70)3 is exposed at
the bacterial surface of BPSQ5 at levels comparable to the
levels of the wild-type BrkA protein in BPZE1.
Lung colonization by B. pertussis BPSY13.1 and BPSQ5.
FHA and BrkA have been shown to play a role in the coloni-
zation efficiency of B. pertussis (1, 18). To study whether the
recombinant BPSQ5 and BPSY13.1 strains retained the capac-
ity to colonize the murine respiratory tract, mice were infected
i.n. with either strain, and the colonization profiles were com-
pared to those of the parental BPZE1 and brkA knockout
BPSY1 strains.
FIG. 2. Detection of the BrkA-(SP70)3 chimera by FACS. Anti-
BrkA polyclonal antibodies were coincubated with intact BPSY1,
BPZE1, and BPSQ5 cells as indicated. The isotype control was BPZE1
bacteria stained with Cy2-conjugated secondary antibody. (A) Graphs
representative of two independent experiments. (B) Average values for
the two independent experiments. The results are expressed as
means 	 standard deviations.
FIG. 3. Detection of the BrkA-(SP70)3 chimera by immunofluorescence microscopy. Anti-BrkA polyclonal antibodies were coincubated with
intact BPSY1 (B and F), BPZE1 (C and G), or BPSQ5 (D and H) cells. The isotype control (A and E) was BPZE1 bacteria stained with
Cy2-conjugated secondary antibody. Panels A to D show corresponding phase-contrast images.
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BPSY13.1 colonized the lungs as efficiently as the parental
BPZE1 strain; a peak of multiplication was observed, followed
by progressive clearance of the bacteria from the lungs (Fig.
4A), indicating that the insertion of three copies of SP70 into
full-length FHA did not impair the adhesion function of the
protein. However, similar to the colonization efficiency of the
brkA knockout strain BPSY1, the colonization efficiency of
BPSQ5 was found to be slightly but significantly (P  0.05)
reduced 7 and 10 days postinfection compared to that of
BPZE1 (Fig. 4B). This observation suggests that the BrkA-
(SP70)3 chimera did not retain the full adhesion function of the
wild-type BrkA protein and/or that other functions of BrkA,
such as resistance to serum killing (20) and to antimicrobial
peptides (21), were impaired in the BrkA-(SP70)3 chimera,
which might account for the reduced colonization ability ob-
served with BPSQ5.
Systemic anti-SP70 and anti-B. pertussis antibody responses
in mice. To examine the abilities of the two recombinant B.
pertussis strains to trigger a systemic anti-SP70 antibody re-
sponse upon nasal administration, groups of six BALB/c mice
were infected i.n. twice at a 4-week interval with BPSY13.1,
BPSQ5, or BPZE1. As a reference for anti-SP70 antibody
production, an additional group of mice was inoculated i.p.
with heat-inactivated EV71 using the same immunization
schedule. The systemic anti-SP70 and anti-B. pertussis IgG
responses were measured by ELISA 2 weeks after the boost.
Both BPSY13.1- and BPSQ5-infected mice developed a
strong systemic anti-B. pertussis antibody response comparable
to the response observed in the BPZE1-infected mice (Fig.
5A). As expected, no anti-B. pertussis antibody response was
seen in the EV71-inoculated animals. However, the EV71-
inoculated mice all showed high anti-SP70 antibody responses,
while the naı¨ve and BPZE1-infected mice displayed only back-
ground absorbance (Fig. 5B). Two of six BPSY13.1-infected
mice (mice M5 and M6) produced significant anti-SP70 IgG
antibody levels. In contrast, five of six BPSQ5-immunized mice
produced significant anti-SP70 antibody levels, and the titers
were significantly higher than the titers obtained for the
BPSY13.1-immunized group (P  0.05). However, the anti-
body titers measured for both groups of mice were found to be
significantly lower than the titers measured for the EV71-
inoculated group.
An anti-SP70 IgG subtype analysis was carried out for the
immune sera from all the mouse groups and showed that there
was production of significant levels of IgG2a/IgG2b antibodies
in the BPSQ5- and BPSY13.1-immunized mice, indicative of a
Th1-oriented immune response (Table 2).
The anti-B. pertussis and anti-SP70 antibody responses were
monitored over a period of 8 weeks after the boost in the
BPSY13.1- and BPSQ5-immunized groups and were found to
be as high as the titers measured 2 weeks after the boost (data
not shown), demonstrating that the antibody responses trig-
FIG. 4. Lung colonization by the recombinant B. pertussis strains. (A) CD1 mice were infected i.n. with 5  106 CFU of B. pertussis BPZE1
(solid squares in panels A and B), BPSY13.1 (open squares in panel A), BPSY1 (solid triangles in panel B), or BPSQ5 (open squares in panel B).
The lungs of infected mice were harvested at the indicated time points, and appropriate dilutions of the lung homogenates were plated to
determine the total number of CFU per lung. Four mice per group and per time point were assessed individually. Asterisk, P  0.05 compared
to BPZE1.
FIG. 5. Detection of specific antibody responses. Groups of six mice were infected i.n. twice at a 4-week interval with 5  106 CFU of BPZE1,
BPSY13.1, or BPSQ5. The EV71 group was inoculated i.p. with 10 g of inactivated virus using the same immunization schedule. The mice were
bled 2 weeks after the boost, and the anti-B. pertussis (A) and anti-SP70 (B) IgG(HL) titers were determined by ELISA with the individual sera
diluted 1/800 and 1/50, respectively, using B. pertussis whole-cell lysate and SP70 peptide as coating antigens, respectively., mouse M1; f, mouse
M2; ‚, mouse M3; , mouse M4; Œ, mouse M5; , mouse M6. The average is indicated by a horizontal line. OD490nm, optical density at 490 nm.
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gered by nasal administration of the recombinant strains was
sustained.
Neutralizing activity of the immune sera against EV71. To
evaluate the functional activities of the sera from the
BPSY13.1- and BPSQ5-immunized mice, an in vitro EV71
neutralization assay was used. Serially diluted sera were coin-
cubated with EV71 before infection of RD cells. CPE were
determined 48 h later. The sera from the naı¨ve, BPZE1-in-
fected, and EV71-inoculated mice were pooled within groups,
while the sera from the BPSY13.1- and BPSQ5-infected mice
were analyzed individually.
In contrast to uninfected cells, which had a flattened and
spindle-like shape, infected cells appeared to be rounded and
swollen with microbodies, as described elsewhere (23; data not
shown). As expected, the sera from the naı¨ve and BPZE1-
infected mice failed to protect RD cells from viral infection
(Table 3). In contrast, the pooled serum from the EV71-inoc-
ulated mice provided complete protection to the cells up to a
serum dilution of 1:128. For the six BPSY13.1-infected mice,
only the serum from mouse M5, corresponding to the highest
anti-SP70 IgG titer, displayed significant neutralizing activity
against the virus. This serum conferred complete protection to
the cells up to a dilution of 1:16. The sera from the five
BPSQ5-infected mice, which were found to produce significant
anti-SP70 antibodies, showed the ability to neutralize the virus,
and complete protection was obtained with serum dilutions
ranging from 1:2 to 1:32. Surprisingly, the highest neutraliza-
tion titer did not correspond to the highest anti-SP70 antibody
titer. For example, the sera from mice M1 and M5, which
contained significantly different anti-SP70 antibody levels (Fig.
5B), were found to be equally able to neutralize EV71 in vitro.
These results show that nasal administration of BPSQ5 and,
to a lesser extent, nasal administration of BPSY13.1 are able to
trigger the production of systemic antibodies capable of neu-
tralizing EV71 infection in vitro.
DISCUSSION
Despite high vaccination coverage, B. pertussis remains en-
demic in many areas, and reports of an increasing incidence of
infection worldwide have been accumulating for the past 20
years (5, 11, 17). The resurgence of pertussis is believed to be
due to waning vaccine-induced immunity in adults and to an-
tigenic shift and adaptation of the circulating B. pertussis
strains to the current acellular pertussis vaccines (43). Natural
infection with B. pertussis has long been known to induce
strong and long-lasting immunity that wanes later than vac-
cine-induced immunity (4). Furthermore, natural infection
with B. pertussis induces measurable antigen-specific Th1 im-
mune responses even in very young children (as young as 1
month of age) (35). However, the neonatal immune system is
too immature for effective development of protective immunity
upon administration of acellular vaccines (54). These observa-
tions suggest that live vaccines that can be administered by the
nasal route in order to mimic as closely as possible natural
infection may be attractive alternatives to the currently avail-
able subunit vaccines. Such a strategy would allow early im-
munization, possibly at birth, thereby reducing the incidence of
pertussis in the very young and most vulnerable age groups.
The highly attenuated B. pertussis BPZE1 strain has been de-
scribed recently as a promising live pertussis vaccine (40). In
this study we investigated the use of BPZE1 as a live vehicle to
deliver a heterologous peptide vaccine candidate via the nasal
route.
The heterologous antigens which have been produced in B.
pertussis so far were fused to either full-length or truncated
FHA (3, 15, 42, 50). To be efficiently secreted, an FHA chi-
TABLE 2. Isotype profiles of the immune sera
Immunogen Mouseserum
Titera
IgG1 IgG2a IgG2b IgG3
Naïve Pooled 0.12 0.08 0.11 0.11
BPZE1 Pooled 0.10 0.10 0.12 0.11
EV71 Pooled 2.36 2.23 2.36 2.33
BPSQ5 M1 0.18 0.80 1.62 0.11
M2 0.11 1.57 2.27 0.11
M3 0.10 0.13 0.22 0.10
M4 0.09 1.52 1.21 0.09
M5 0.10 0.65 2.54 0.12
M6 1.42 2.17 2.34 0.13
BPSY13.1 M1 0.22 0.25 0.78 0.07
M2 0.08 0.08 0.08 0.09
M3 0.09 0.07 0.07 0.07
M4 0.27 0.71 0.08 0.08
M5 2.16 1.42 1.33 0.17
M6 0.39 2.00 2.03 0.19
a The anti-SP70 IgG1, IgG2a, IgG2b, and IgG3 titers were determined by
ELISA using the sera diluted 1/50 and using SP70 peptide as the coating antigen.
Sera from individual mice belonging to the naı¨ve, BPZE1, and EV71 groups were
pooled, while serum from each BPSY13.1- and BPSQ5-immunized mouse was
tested individually.
TABLE 3. Neutralizing activities of the immune seraa
















a Twofold serial dilutions of the sera from each group were incubated with
EV71 before infection of RD cells, and the CPE were observed 48 h later. Sera
from individual mice belonging to the naı¨ve, BPZE1, and EV71 groups were
pooled, while serum from each BPSY13.1- and BPSQ5-immunized mouse was
tested individually.
b Highest dilution with which total protection was observed. NP, no protection.
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mera must be in an unfolded conformation, precluding the
fusion of any foreign antigens with cysteine residues suscepti-
ble to formation of disulfide bonds (24, 50). To further develop
B. pertussis as a vehicle for vaccine delivery, we explored the
use of the autotransporter BrkA as a surface display system.
The efficient translocation across the outer membrane of
folded protein domains containing disulfide bonds has been
demonstrated for autotransporters in other bacterial species
(58). We report here that insertion in tandem of three copies
of the 15-amino-acid SP70 peptide within the full-length FHA
and within the truncated passenger domain of BrkA does not
impair the secretion and surface exposure, respectively, of the
chimeras.
The colonization efficiency of BPSQ5, which produces the
BrkA-(SP70)3 chimera, was found to be slightly reduced com-
pared to that of BPZE1, and the profile was comparable to that
of a B. pertussis brkA knockout mutant. A previous study using
a B. pertussis brkA knockout mutant showed that BrkA is in-
volved in colonization efficacy in mice (18). Our findings fur-
ther suggest that the A52-H263 region of the passenger do-
main of BrkA likely plays a role in this process. A role of BrkA
in direct adherence to and invasion of the host cells has also
been described (19, 20). However, whether the A52-H263 re-
gion of the BrkA passenger domain is part of the adhesion
domain of the protein is not known. Other functions of BrkA,
such as resistance to serum killing (20) and to antimicrobial
peptides (21), might be impaired in the BrkA-(SP70)3 chimera,
which might account for the reduced colonization ability ob-
served with BPSQ5.
Both BPSQ5- and BPSY13.1-immunized mice developed a
strong anti-B. pertussis antibody response, and the titers were
comparable to those obtained for mice immunized with paren-
tal strain BPZE1, demonstrating that fusion of three copies of
SP70 to either FHA or BrkA did not alter the immunogenicity
of the bacterial vector. The systemic anti-SP70 IgG response
measured in the BPSQ5-immunized mice was found to be
significantly higher than the response measured in the
BPSY13.1-immunized mice. Several factors might account for
the differential ability to trigger an anti-SP70 antibody re-
sponse using BrkA or FHA as the carrier. These include the
yield of each chimera produced by the recombinant strains and
the size ratio between the carrier and the three copies of SP70
peptide, as well as the intrinsic immunogenicity of the carrier.
Indeed, FHA is known to be highly immunogenic (2, 8, 52).
However, this feature, if too prominent, may be a handicap as
it may skew the immune response towards the carrier at the
expense of the passenger antigen. Moreover, the subcellular
localization of the chimera might also play a role in the pre-
sentation of the heterologous antigen. A recent study showed
that B. pertussis BrkA, as well as autotransporters from other
rod-shaped gram-negative bacteria, is localized at the bacterial
pole, which may have profound implications for the nature and
efficiency of the pathogen-host interactions (30). Thus, concen-
tration of the BrkA-(SP70)3 molecules at one pole of the
bacteria might allow more efficient presentation to and pro-
cessing by the host’s antigen-presenting cells.
The lack of a suitable animal model to examine vaccine
efficacy is a major obstacle to the development of EV71 vac-
cines. Mice are susceptible to EV71 infection in the first 4 days
of life and then become completely resistant by 6 days of age
(61, 51). EV71 infection has been found to be asymptomatic in
all strains of adult mice tested, including BALB/c, C3H, ICR,
CD28 knockout, and tumor necrosis factor alpha receptor
knockout mice (59). Therefore, the efficacy of an EV71 vaccine
candidate cannot be evaluated with actively immunized mice
but can be addressed only using passive immunization, in
which newborn (1-day-old) mice are challenged with EV71 and
subsequently inoculated with the immune serum from actively
immunized adult mice, as previously described (22, 61). We
recently reported that anti-SP70 antisera with a neutralizing
titer of 1:32 were able to confer up to 80% in vivo passive
protection in suckling mice and that the survival rate corre-
lated well with the neutralizing titers measured in vitro (22).
Here, we found that the sera from the BPSQ5-immunized mice
displayed significant neutralizing activities against EV71 in
vitro and had titers of up to 1:32, demonstrating the presence
of anti-SP70 neutralizing antibodies in the antisera. Moreover,
the anti-SP70 serum antibody isotypes induced in the BSQ5-
immunized mice were predominantly IgG2a and IgG2b, indic-
ative of a Th1-oriented immune response. In contrast, paren-
teral administration of conjugated SP70 peptide induced a Th2
immune response with production of high levels of anti-SP70
IgG1 antibodies (23). This apparent discrepancy, very likely
due to the vehicle used to deliver the SP70 peptide (live re-
combinant bacteria versus conjugated SP70 emulsified in
Freund’s adjuvant), suggests therefore that the neutralizing
activity of the anti-SP70 antibodies is not restricted to one
particular IgG isotype.
In conclusion, we describe here the feasibility of using the
highly attenuated B. pertussis BPZE1 strain as a bacterial vec-
tor to deliver heterologous vaccine candidates, thereby allow-
ing simultaneous protection against pertussis and the target
disease. Since whooping cough and hand, foot, and mouth
disease are two childhood diseases, combined immunization
soon after birth would be highly desirable. Furthermore, we
show that the BrkA autotransporter is a promising display
system for foreign antigens in B. pertussis. This study opens up
new avenues for the development of safe live attenuated B.
pertussis as a vehicle for vaccine delivery via the nasal route.
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